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Human embryonic stem cells are pluripotent 
cells capable of sustained self-renewal and 
differentiation to derivates of the three germ 
layers ectoderm, endoderm and mesoderm. 
Because of these unique properties, the cells 
hold great potential as a model for human 
development, disease pathology, drug 
discovery and safety pharmacology. All these 
applications will depend on comprehensive 
knowledge of their biology and control 




human embryonic stem cells
Human embryonic stem cells (hESC) were first derived in 19981 under conditions similar 
to those developed for mouse embryonal carcinoma and embryonic stem cells (mESC). 
This involves co-culture with mitotically inactivated fibroblasts that function as ‘feeder’ 
layers2,3.  Retrospectively it appears a lucky coincidence that these fibroblasts supported the 
undifferentiated growth of both mESC and hESC. Although mESC and hESC are both derived 
from the inner cell mass of blastocyst stage embryos there are clear differences in morphology, 
behavior and growth factor requirements. mESC self-renewal depends on leukemia inhibitory 
factor (LIF) supplemented with bovine serum, LIF and BMP4 or dual inhibition of GSK3 and 
MAPK4,5. By contrast, hESC rapidly differentiate upon exposure to BMP46 and require basic 
fibroblast growth factor (bFGF) and transforming growth factor b (TGF-b) /Activin A signaling 
for undifferentiated growth7. The apparent differences between the two cell types have 
recently been attributed to their state of differentiation8. Cell lines from mouse epiblast can 
be isolated under conditions established for hESC culture8,9. These epiblast stem cells share 
signaling pathways for self-renewal, gene expression signatures and ability to differentiate 
with hESC. 
pluripotency and exit from the pluripotent state
Pluripotency of stem cells is regulated by a complex interplay of cell-matrix interaction, 
transcriptional regulation, chromatin-modifying enzymes, miRNAs and specific signal-
transduction pathways10. Interestingly, the primary signaling pathway in hESC, FGF2, is highly 
dependent on the ECM in various cell systems11. However it remains to be investigated how 
growth factor signaling converges with matrix-integrin signaling in hESC and specifically which 
matrices and integrins are important for pluripotency. Furthermore it is presently unclear how 
external stimuli affect the pluripotency transcriptional regulators OCT4, SOX2, NANOG. However 
it is clear that SOX2 and OCT4 function by heterodimerization and act synergistically to activate 
Oct-Sox enhancers present in the core promoters of pluripotency genes. NANOG is thought to 
stabilize the pluripotent state, but is not essential for pluripotency12. Genome wide chromatin 
IP Chip experiments in hESC for OCT4, SOX2 and Nanog showed that OCT4, SOX2, and NANOG 
bind together at their own promoters to form an interconnected autoregulatory feed forward 
loop13.  All three transcription factors co-occupy several hundreds of genes at overlapping 
sites in the genome. This strongly suggests that they act in a coordinated way to maintain the 
pluripotent transcriptional network. Interestingly, functional clustering of the putative genes 
regulated by OCT4, SOX2, and NANOG results in two distinct gene sets. The first set is actively 
expressed and includes transcription factors, signal transduction components and chromatin 
modifying enzymes that promote pluripotency. The second set of genes is not expressed but 
their expression is associated with lineage commitment and differentiation. Silencing of this 
class of genes is probably actively contributing to maintenance of the undifferentiated state. 
Exactly how hESC downregulate the core pluripotency network and initiate a differentiation 
program is unclear. Nevertheless differentiation protocols for directed differentiation to 
various lineages have been described. However differentiation is accompanied by severe 
heterogeneity and the amount of desired cells is typically limited to a few percent of the 
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total cell yield. Nevertheless, both gene expression as well as protein analyses confirm that 
differentiating cells follow a gene expression pattern during differentiation as observed in the 
developing embryo. For example; during gastrulation, cardiac progenitors form when they 
migrate laterally from the primitive streak. These cells express markers like Brachyury T and 
MESP114. MESP1 is thought to be the first marker of cardiac committed mesoderm and directly 
induces epithelial-mesenchyme transition and activates many members of the core cardiac 
regulatory network including NKX2-515. Whole genome micro-array analyses of differentiating 
hESC cultures to the cardiac lineage confirms these temporal gene expression patterns16. 
applications of hESC and their derivates
The isolation of hESC in 1998 led to great excitement in various areas of biomedical research1. 
For the first time, a non-transformed human cell capable of sustained self-renewal and 
directed differentiation to any cell type was available. These unique properties prompted 
fundamental research into translational medicine. Restoration of organ function by replacing 
damaged tissue from stem cells was among the most appealing applications. However, 
issues like effective transplantation techniques, immune rejection of foreign cells, proper 
functional integration, safety related to introduction of foreign dividing cells and teratoma 
formation by residual undifferentiated cells are considered to represent significant hurdles 
to clinical introduction for cell transplantation therapy17. Other applications like the use of 
differentiated hESC as human in vitro models for dissection of molecular pathways controlling 
differentiation, self renewal and biology of disease has a huge biomedical potential in the 
short term. hESC differentiated to neurons, hepatocytes or cardiomyocytes could be used 
for the pre-clinical safety evaluation of novel drug candidates18. Mutations observed in the 
clinic can be directly introduced in human stem cells, because there is no species difference. 
Disease models based on these mutant hESC lines may have huge potential as model for drug 
development and safety pharmacology. More recently, the landmark discovery of another 
source human pluripotent stem cells derived from somatic cells by reprogramming (induced 
pluripotency stem cells, iPS cells) greatly boosted this field of research19,20. Human iPS cells 
derived from patients with specific genetic diseases are now complementing hESC as a tool 
for basic research.  
Differentiation of hESC to beating clusters of cardiomyocytes has always attracted significant 
attention and various methods have been described to induce cardiomyogenesis in 
pluripotent cell lines21. Cardiomyocytes from human stem cells are of great interest for the 
pharmaceutical industry as model for drug development and drug safety pharmacology22. 
The heart has proven to be particularly sensitive to off-target, toxic effects of drugs. Reports 
of unexpected drug-induced cardiac arrhythmias associated with sudden cardiac death, has 
led to the withdrawal of a number of these non-cardiac drugs from clinical use23. Currently, 
assessing risk for arrhythmias is part of the standard required pre-clinical evaluation of all 
drugs in development (ICH topic S7B)24.
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challenges
Progress in implementation of human embryonic stem cell technology in both academic 
research laboratories and the biopharmaceutical industry has lagged behind expectations. 
Basic technology available for research on mouse ESCs, like gene targeting and defined 
feeder-free culture and differentiation, has been challenging in hESC25. These techniques are 
essential for all further biomedical applications. Cell transplantation, basic studies on human 
developmental biology, drug target discovery and safety pharmacology all benefit from 
defined selected cell populations. However, the availability of lineage specific cell surface 
antigens for selection of a particular cell type is very limited26. hESC lines expressing fluorescent 
or selectable cassettes from lineage specific promoters will therefore be essential for pure 
populations of the desired cell type. Functional analyses of signaling pathways in human 
physiology and pathophysiology will require targeted gene disruption by RNA interference or 
homologous recombination. This will facilitate the development of human non-transformed 
cell models that can be cultured indefinitely. 
One intrinsic problem that has turned out to underlie the majority of challenges associated 
with hESC is the culture system. hESC culture traditionally required undefined components like 
feeders and fetal calf serum. The undifferentiated cells are growing in multilayered colonies, 
expand quite slowly and are difficult to manipulate.  Both of these issues hamper the 
understanding of self-renewal and further technology development based on these cells. It is 
therefore crucial to develop defined monolayer culture systems that are amenable to efficient 
genetic manipulation of hESC, and that support sustained self-renewal robustly. Targeted cell 
lines expressing fluorescent reporters from lineage specific promoters can be subsequently 
used for efficient (high-throughput) optimization of differentiation and selection of a desired 
cell type. 
Aims and scope of this thesis
All future applications of human embryonic stem cells will depend on exquisite knowledge of 
their biology and control of their signaling and fate. Chapters in this thesis describe multiple 
aspects of human embryonic stem cell biology and technology development to achieve these 
goals. In Chapter 2 a feeder-free human embryonic stem cell culture protocol is described, 
which has been optimized for 12 independent lines. The system is optimal for clonal growth 
and efficient gene transfer without loss of pluripotency. In Chapter 3 detailed bench protocols 
for culture adaptation and genetic manipulation are presented. In Chapter 4 the plasma 
membrane characteristics of feeder-free human embryonic stem cell cultures are further 
investigated. It is shown that these cells express a uniform epithelial plasma membrane 
profile and that VIMENTIN, normally associated with mesenchymal cells is also expressed. 
We show that this expression is related to stress and associated with hardness of the tissue 
culture plastic substrate rather than differentiation. In Chapter 5 the plasma membrane of 
hESC is further investigated through functional analysis of the expression of integrins, the 
surface receptors of extracellular matrix proteins. Recombinant vitronectin was identified as 
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the first defined substrate that supports human embryonic stem cells in completely defined 
culture medium. In Chapter 6 SILAC technology and quantitative phopspho-proteomics 
are used to investigate how human embryonic stem cells exit the pluripotent state upon 
BMP4 exposure. Approximately 50% of the 3067 identified phosphosites were regulated 
within 1 hr of differentiation induction, revealing a complex interplay of phosphorylation 
networks spanning different signaling pathways. Among the phosphorylated proteins was the 
pluripotency-associated protein SOX2, which was SUMOylated as a result of phosphorylation. 
Using the data to predict kinase-substrate relationships the hESC kinome is reconstructed; 
CDK1/2 emerged as central in controlling self-renewal and lineage specification. In Chapter 7 
gene targeting and defined culture systems are used to optimize and study the differentiation 
to the cardiac lineage. EGFP is targeted to the NKX2-5 locus – one of the earliest markers 
of cardiac commitment. The early NKX2-5 positive cell population contained multipotent 
progenitor cells capable of directed differentiation to the cardiac, endothelial and vascular 
smooth muscle cells. In Chapter 8 human cardiomyocytes derived from hESC are described as 
a scalable reproducible system on which to base cardiac safety pharmacology assays. Evidence 
is provided that patient serum levels of drugs and known responses on QT interval overlap 
with field potential duration values derived from hESC-CM, as predicted. On this basis, field 
potential duration prolongation is proposed to be a directly applicable safety criterion for 
pre-clinical evaluation of new drugs in development. In Chapter 9 we review the state of 
the art and discuss that the ability to reprogram adult cells to pluripotent stem cells and 
genetically manipulate stem cells present opportunities to develop human disease models. 
The availability of human cardiomyocytes from stem cell sources is now expected to accelerate 
cardiac drug discovery and safety pharmacology by offering more clinically relevant human 
culture models than presently available. Finally, in Chapter 10 the results and conclusions of 
the previous chapters are discussed, together with their future implications.
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Genetic manipulation of hESC 15
Low efficiency of transfection limits the 
ability to genetically manipulate human 
embryonic stem cells (hESC), and differences 
in cell derivation and culture methods 
require optimization of transfection 
protocols. We transiently transferred multiple 
independent hESC lines with different growth 
requirements to standardized feeder-free 
culture, and optimized conditions for clonal 
growth and efficient gene transfer without 
loss of pluripotency. Stably transfected lines 
retained differentiation potential, and most 
lines displayed normal karyotypes. 
Abstract
Chapter 216
To realise the full potential of human embryonic stem cells (hESC), efficient methods to 
manipulate their genome are required. hESC lines expressing fluorescent reporters from 
lineage-specific promoters will be important for selecting specific lineages where no 
appropriate cell surface antigens are expressed and for in vitro toxicological screening. 
Targeted gene disruption by RNA interference or homologous recombination will facilitate in 
vitro modelling of human disease where clinically relevant mutations or deletions are known. 
However, progress has lagged behind expectations in part because of poor transfection and 
single cell cloning efficiencies. Lentiviral infection is presently the most efficient method for 
gene transfer but has major limitations including silencing of randomly integrated copies of 
the transgene1, incompatibility with homologous recombination and costly, time-consuming 
large scale production of multiple constructs. Adenoviral constructs yield modest (~11%) 
infection efficiencies2 and plasmid transfection shows highly variable transfection efficiencies, 
ranging from 3-35% in independent lines3. Furthermore, the most efficient transfection 
methods have been optimized using two WiCell (US) hESC lines, H1 and H9. For non-US or 
non-NIH funded researchers, >400 other lines are available.  Although various stable3-5 and 
inducible gene expression systems have been reported for hESC6-8 none have yet been applied 
to multiple cell lines and growth conditions presently available. In addition, initial gene 
delivery was often inefficient. Low transfection efficiency in hESC lines therefore remains an 
unsolved problem.  
hESC are usually cultured with mouse embryonic feeders (MEF) to support self renewal but 
more recently human feeders (HF) and feeder-free Matrigel™ substrates have been used in 
combination with enzymatic or non-enzymatic passage and  growth factor-supplemented 
basal media. 
To develop a generic method for ectopic gene expression in hESC, we investigated whether 
twelve independently derived cell lines (HES-2, Envy, HUES1,5,7,15, HESC-NL1,2,3,4 and 
NOTT1,2) could be transferred to common feeder-free culture conditions and undergo efficient 
transfection using electroporation, lipofection, lentivirus and adenovirus, without loss of 
pluripotency or karyotypic stability. The lines selected were derived and grown under the 
most diverse conditions we had available: mechanical passage on MEFs in serum containing 
medium, mechanical passage on HFs in KSR medium and enzymatic passage on MEFs in KSR 
medium (Supplementary Methods online). Transfer to feeder-free conditions on Matrigel in 
KSR-containing MEF-conditioned medium (CM)9 was achieved in two stages: first adaptation 
to Matrigel; second, adaptation to trypsin (if necessary) (Figure 2.1A). Success, particularly 
for mechanically passaged lines, was critically dependent on very high density culture during 
the first passages. The combination of these two steps rapidly allowed plating of cells at 
low density for gene transfer without major loss of cells or pluripotency, as indicated by 
immunostaining/FACS analyses for cell surface markers Tra-1-60, GCTM2 and SSEA4, and 
transcription factors OCT4 and SOX2 (Figure 2.1B-I, Table S1 and Figure S1).  After adaptation, 
all hESC cultures were easier to maintain than using their original culture method. To test 
the specific gene delivery methods functionally we selected three cell lines, HES2, HUES7 and 
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(A) Schematic representation of 
culture procedure: (I) hESC grown 
on feeders are mechanically or 
enzymatically passaged and plated 
at high density (ratio 1:2) on 
two Matrigel-coated IVF (in vitro 
fertilization) organ-dishes and 
grown for an additional 4 days. (II) 
Differentiated 3D-structures are 
removed and hESC are trypsinized for 
3 min. hESC are replated in MEF-CM 
at high density by combining cells 
from two equivalent size plates (i.e. 
ratio 2:1). (III) hESC are then grown 
for another 2-3 days and split at 
a 1:2 ratio to scale-up the culture. 
(B-F) Immunostaining for stem cell 
markers and DNA for HES2 (overlay). 
(B) Tra-1-60, (C) SSEA4, (D) GCTM2, (E) 
SOX2, (F) OCT4. Scale bar, 50 μm. (G) 
FACS analyses of HES2 for Tra-1-60 
97,2% pos, (H) GCTM2 99,5% pos 
and (I) SSEA4 75,3% pos.
Figure 2.1 









HESC-NL4, again maintained on the widest range of conditions for detailed investigation but 
also included nine others in the efficiency analysis since the applicability of these methods to 
multiple lines is of utmost importance (Table S1).
Transfection was efficient in all twelve lines, independent of previous growth on MEFs or HFs, 
enzymatic or mechanical passage or maintainance in serum-containing or serum-replacement 
conditions (Table S1). As transfection of plasmid DNA is of interest for analyses of gene function. 
We used pCAG-GFP-IRES-Puror, a plasmid expressing GFP driven by a modified chicken actin 
promoter, to optimize transfection efficiency using the non-toxic polyamine-based reagent 
Genejammer9. Transfection efficiencies for all lines under their original conditions were 
extremely low (Figure 2.2A-D). However, once adapted, transfection efficiencies close to 80% 
were achieved by altering the ratio of DNA and transfection reagent, incubation time and 
volumes in the Matrigel cultures (Figure 2.2E, Table S1 and Supplementary Methods). 
For homologous recombination, electroporation is the preferred method, since lipofection 
is less efficient in generating correctly gene-targeted clones10,11. We therefore used the 
same pCAG-GFP-IRES-Puror plasmid to optimize electroporation conditions by varying 
pulsation parameters, voltages and capacity. Optimal parameters for both cell survival and 
transfection efficiency resulted in a transfection efficiency of ~45% (Figure 2.2E, Table S1 and 
Supplementary Methods).   
For high-throughput functional screening of gene or siRNA libraries, usually available in a 
viral background, transduction efficiencies of >80% are generally required. Using the original 
culture conditions, viral vectors driving GFP infected the feeder cells at high efficiency but 
left hESC colonies uninfected (data not shown). By varying the volumes, titres and incubation 
times we achieved efficiencies of up to 90% on the Matrigel cultures, using both adenoviral 
and lentiviral vectors, although lentiviral mediated gene transduction was more efficient 
than adenoviral using the same titre (Figure 2.2E and Supplementary Methods). Double 
stranded RNA is a widely-used tool for knocking down specific genes. Using an Alexa Fluor 
488-conjugated negative control siRNA with Lipofectamine 2000, transfection efficiencies of 
~90% were obtained (Figure 2.2E, Table S1 and Supplementary Methods). 
The greatly enhanced transfection efficiencies for plasmid, siRNA and viruses using our 
protocol was in part attributable to the absence of feeder cells which sequester transfection 
reagents9 but predominantly due to the low density plating in monolayer; this allowed cells to 
spread and interact optimally with the transfection agent. This was evident from the inverse 
correlation between cell density and plasmid transfection efficiency (Figure 2.2F). A similar 
inverse correlation was observed for adenoviral infections (Figure 2.2G). To show that the 
method supported production of stable hESC lines, HUES7 was transfected with the pCAG-GFP-
IRES-Puror plasmid and selected for puromycin resistance. The combination of transfection 
at low cell density with culture for a few days, allowed reproducible expansion of targeted 
cells which formed small drug-resistant clusters. These represented a surrogate solution for 
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(A) Genejammer pCAG-GFP-IRES-
Puror plasmid transfection in feeder 
co-culture. Scale Bar 250 μm. (B) 
SSEA4 positive gated HESC-NL4 cells 
cultured on feeders transfected with 
Genejammer and analysed by FACS 
for GFP expression, 1,5% pos. (C) 
idem, but transfected with siRNA, 
46% pos (D) idem, but transfected 
with Lentivirus, 2.5% pos. (E) 
Summary of various transfection 
methods in HES2, HESC-NL4 and 
HUES7, data are presented as mean 
+/- S.D n=3. (F) HES2-Matrigel pCAG-
GFP-IRES-Puror plasmid Genejammer 
transfection as a function of cell 
density; n.b. the slightly lower 
effi ciency compared to fi gure 2c 
is due to a 4 hour incubation 
period instead of overnight. This 
was to prevent toxicity when the 
concentration of Genejammer:DNA 
was adjusted to higher cell numbers 
(corrected). Data are presented as 
mean +/- s.e.m n=3. Anova multiple 
comparison revealed statistically 
signifi cant differences between 
groups (p<0.01). (G) HES2-Matrigel 
Adenovirus infection as a function of 
cell density; n.b. viral volume was 
kept constant with increasing cell 
densities (i.e. MOI 2500, 1250, 625, 
312; not corrected) and adjusted to 
altered cell densities (MOI 1250 for 
all cell densities; corrected). Data are 
presented as mean +/- s.e.m n=3. 
Anova multiple comparison revealed 
statistically signifi cant differences 
between groups (p<0.01).
Figure 2.2








the low clonal survival of hESC, although we cannot exclude multicellular contributions to 
colonies. In two independent experiments, the average stable cloning rate was 1.9x10-4 
and 2.28x10-4, considerably more efficient than reported previously12. A pool of puromycin 
resistant, GFP-positive clones was trypsinized and further cultured on Matrigel in MEF-CM. 
This polyclonal line showed a normal 46,XY  karyotype (Figure S2A). HESC-NL2, HESC-NL3 and 
HESC-NL4 were similarly stably transfected with the pCAG-GFP-IRES-Puror plasmid.  To confirm 
quantitatively that stable lines were undifferentiated we determined SSEA3 expression by 
FACS in 5 independent randomly-selected HESC-NL2 clones (21 days after transfection). In 
agreement with their morphology, SSEA3 expression was high (Figure S3). Altogether, we 
generated stable hESC lines reproducibly in >10 independent experiments using the method 
described. Several transgenic lines were transferred back to their original (human) feeder 
fibroblasts. Culture on feeders is crucial for long term maintenance of a normal karyotype13,14. 
Transient transfer to feeder-free conditions had not caused chromosomal abnormalities in 
any of the HESC-NL2 and -3 clones (Figure 2.3L and Figure S2C), although exceptionally in 
HESC-NL4, the karyotype was 46,XYqh+,i(7)(p10) for all cells analyzed in three independent 
clones (Figures S2B).
All hESC clonal derivatives transferred to feeders grew out into colonies with undifferentiated 
cell morphology (large nuclei, high nucleus to cytoplasm ratio). We observed transgene 
silencing within 3 weeks of transfer to feeder culture in approximately 50% of the clones, 
as reported by others previously3. In the remaining clones, robust GFP expression driven by 
the transgene was sustained for at least 10 passages (Figure 2.3A-C). One transgenic line, 
GFP-HESC-NL3, was further characterized in more detail by FACS analyses for stem cell surface 
markers Tra-1-60, GCTM2 and SSEA4 (Figure 2.3D-F) and multi-lineage differentiation by co-
culture with END2 cells15. Immunostaining with antibodies against cardiac myosin heavy chain 
(mesoderm) (Figure 2.3G) betaIII-tubulin, (ectoderm) (Figure 2.3H) and alpha-fetoprotein 
(endoderm) (Figure 2.3I) confirmed pluripotency. Next we used three siRNAs and a control to 
knockdown SOX2. Two of three siRNAs successfully knocked down SOX2 independent of general 
translational attenuation, as controlled by b-actin staining (Figure 2.3J,K and Figure S4). 
Finally we used our improved method to target the POU5F1 3’ UTR with IRES-GFP-IRES-Neor 10 
by homologous recombination. Electroporation of 5x106 HUES7 cells followed by G418 selection 
resulted in >150 colonies. PCR genotyping showed 4 positives in 48 clones analyzed. Targeting 
was confirmed by Southern hybridization (Figure S5). The targeting efficiency was 8.3%, lower 
than reported previously for H1.1. This may be related to the use of heterogenic rather than 
isogenic DNA, important for determining targeting efficiency in mouse ESCs although direct 
comparisons of isogenic versus heterogenic DNA in hESC have not yet been reported. 
Further analyses of one clone showed homogenous GFP expression and immunoreactivity 
for OCT4 (data not shown). Upon differentiation, most cells became GFP negative and 
lost OCT4 immunoreactivity. Some cells remained GFP positive and showed overlapping 
immunofluorescent staining for OCT4, confirming the specificity of the OCT4-GFP reporter line 
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(A-C) Morphology of undifferentiated 
stable transfected pCAG-GFP-Puror 
GFP-HESC-NL3 lines.  FACS analyses 
of stem cell markers (D) Tra-1-60 
95,5% pos (E) GCTM2 91.5% pos. (F) 
SSEA4 76.2% pos. Immunostaining 
shows expression of GFP and 
specifi c lineage markers in red 
(G) b-MHC staining on dissociated 
cells (mesoderm) , (H) b	III tubulin 
(ectoderm), (I) alpha-fetoprotein 
(endoderm), (J) control siRNA and 
(K) SOX2 siRNA knockdown stained 
for SOX2 (red), and DNA (blue). (L) 
Karyogram of GFP-HESC-NL3 showing 
a normal diploid karyotype after 
transfection and clonal growth. (M-
P) Validation of an OCT4-GFP reporter 
line, (M) GFP epifl uorescence, (N) 
endogenous OCT4 staining using 
antibodies, (O) DAPI staining, (P) 
overlay. Scale bars, 50 μm.
Figure 2.3
















(Figure 2.3M-P). Karyotype analysis showed 47, XY, t(21;21), +12 and normal 46,XY cells 
in the culture indicating that the targeted cell was normal but a subset of daughter cells 
had undergone chromosomal changes during culture upscale. Karyotypic abnormalities have, 
however, been reported previously in this particular line14. 
Although recently other groups have shown the feasibility of transfecting hESC3,8, rapid adaption 
to Matrigel monolayer cultures, combined with low cell densities described here, resulted in 
transfection efficiencies far higher and more consistent than conventional methods. Twelve 
independently derived hESC lines cultured under completely different conditions behaved 
very similarly, demonstrating that in contrast to previous reports this method is robust and 
widely applicable for multiple purposes to a variety of cell lines. 
supplemental data
Supplemental Data contains 5 Supplemental Figures, Supplemental Methods and Supplemental 
references which can be found on-line at http://www.nature.com/nmeth/journal/v5/n5/full/
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Feeder-free culture of 
human embryonic stem 
cells in conditioned 
medium for efficient 
genetic modification
 
Stefan R. Braam1,3,4, Chris Denning2,4, Elena Matsa2, Lorraine E. Young2,  
Robert Passier1,3,  Christine L. Mummery1,3 
Realizing the potential of human embryonic 
stem cells (hESC) in research and commercial 
applications requires generic protocols for 
culture, expansion and genetic modification 
that function between multiple lines. Here 
we describe a feeder-free hESC culture 
protocol that was tested in 13 independent 
hESC lines derived in 5 different laboratories. 
The procedure is based on Matrigel 
adaptation in mouse embryonic fiboblast 
conditioned medium followed by monolayer 
culture of hESC. When combined, these 
techniques provide a robust hESC culture 
platform, suitable for high efficiency genetic 
modification via plasmid transfection 
(using lipofection or electroporation), siRNA 
knockdown and viral transduction. In 
contrast to other available protocols, it does 
not require optimization for individual lines. 
hESC transiently expressing ectopic genes are 
obtained within 9 days and stable transgenic 




hESC hold great promise as models for human development and disease, as well as for drug 
discovery and cell replacement therapies. Progress towards these goals has been impeded 
by technical issues, exemplified by the lack of generic strategies to culture multiple hESC 
lines in a format that is permissive to high efficiency genetic manipulation. Most protocols 
are optimized on individual hESC lines and so do not readily translate effectively between 
independently-derived lines or between laboratories. It is not surprising that most optimiza-
tion is restricted to specific hESC lines given the labor intensiveness of maintaining multiple 
lines and the desire to select lines with greater propensity to differentiate towards particular 
lineages that are relevant to the research goals of the laboratory. For example, expression of 
the endodermal marker, alpha fetoprotein (AFP), was up to 3,000-fold higher in differenti-
ating HUES-8 cells than 16 other HUES lines derived, cultured and differentiated in parallel 
conditions by the same group1. 
Recently a variety of methods for genetic manipulation of hESC have been described including 
siRNA knockdown and transient- and stable over-expression. DNA delivery was often inef-
ficient and largely dependent on viral vectors (reviewed in 2).  To date only four labs have 
reported successful gene-targeting in hESC3-7. In general all of these methods have relied on 
the use of feeder cells to maintain the hESC in an undifferentiated state. Drug selection has 
consequently necessitated the use of either drug resistant feeders or re-supplementation of 
feeders during the procedure to compensate drug-induced feeder loss. Feeder-layers also 
limit the transfection efficiency8 and are a major source of variability, as illustrated by a recent 
study where a single plasmid transfection protocol applied to several independently-derived 
lines resulted in transfection efficiencies ranging from 3 to 35%9.
To develop highly efficient generic transfection in hESC, we tested protocols in 13 different 
lines (BG01, HES-2, ENVY, HUES-1, -5, -7, -15, HESC-NL1, -2, -3, -4, NOTT-1, -2). These lines 
were derived in 5 independent laboratories and grown under the most diverse conditions 
we had available: mechanical passage on MEFs in serum containing medium, mechanical 
passage on human feeders in KnockOut-serum replacement (K-SR) medium and enzymatic 
passage on mouse embryonic fibroblast (MEFs) in K-SR medium. hESC lines were temporarily 
transferred to feeder-free conditions at high density, where they adapted quickly in the ab-
sence of gross karyotypic changes (tested by G-banding for HUES-7, HESC-NL-1,-2 and NOTT-
1,-2). The expression of high levels of stem cell markers was reproducible in all lines8, making 
the cells particularly suitable for studying stemness and signal transduction. Furthermore 
we found hESC grown under these conditions particularly suitable for proteomics studies10. 
Replating hESC at lower densities resulted in a substantial increase in genetic modification 
efficiency, enabling efficiencies of up to 90% for chemical transfection and viral transduction 
and 50% for electroporation in all hESC lines tested. The culture conditions also supported 
clonal growth. Stably transfected cells could then be returned to their original growth condi-
tions, if required, where they retained their differentiation capacity8. 
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The protocols described here result in a robust, reproducible, simple and efficient platform 
for hESC culture that allows highly efficient transfection/transduction without altering self-re-
newal and pluripotency. The major difference from procedures described by others previously 
is the use of Matrigel in combination with feeder cell conditioned medium to culture the cells 
in a true monolayer rather than in tight colonies of multilayered cells. Although our protocol is 
not based on potentially clinically compliant, xenoreagent free growth media and substrates 
recently described by others11,12, for all non-therapeutic uses of hESC, requiring transient or 
sustained gene expression, the method will be extremely useful. Applications include genetic 
lineage marking using tissue specific promoter-reporter constructs to select subpopulations 
of (differentiated) cells, introduction of gene constructs for targeting and knock-in strate-
gies,  ectopic overexpression and siRNA mediated knockdown, including high throughput 
approaches using siRNA or gene expression libraries. The protocol is applicable to any research 
requiring high efficiency introduction of genes or gene constructs into hESC. 
Experimental design
dna construct and transfection
Vectors for use in hESC can be generated using either conventional restriction enzyme based 
plasmid cloning or recombineering13. If a source of genomic DNA is required in the cloning pro-
cess, bacterial artificial chromosome (BAC) DNA is recommended because of its high quality. 
Successful expression of the transgenic cassette is particularly dependent on the heterologous 
promoter and the use of the phosphoglycerate kinase (PGK) or CAG (chicken b-actin / CMV 
hybrid) promoter is recommended. However even with these promoters, locus dependent 
silencing can occur. This is likely related high level expression of de novo DNA methyltrans-
ferases in hESC, causing methylation of CpG islands and rendering the promoter inactive14. 
This problem can be partially resolved by using bicistronic cassettes that enable continu-
ous drug selection of the cells retaining transgene over expression. For example, we have 
successfully used the phosphoglycerate kinase-green fluorescent protein-internal ribosome 
entry site-neomycin phosphotransferase (pPGK-GFP-IRES-Neor) or pCAG-GFP-IRES-PAC (puro-
mycin-N-acetyltransferase) cassettes8,15, which allow selection by neomycin / G418 or puro-
mycin, respectively These expression cassettes also provide validated controls for performing 
transient and stable transfections / transductions. Alternatively, for vector based micro-RNA 
gene knockdown, we have successfully used the pcDNA6.2-GW/EmGFP-mIR from Invitrogen. 
Although GFP and the miRNA are both driven by a CMV promoter, this vector is suitable for 




HUES1, -5, -7, 15; supplied by Harvard University•	 16   
http://www.mcb.harvard.edu/melton/hues/
NOTT1 and NOTT2; derived by the University of Nottingham •	 17 and available from the UK 
stem cell bank http://www.ukstemcellbank.org.uk/catalogue.html
BG01; available from NSCB (National Stem Cell Bank) •	 18 
http://www.nationalstemcellbank.org
HES2•	 19, available from NSCB  http://www.nationalstemcellbank.org
Envy•	 20; contact ES Cell International http://www.escellinternational.com
HESC-NL LINES 1,-2,-3,-4 derived by the Hubrecht Institute, contact ES Cell Interna-•	
tional http://www.esellinternational.com
HEK293T available from ATCC (CRL-11268) •	 http://www.lgcpromochem-atcc.com/
Mouse embryonic fibroblast (strain CD1; 13.5 days post coitum, (for protocol see 21)•	





 (Invitrogen, Gibco, 14190) 
Opti-MEM I Reduced-Serum Medium  (Invitrogen, Gibco, 31985) •	
Genejammer (Stratagene, 204130)•	
Lipofectamine 2000 (Invitrogen, 11668-019)•	
AllStars Negative Control siRNA (20 nmol), Alexa488 conjugated (Qiagen, 1027292•	
Matrigel growth factor reduced (BD, 354230)•	
0.05% Trypsin-EDTA (Invitrogen, Gibco, 25300)•	
Geneticin (Invitrogen, Gibco, 11811)•	
Puromycin (Invivogen, ant-pr-1)•	
Plasmocin (Invivogen, ant-mpt)•	




KaryoMAX•	 ® Colcemid® Solution, liquid (10 μg/ml), in PBS (Invitrogen, Gibco 15212) Cau-
tion wear safety glasses and protective gloves
D-MEM/F-12 (1:1) (1X), liquid - with GlutaMAX™ (Invitrogen, Gibco, 31331)•	
KnockOut™ Serum Replacement (Invitrogen, Gibco, 10828) •	
Non-essential amino acids (Invitrogen, Gibco, 11140)•	
Penicillin/streptomycin  (Invitrogen, Gibco, 15070) •	
b•	 -mercaptoethanol (Invitrogen, Gibco, 31350-010) 
Basic fibroblast growth factor (bFGF; Peprotech, 100-18b) Critical: specific activity of •	
bFGF may vary among companies.
D-MEM (Invitrogen,Gibco, 11960) •	
Fetal calf serum (FCS; Sigma, F7524) •	
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Glutamine (Invitrogen, Gibco, 25030)•	
Hybrimax dimethylsulphoxide (DMSO; Sigma D2650) Caution: Keep away from sources •	
of ignition. Take measures to prevent the build up of electrostatic charge. Wear safety 
glasses and protective gloves
Mitomycin C (Sigma, M0503) Caution: Do not breathe dust. Do not get in eyes, on skin, •	
on clothing. Avoid prolonged or repeated exposure. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) or 
CEN (EU). Wear compatible chemical-resistant gloves and chemical safety goggles.
Methanol, (Sigma 322415) Caution: Avoid contact with skin and eyes. Avoid inhalation •	
of vapour or mist. Keep away from sources of ignition. Take measures to prevent the 
build up of electrostatic charge. Work in a chemical hood, wearing safety glasses and 
gloves
Glacial acetic acid, Sigma 695084 Caution Do not breath vapor. Do not get in eyes, on •	
skin, on clothing. Avoid prolonged or repeated exposure. Work in a fume hood wearing 
compatible chemical-resistant gloves and chemical safety goggles
Leishman’s stain, Sigma L6254•	





 Fisher P285-500 
Potassium-di-hydrogen-ortho-phosphate KH2HPO4 Fisher BP332-500 •	
equipment





IVF organ dishes (Falcon, 353037) •	
6 well culture plates (Greiner, 657160)•	
12 well culture plates (Greiner, 665120)•	
24 well culture plates (Greiner, 662160)•	
25 cm•	 2 tissue culture flask (Greiner, 690160) 
Cryo Ampoules (Greiner, 123263)•	
Electroporator (Gene pulser, Bio-Rad)•	
Electroporation cuvettes (Eurogentec ce-004-06)•	
Nalgene “Mr. Frosty” Freezing Container (Fisher Scientific, Cat: 15-350-50)•	
Amicon Ultra-15 Filter Unit (100NMWL from Millipore UCF910008)•	
reagent set-up
hESC medium:•	  D-MEM/F-12 (1:1) (1X), liquid - with GlutaMAX™, 15% (v/v) KnockOut™ 
Serum Replacement, 10mM non-essential amino acids, 0.1% (v/v) penicillin/strepto-
mycin, 100 μM b-mercaptoethanol, 4 ng ml-1 basic fibroblast growth factor. 
Medium for MEFs and HEK293T cells:•	  D-MEM, 10% (v/v) fetal calf serum, 0.5% (v/v) 
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penicillin/streptomycin, 1% (v/v) Glutamine, 10mM non-essential amino acids.
Freezing medium:•	  20% Hybrimax dimethylsulphoxide, 80% (v/v) FCS.
MMC treatment MEFs:•	  Confluent mouse embryonic fibroblasts (MEFs) are mitotically in-
activated for 2.5 hours with mitomycin C (10 μg ml-1 in MEF medium). Cells are washed 
with medium and then twice with PBS, trypsinized and seeded at 6.4 x 104 cells per 
cm2 in MEF medium. 
Karyotype fixative:•	  5 parts methanol : 1 part glacial acetic acid
Leishman’s Stain:•	  1.5 g Leishman’s stain added to 1 liter of methanol.  The stain is left 
to “mature” for several days at room temperature (18-20 oC) before use. To produce a 
working solution, dilute Leishman’s stain 1 in 5 with Sorenson’s buffer immediately 
prior to use. 
Sorenson’s buffer:•	  9.47g di-sodium-hydrogen-ortho-phosphate and 9.08g potassi-
um-di-hydrogen-ortho phosphate made up to one liter with deionised water.
Trypsin for G-banding:•	  1.2g of trypsin dissolved in 1 liter of Sorenson’s buffer for 20 
min. Decant solution into 20 ml aliquots and store at -20oC until use. 
Procedure 
 
MEF conditioning: day 1-8
Allow mitomycin C inactivated MEFs (see REAGENT SETUP) to attach for a minimum 1. 
of 4-hours, preferably 24-hours. Wash with PBS and replace medium for hESC 
medium. Use 25 ml for a T75 flask.
After 24 hours, harvest MEF conditioned medium (CM) and replace with fresh un-2. 
conditioned hESC medium. Add 4 ng ml-1 bFGF to the fresh CM. Harvest the CM for 
up to seven consecutive days. Filtration is not essential but helps to remove any 
dead fibroblast cells. CM can be used fresh or stored frozen at -20oC or -80oC for up 
to 6 months.
aliquotting MatrigEl: 15 Min.
Thaw one bottle of Matrigel overnight at 4 3. oC in at least 500 gram ice.
Transfer the bottle on ice to a tissue culture hood. 4. 
Pippette 500 μl Matrigel to each sterilized pre-chilled Eppendorf tube using pre-5. 
chilled pipettes. Critical step; Keep Matrigel on ice since it naturally polymerizes as 
the temperature rises above 4oC).
Freeze aliquots immediately at -206. oC or -80oC for up to 6 months.
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MatrigEl coating: 1-hour
Thaw and dilute one aliquot of Matrigel (0.5 ml) by repetitive pipetting in 50 ml of 7. 
cold DMEM/F12 (directly from the fridge). 
Pipette the diluted Matrigel immediately into culture vessels and allow to polym-8. 
erize for at least 45 min at room temperature. Note that the layer of polymerized 
Matrigel is only a few microns thick and should not be visible even under the mi-
croscope. Appearance of lumpy areas indicates premature polymerization. Use 0.5 
ml for 24-well plates, 1 ml for IVF organ culture and 12-well plate, 2ml for 6-well 
plates, 5 ml for T25 and 12 ml for T75.
Plates can be used immediately or stored at 49. oC. Before use, aspirate excess medium 
and un-polymerized Matrigel, and then rinse once with PBS. Critical step: Never let 
Matrigel dry out as this causes irreversible loss of extracellular matrix properties. 
PAUSE POINT: For storage wrap plates and dishes with Parafilm to prevent contamination and 
drying of the Matrigel. Use the plates within 4 weeks of preparation. 
transFEr oF hEsc to FEEdEr-FrEE culturE: day 2-7
Start with a high quality undifferentiated hESC culture (Figure 3.1A,B). Using a 10. 
glass needle, slice 10 colonies from one IVF organ dish (Figure 3.1C) release the 
cells by vigorously pipetting with a P1000 Gilson pipette and transfer them to two 
Matrigel coated IVF organ dishes containing 1ml CM (from step 2). At this stage dis-
pase may be used to release the cells from the feeders. In our experience dispase 
helps to release the cells but is not necessary if the cells are cultured for example 
on human foreskin fibroblast feeders.   
CRITICAL STEP: Steps 10-15 are specifically for cells maintained by mechanical ‘cut 
and paste’ passaging. For optimal maintenance of genetic stability, hESC cultures 
should in our experience be routinely maintained by mechanical passaging7,22 and 
scaled up for experimentation for up to 10 enzymatic passages under feeder-free 
conditions. For cells already adapted to enzymatic passage, go to step 12. 
Refresh CM daily for 4-5 days while cells are spreading and growing (Figure 3.1D,E) 11. 
until colonies start to touch each other. When confluent, remove 3D differentiated 
areas from the middle of a colony with a glass needle or P200 Gilson pipette (Fig-
ure 3.1F).
Wash remaining attached undifferentiated cells with PBS, add 200 μl trypsin and 12. 
incubate for 2-3 min at 37oC. Critical step; short incubation will not release cells, 




Photographs of hESC at different stages 
(A,B) Day 7 hESC colonies grown on 
MEFs, (C) Day 7 hESC colony sliced 
before dislodgement and transfer 
to Matrigel, (D) hESC grown on 
Matrigel in conditioned medium at 
day 1, (E) hESC grown on Matrigel 
in conditioned medium at day 2 
(F) hESC grown on Matrigel with 
the central area removed; these 
cultures are ready for trypsinization 
(G) hESC monolayer culture on 
Matrigel (H) GFP positive primary 
hESC colonies after Genejammer 
transfection with a GFP vector. 
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Add 1 ml of hESC medium and resuspend the cell suspension vigorously with a 13. 
P1000 pipet to release the cells. Collect the cells into a 15 ml centrifuge tube, add 
another 4 ml of hESC medium to dilute the trypsin and pellet the cell suspension 
(180 x g, room temperature, 4 min.). Critical Step; Trypsinization and resuspension 
should yield a cell-suspension of smaller and larger hESC clumps. 
Following centrifugation, resuspend the cells in 1ml CM and replate at very high 14. 
density (approximately 1-2.105 per cm2) i.e from two organ dishes to one Matrigel 
coated IVF organ dish. A small proportion of cells die during this first enzymatic 
passage.  
The next day refresh the medium for 1 ml fresh CM and carefully check morphology 15. 
off individual cells at 100-400x magnification, keep refreshing the medium daily 
until the cells form a confluent monolayer. Generally this takes 1-2 days. Conflu-
ent cells growing in a monolayer should be morphologically similar to individual 
cells in colonies (Figure 3.1G). Critical step; the medium may be very acidic (yel-
low). This is normal and does not influence the results. Troubleshooting
When confluent, wash cells with PBS and add 200 μl trypsin for exactly 1,5 min. 16. 
Dilute cells / trypsin in at least 5 ml of hESC medium and centrifuge immediately to 
remove the trypsin (180 x g, room temperature, 4 min.). Resuspend in 2ml CM and 
seed at appropriate split ratio; depending on cell line, split ratios are usually 1 in 
3 and should reach confluency after 48-72h. Some fast growing lines can be split 
occasionally in a 1 in 5 ratio. Critical step; cells split at low density which are cul-
tured for at least 72h might require slightly longer trypsin incubations. In general; 
using a 1 in 3 split max. 1,5 min trypsin should be enough to yield a cell suspen-
sion with some single cells and clumps of 3-10 cells. Troubleshooting
Scale culture up to T25 flasks without exceeding a 1 in 3-5 split ratio and with 17. 
daily replacement of CM. This culture method preserves genetic integrity for at least 
10-20 passages for the lines tested in longer-term culture (HUES7, NOTT-1, -2, 
HESC-NL-1, -2). hESC cultured in this system have been shown to be highly posi-
tive (>90%) for all stem cell markers tested (OCT4, SOX2, GCTM2, Tra-1-60, SSEA4)8. 
The culture is now ready for further manipulation or cryopreservation (as described 
in Box 1). Troubleshooting 
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Trypsinize a confluent T25 culture flask as described in step 16, resuspend in hESC 1. 
medium and pellet cells. 
Following centrifugation, resuspend the cell pellet in 750 μl of 100% FCS on ice. 2. 
Add 750 μl freezing medium, mix gently and divide between three ampoules (final 3. 
concentration of DMSO is 10%).
Immediately place ampoules in a Nalgene cryopreservation container containing 4. 
propan-2-ol. Transfer to -80oC and after 24 hours to liquid nitrogen for long-term 
storage.
The following options can be used to transfect/transduce the cultured hESC with 18. 
desired sequences to obtain stably transfected transgenic cells. Option A can be 
followed for si-RNA transfection, Option B for Genejammer plasmid transfection, 
option C for electroporation and option D for lentiviral transduction. Critical step; 
Some hESC clones will progressively silence stably transfected constructs even when 
an appropriate promoter is used. It is highly recommended to include a reporter 
construct (e.g. fluorescent protein or drug resistance marker) in the vector to allow 
visualization or continuous drug selection of transgene expression. 
a. si-RNA transfection (3 days)
 The day before transfection, trypsinize cells as described in step 16 and plate in  I. 
 CM at a density of 1-2 x 105 cells per well onto a Matrigel-coated 12-well plate.
 For each well to be transfected, prepare siRNA-Lipofectamine complexes as fol- II. 
 lows: Dilute 3 μl siRNA in 75 μl of Opti-MEM I medium and mix by flicking the  
 tube. Note: the stock siRNA solution should be made at 20μM, according to the  
 manufacturers’ instructions 
Mix Lipofectamine 2000 by inversion before use and then dilute 1,5 μl in 75 μl of  III. 
 Opti-MEM I Medium. Mix gently and incubate for 5 min. at room temperature. 
After the 5 min. incubation, combine the diluted siRNA with the diluted Lipo IV. 
 fectamine 2000; total volume is 154,5 μl. Mix gently and incubate for 20 min. at  
 room temperature to allow the siRNA:lipid complexes to form.  
 Critical step: It’s highly recommend to use a fluophore conjugated siRNA as control  
 to monitor transfection efficiency.
Aspirate medium from target cells and replace with 450 μl of CM. V. 
Add the 154,5 μl of siRNA:Lipofectamine complexes dropwise to each well.  VI. 
 This gives a final concentration of 100nM siRNA. Mix gently by rocking the plate  
 back and forth. 
Add 1.5 ml CM after 4 hours.VII. 
Incubate the cells at 37°C for 48 hours changing CM daily and analyze 1-5x10VIII. 4  
 cells by FACS23 or fluorescence microscopy24. › troublEshooting
box 1. cryopreserving cells: 30-min 
Protocol for genetic manipulation of hESC 35
b. genejammer plasmid transfection (3 days)
 The day before transfection, trypsinize cells as described in step 16 and plate cells  I. 
 in CM at a density of 1-2 x 105 cells per well onto a Matrigel-coated 12-well plate.
 For each transfection sample; prepare DNA-Genejammer complexes as followsII. 
Mix 5,25μl Genejammer to 75μl Opti-MEM •	
Incubate at room temperature for 10 min.•	
Add 1,75 μg target vector to the solution and mix gently, incubate at room •	
temp for a further 10 min. Critical step: It is highly recommended that a 
vector encoding a fluorescent protein (e.g. pPGK-GFP-IRES-Neo or pCAG-GFP-
IRES-PAC) be used as a control to monitor transfection efficiency
 Replace medium for 400 μl CMIII. 
 Add the 82 μl of DNA:Genejammer complexes drop wise to each well. This gives  IV. 
 a final concentration of 3.6ng μl-1 plasmid. Mix gently by rocking the plate back  
 and forth. 
 Add 1.5 ml CM after 4-hour V. 
 Incubate the cells at 37°C for 48 hours changing CM daily and analyze 1-5x10VI. 4  
 cells by FACS23 or fluorescence microscopy24.
 › troublEshooting
c. electroporation (2 days)
 Trypsinize a confluent T25 culture flask as described in step 16.I. 
 Following centrifugation (180 x g, room temperature, 4 min.) resuspend the cells  II. 
 in 800 μl CM containing 15-50 μg linearized DNA
 Transfer the cell/DNA mix to an 800μl / 4mm gap electroporation cuvettes and  III. 
 incubate for 5 min at room temperature
 Flick the cuvette to ensure a homogeneous cell suspension and electroporate at  IV. 
 320 Volts (V) / 240 micro Faradays (μF). Critical step: It is highly recommended that  
 a vector encoding a fluorescent protein (e.g. pPGK-GFP-IRES-Neo or pCAG-GFP- 
 IRES-PAC) be used as a control to monitor transfection efficiency.
 Incubate for 5 min at room temperate and resuspend the cells in at least 10-15 ml  V. 
 of CM. Critical step: If smaller numbers of cells are electroporated, resupend cells  
 in at least 5 ml CM to prevent cell death arising due to debris and DNA toxicity.
 Plate cells on 2-3 Matrigel-coated 60 mm dishes. This is largely dependent on  VI. 
 growth characteristics of a particular hESC line.
 Incubate the cells at 37°C for 48 hours changing CM daily and analyze 1-5x10VII. 4  
 cells by FACS23 or fluorescence microscopy24. 
d. hESC lentiviral transduction (6 days)
 To prepare lentiviral particles for hESC transduction, first seed a T175 culture flask  I. 
 with 5 x 106 HEK293T cells in 20 ml of medium and allow the cells to attach over- 
 night in the incubator. HEK293T cells are used as a packaging cell line for the pro- 
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 duction of a viral supernatant that contains infectious particles. 
 For each flask of HEK293T cells to be transfected, combine into 2ml of Opti-MEM  II. 
 I medium, 50μg of packaging plasmid (e.g. psPAX2), 20μg of envelope plasmid  
 (e.g. pMD2G) and 67μg transfer plasmid (e.g. GFP expressing plasmid such as  
 pWPI). Critical step: These plasmids will generate 2nd generation, replication deftive 
 lentiviral particles. Ensure the transfer plasmid to be used is second generation as  
 first and third generation systems will require different combinations of plasmid.
 To a separate tube, add 40III. μl of Lipofectamine 2000 to 2ml of Opti-MEM I medium  
 and mix gently. Incubate for 5 min. at room temperature.
 After the 5 min incubation, combine the diluted plasmid DNAs with the diluted  IV. 
 Lipofectamine 2000. Mix gently and incubate for 20 min. at room temperature to  
 allow the DNA:lipid complexes to form. 
 Aspirate medium from target HEK293T cells and replace with 16ml of  V. 
 Opti-MEM I medium. 
 Add the DNA:lipid complexes (~4ml) to each T175 flask. Mix gently by rocking the  VI. 
 plate back and forth and incubate for 4 hours.
 Aspirate the transfection medium and replace with 20ml HEK293T medium. VII. 
 Incubate for 48 hours, during which time lentiviral particles will be produced and  VIII. 
 released into the medium.
 Trypsinize hESC as described in step 16 and plate cells in CM at a density of 5 x  IX. 
 104 cells per well onto a Matrigel-coated 6-well plate. Allow the cells to attach for  
 4-6 hours in the incubator.
 To harvest lentiviral particles for the transduction of hESC, harvest the medium  X. 
 (20ml) from the HEK293T cells. This supernatant contains the replication defective  
 lentiviral particles.  
 Pass the lentiviral supernatant through a 0.2mm filter to eliminate any detached  XI. 
 HEK293T cells.
 Concentrate the virus by transferring to an Amicon Ultra-15 Filter Unit by centrifug XII. 
 ing at 4000 x g for 20 min. at room temperature. This will provide 200μl of con- 
 centrated viral supernatant. Critical step: for best results, use the virus fresh.  
 Storage at 4oC or  -80oC can reduce the number of active transducing units in  
 the superatant. 
 Aspirate medium from the hESC and replace with 4ml CM. Add increasing amounts  XIII. 
 of the concentrated virus (i.e. add no virus to well 1 of the 6-well plate of hESC,  
 1μl to well 2, 3.3μl to well 3, 10μl to well 4, 33μl to well 5 and 100μl to well 6).
 Incubate the cells at 37°C for 72 hours changing CM daily and analyze 1-5x10XIV. 4  
 cells by FACS23. First, plot FACS-based transduction efficency on the Y-axis of a  
 graph and volume of viral supernatant on the X-axis. Second, from a linear point  
 on the curve, read off the transduction efficiency and volume of viral supernatant.  
 Put these figures into the following equation:   
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For example, if 20ml of viral supernatant resulted in 50% transduction efficiency of 
5x104 cells, then:
sElEction oF stably transFEctEd cElls 
Apply selection 48 hours after electroporation, Genejammer transfection or viral 19. 
transduction while changing CM daily. By this stage the dish should be ~60-90% 
confluent. Critical step: If cells are too confluent, the action of the antibiotics will 
be delayed or ineffectual and death of untransfected cells will not be observed. 
The recommended final concentration for the antibiotic G418 is 50 μg ml-1 where-
as puromycin is 300 ng/ml-1. Critical step; the antibiotic may need to be titrated 
and optimized for different hESC lines.
Suspend antibiotic selection when approximately 50-80% of the cells are killed. 20. 
This slows the kill rate so that residual untransfected cells act as feeder cells to the 
stably transfected cells to reduce the stress of clonal growth. Critical step; when 
cells are growing extremely fast this step may not be necessary. However it greatly 
improves clonal growth especially with slower growing cells
Restart antibiotic selection after an additional 2 days, while changing CM daily. It 21. 
is advisable to maintain selection thereafter to eliminate cells that may silence the 
transgene.
After approximately 14 days individual colonies should be visible (Figure 3.1H).22.  
Troubleshooting
colony transFEr 
Let the colonies grow until they are approximately 400 μM in diameter or until 23. 
they start to touch each other. Using a P200 pipette or glass needle, slice colonies 
into a grid motif and transfer to 12- or 24-well plate.  RNA or DNA analyses can 
be performed directly on lysed colony fragments or later from the expanded cell 
No. of transducing particles / µl =
% transduction efficiency x starting hESC number
100 (converts percentage) x volume of viral supernatant
  50 x 5 x 104 
    100 x 20 
1250 / μl 
1.25x106 / ml




populations. Cells can be cultured further on Matrigel or feeders, as required. 
Check clones for their karyotype, as below, and differentiation potential24. 
 
KaryotypE procEdurE For g-band analysis
To hESC cultures in log phase growth, add Karyomax Colcemid to the medium at 25. 
a 1:100 dilution to give a concentration of 100ng/ml (50μl into 5ml). Incubate at 
37oC for 60 min.
Remove medium+karyomax+floating cells to a tube. Passage as in step 12, add 26. 
cells to the same tube as before and collect by centrifugation.
Aspirate and resuspend the pellet in 0.3ml hESC medium with a P1000 pipette. 27. 
Critical step: Pipetting ensures that a single cell suspension is produced to prevent 
clumping and to maximize swelling in the hypotonic solution.
Add 8ml of fresh hypotonic solution (0.6% sodium citrate in H28. 
2
O) dropwise whilst 
vortexing. Critical step: adding the hypotonic solution dropwise reduces the risk of 
osmotic shock.
Incubate cells for 20 min at room temperature to swell.29. 
Centrifuge the cell suspension at 300 x g for 5 min. Aspirate and resuspend in 30. 
0.3ml of hypotonic solution with a P1000 pipette. Critical step: Pipetting ensures 
that a single cell suspension is produced to prevent clumping in the fixative. 
Add 8ml karyotype fixative dropwise whilst vortexing. 31. 
Spin the cell suspension (300 x g, room temperature, 4 min.) and resuspend the 32. 
pellet in fixative. Then repeat this step twice more.
Centrifuge and resuspend the pellet in a 0.5-1ml of fix. 33. 
Drop cells from a height of ~30 cm onto polished slides to burst the cells and 34. 
spread the metaphase chromosomes. Incubate slides at 75oC overnight prior to 
G-banding.
Treat the slides with trypsin for 3 min. and then with diluted Leishman’s stain 35. 
(diluted 1 in 5 with Sorenson’s buffer immediately prior to use, as under Reagent 
Set up) for 2 min. Finally, rinse with water and air dry. 
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 36. Analyze 30 metaphase spreads per sample line to determine karyotype to greater 
than 95% confi dence limits. This highly specialized procedure is best performed by 
a clinical cytogenetics service division. 
timing 

























Flowchart for experimental procedures
(A) hESC grown on feeders are 
plated on Matrigel and grown 
for an additional 4-5 days. 
Differentiated three-dimensional 
structures are removed and 
hESC are trypsinized, replated 
in MEF-conditioned medium at 
high density by combining cells 
from two equivalent-size plates, 
grown for another 1–2 d and 
split several times to scale up 
to at least a T25 culture fl ask. 
These cells can now be used for 
(B) Immunofl uorescence/FACS, (C) 
stable transfection, (D) transient 








15,17 (a) Cells dying or 
differentiating
Cell density too low. Culture cells until they are confluent and fully 
compacted. hESC interact with Matrigel, which leads to cell spreading 
and loss of their typical morphology in colonies. High density cultures 
should have a similar morphology as hESC in colonies. Split cells 1:1 
or max 1:2 until they look healthy. At this point hESC may be split 
1:3 – 1:5 max.
Bad quality conditioned medium. In general when feeders are 
capable of supporting hESC they should be suitable for feeder 
conditioning
Mycoplasm infection. Check cultures regularly using a mycoalert kit 
(Cambrex LT07-118). If positive it is best to dispose of cultures as the 
infection can rapidly spread to other culture flasks. However, if they 
culture is very precious, it may be possible to cure the infection with 
plasmocin
Low specific activity of bFGF, It is recommended that new batches 
bFGF be compared side by side with the previous batch. If problem 
persists, increasing the bFGF concentrations to 10 ng/ml may help.
Differentiating cultures can sometimes be rescued by stepwise 
trypsinization. Compacted hESC colonies are usually more difficult 
to trypsinize compared with differentiated (mesenchyme-like) 
cells. Trypsinize cells under a stereomicroscope and wash away 
differentiated cells using PBS. Use fresh trypsin to release the 
undifferentiated cells and seed them on a new Matrigel coated dish. 
A 1:1 split is recommended at this stage.
A,B,C,D (b) low transfection 
efficiency
Check for Mycoplasm infection regularly using a mycoalert kit 
(Cambrex LT07-118). Treatment as indicated for steps 10-17.
Cell density too high. Lower cell densities gives generally much higher 
transfection efficiencies8. Lower the cell density.
B (c) transfection 
induced toxicity
Use pure plasmid DNA from either a midi-, or maxiprep. Endotoxin-
free plasmid purification kits (e.g. from Qiagen) may also be 
beneficial.
19-22 (d) No drug 
resistant colonies
Confirm that the expression vector works in another cell type, for 
example HEK293 or COS
19-21 (e) Cells not dying 
during drug 
selection
Increase drug concentration. It is recommended to titrate the 
antibiotic dose for each cell line and every new drug batch
Cell density at onset of drug treatment too high. Reduce to ~60% 
confluence in next experiment.
36 (f) Karyotypic 
abnormalities
If normal cells are present, single cell cloning can be considered. 
Otherwise restart the process, ensuring that the culture is 
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troubleshooting
Troubleshooting advice can be found in Table 3.1.
anticipated results
Starting with any high quality undifferentiated culture of hESC cells and following steps 1-17, 
hESC should yield a robust growing monolayer culture within two weeks. These cells should 
express high levels of hESC markers (e.g. OCT4, SOX2, NANOG, SSEA4, TRA1-81, GCTM2) and be 
amenable for genetic manipulation.  
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Human embryonic stem cells (hESC) are often 
co-cultured on monolayers of mitotically-
inactive fibroblast feeder cells to maintain 
their undifferentiated state. Under these 
growth conditions, hESC form multi-layered 
colonies of morphologically heterogeneous 
cells surrounded by flattened mesenchymal 
cells. In contrast, hESC grown in feeder cell-
conditioned medium and maintained on 
Matrigel instead of feeder cells tend to grow 
as monolayers with a uniform morphological 
phenotype. Using mass spectrometry and 
immunofluorescence microscopy, we show 
that hESC under these conditions primarily 
express proteins belonging to epithelium-
related cell-cell adhesion complexes, 
including adherens junctions, tight junctions, 
desmosomes and gap junctions. This indicates 
that monolayers of hESC cultured under 
feeder-free conditions retain a homogeneous 
epithelial phenotype similar to that of the 
upper central cell layer of colonies maintained 
on feeder cells. Notably, feeder-free hESC 
also coexpressed VIMENTIN, which is usually 
associated with mesenchyme, suggesting that 
these cells may have undergone epithelium-
to-mesenchyme transitions, indicating 
differentiation. However, if grown on a “soft” 
substrate (Hydrogel), intracellular VIMENTIN 
levels were substantially reduced. Moreover, 
when hESC were transferred back to feeder 
cells, expression of VIMENTIN was again 
absent from the epithelial cell population. 
These results imply that on tissue culture 
substrates, VIMENTIN expression is most likely 





Human embryonic stem cells (hESC) are derived from the inner cell mass (ICM) of blastocyst-
stage embryos and can self-renew indefinitely, as well as give rise to any adult cell type1-
3 Conventionally, hESC are grown as colonies on monolayers of mitotically inactive mouse 
embryonic fibroblast feeder cells (MEFs) in serum-containing medium. More recently, hESC 
have also been derived and maintained on human feeder cells and on feeder-free matrices 
in various growth factor-supplemented basal media4-8.
hESC on feeder cells have been described as multilayered colonies with, on their periphery, 
epithelium-like polarized cells that are connected by desmosomes9. In addition to ESC-
associated transcription factors, such as OCT4, SOX2, and NANOG, epithelial proteins have 
been reported to be expressed by hESC on feeder cells10-14. 
When transferred to feeder-free conditions, hESC were reported to grow initially as three-
dimensional colonies  composed of three distinct cell types15. At the core were ICM-like polygonal 
cells with large nuclei, relatively little cytosol, few desmosomes, and no gap junctions. On top 
was a single layer of polarized epithelium-like cells connected at their apical-lateral side by 
cell-cell adhesion complexes containing epithelial cadherin (E-cadherin) and gap junction 
protein a1 (connexin 43). At the periphery were mesenchyme-like cells with low nucleus-
to-cytosol ratios, lacking polarity, and only a few were connected by cell junctions. It was 
suggested that cells at the upper layer go through an epithelium-to-mesenchyme transition 
(EMT) and move to the periphery16. On the other hand, hESC cultured for longer periods in the 
absence of feeder cells tend to grow as monolayers5 coupled by functional gap junctions12.
In a mass spectrometry (MS)-based plasma membrane proteome analysis of hESC cultured 
as monolayers on Matrigel (BD Biosciences, San Diego, http://www.bdbiosciences.com) 
in MEF-conditioned medium, we identified 237 plasma membrane proteins17. In contrast 
to the heterogeneous multilayered hESC colonies on feeder cells, monolayers exhibited an 
exceptionally uniform morphology. Here we show that these feeder-free hESC express an 
epithelial plasma membrane protein profile. Cell surface localization of proteins associated 
with epithelial cell-cell adhesion complexes (adherens junctions, tight junctions, desmosomes, 
and gap junctions) identified by MS was confirmed by immunofluorescence microscopy. 
Expression of VIMENTIN in these cells resulted most likely from mechanical stress rather than 
an EMT, since growth on mechanically soft substrates reduced intracellular VIMENTIN to levels 
similar to that of the epithelial cell population at the top of hESC colonies cultured on MEFs.
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Materials and Methods
hESC culture
HUES-7 hESC3 were cultured on Matrix Growth Factor Reduced Matrigel (BD Biosciences, San 
Jose, CA, http://www.bdbiosciences.com) as described previously4, on a thick layer of Extracel-
HP Hydrogel (Glycosan BioSystems, Salt Lake City, http://www.glycosan.com) containing 10 
mg/ml fibronectin (Harbor Bioproducts, Norwood, MA), or on MEFs, such as HES-2 hESC2 as 
described previously13,18.
plasma membrane protein extraction and ms analysis
Extraction and MS analysis of plasma membrane proteins from HUES-7 cells was performed 
as described previously17.
immunofluorescence microscopy
Immunofluorescence microscopy was conducted as described previously13. Primary rabbit 
anti-SOX2 antibody (Chemicon, Temecula, CA, http://www.chemicon.com) at 1:400 was used 
in combination with mouse anti-human E-CADHERIN (clone HECD-1; Zymed Laboratories 
Inc., San Francisco, http://www.invitrogen.com), 1:200; mouse anti-OCCLUDIN (clone 
OC-3F10; Invitrogen, Carlsbad, CA), 1:200; mouse anti-DESMOPLAKIN (mixture of clones 
DP-2.15, DP-2.17, and DP-2.20; Progen Biotechnik, Heidelberg, Germany, http://www.
progen.de), undiluted; mouse anti-CONNEXIN 43 (clone 2; BD Transduction, BD Biosciences), 
1:200; or mouse anti-human VIMENTIN (clone V9; Sigma-Aldrich, St. Louis, http://www.
sigmaaldrich.com), 1:200. Secondary antibodies were Cy3-conjugated goat anti-rabbit 
(Jackson Immunoresearch Laboratories, West Grove, PA, http://www.jacksonimmuno.com) at 
1:200 and fluorescein isothiocyanate-conjugated goat anti-mouse (Jackson Immunoresearch 
Laboratories) at 1:200. Cells were imaged with confocal laser microscopes, types SP2 and SPE 
(Leica, Heerbrugg, Switzerland, http://www.leica.com). Maximal projections were made using 
the accompanying Leica software, and z-stacks were merged using Paint Shop Pro 9 (Corel, 
Fremont, CA, http://www.corel.com).
western blotting
Western blotting was conducted as described previously13, using rabbit anti-DPI/DPII (NW6) 
at 1:5,000, and mouse anti-human VIMENTIN (clone V9; Sigma-Aldrich) at 1:1,000 in 
combination with mouse anti-b-actin (clone AC-15; Sigma-Aldrich) at 1:5,000.
Results
Enzymatically-passaged hESC (line HUES-7) cultured on Matrigel in MEF-conditioned medium 
grow as monolayers19. MS analysis of these cells17 indicated that they express proteins 
associated with four cell-cell adhesion complexes that are characteristic of epithelial cells: 
(a) adherens junctions, (b) tight junctions, (c) desmosomes, and (d) gap junctions (Table 1). 
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Figure 4.1
z-Stacks showing the plasma 
membrane localization of protein 
components belonging to cell-cell 
adhesion complexes that connect 
adjacent epithelium-like HUES-
7 human embryonic stem cells 
(hESC), which grow as monolayers 
under feeder-free conditions. 
Undifferentiated hESC expressing 
SOX2 ((A-D), shown in red) were 
also positive for the adherens 
junction protein E-CADHERIN 
((A), shown in green), the tight 
junction protein OCCLUDIN ((B), 
shown in green), the desmosomal 
protein DESMOPLAKIN ((C), shown 
in green), and gap junction 
protein CONNEXIN 43 ((D), shown 
in green). Western blot shows that 
both desmoplakin I and II were 
expressed by HUES-7 hESC grown 
on Matrigel (E). Scale bars = 50 
μm (A-D). 
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To confi rm plasma membrane localization of these proteins, we used antibodies specifi cally 
recognizing single proteins of each of the different adhesion complexes. E-CADHERIN 
(Figure 4.1A) is present in adherens junctions20,21, OCCLUDIN (Figure 4.1B) is specifi c for tight 
junctions20,22, DESMOPLAKIN (Figure 4.1C) is located in desmosomes23, and CONNEXIN 43 (Figure 
4.1C) is one of the 18 gap junction proteins24,25 that were detected in hESC10,12. Concomitant 
staining of SOX2 indicated that hESC positive for these plasma membrane-associated proteins 
were undifferentiated (Figure 4.1). Both DESMOPLAKIN I and II are expressed by hESC (Figure 
4.1E). Immunostaining of HUES-7 colonies grown for 1 week on MEFs showed that these cells 
retain their epithelial characteristics (Figure 4.2A-D). Lower staining of cells at the periphery 
Maximal projections showing the 
expression and distribution of 
proteins associated with cell-cell 
adhesion complexes in HUES-7 
human embryonic stem cell (hESC) 
colonies cultured for 1 week on 
mouse embryonic fi broblast feeder 
cells (MEFs). All cells in HUES-7 
hESC colonies were positive for 
SOX2 ((A-D), shown in red). 
E-cadherin ((A), shown in green), 
OCCLUDIN ((B), shown in green), 
and CONNEXIN 43 ((D), shown in 
green) showed the highest levels 
on the plasma membranes of cells 
located in the center. Desmoplakin 
was expressed in hESC, as well as 
MEFs ((C), shown in green). Scale 
bars = 100 μm (A-D).
Figure 4.2






Differential expression of VIMENTIN 
in HUES-7 and HES-2 human 
embryonic stem cell (hESC) 
colonies and in HUES-7 hESC 
grown on rigid or soft substrates. 
All HUES-7 and HES-2 hESC grown 
as colonies on mouse embryonic 
fi broblast feeder cells and HUES-
7 hESC grown on Matrigel or 
fi bronectin-containing Hydrogel 
expressed SOX2 ((A-D), shown 
in red). VIMENTIN was almost 
exclusively expressed in cells at 
the periphery of the hESC colonies 
((A, B), shown in green). Feeder-
free HUES-7 hESC grown on a thin 
layer of rigid Matrigel expressed 
higher levels of VIMENTIN ((C), 
shown in green) than those on 
a thick layer of soft, fl exible 
Hydrogel that was supplemented 
with fi bronectin ((D), shown 
in green). These differences 
in VIMENTIN expression were 
confi rmed by Western blot (E). 
Scale bars = 100 μm (A, B) and 
50 μm (C, D).
Figure 4.3
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of colonies supported the suggestion that these cells had undergone an EMT16.
VIMENTIN was almost completely absent from the epithelial-like cells but was highly expressed 
in peripherally located cells (Figure 4.3A). A similar distribution of VIMENTIN was observed for 
HES-2 hESC colonies maintained on MEFs for 58 passages (Figure 4.3B). Remarkably, all hESC 
cultured on Matrigel also express VIMENTIN (Figure 4.3C). However, substantially less VIMENTIN 
was found when they were grown on soft Hydrogel (Figure 4.3D,E). This implied that VIMENTIN 
expression in hESC maintained as monolayers under feeder-free conditions is the result of 
mechanical stress rather than an EMT associated with differentiation.
Discussion
Transfer of multilayered hESC colonies from feeder cells to feeder-free conditions has been 
described as enhancing differentiation through an EMT16. However, our results indicate 
that hESC grown in the absence of feeder cells in fact retain their epithelial character, even 
though they express VIMENTIN. MS-based proteomics and immunofluorescence microscopic 
verification showed that feeder-free monolayers of hESC have a highly uniform morphology 
and express an epithelial plasma membrane protein profile. After nine passages (3 weeks) 
under feeder-free conditions, these cells collectively retained expression of SOX2 in addition 
to components of epithelium-associated cell-cell adhesion complexes. They thus resemble 
the central top layer of hESC colonies cultured on feeder cells9,16.
Like cells located at the periphery of hESC colonies cultured on feeder cells (as described 
here for lines HUES-7 and HES-2, and previously for VUB0116, feeder-free hESC also express 
VIMENTIN, which could indicate that they had undergone an EMT16. However, VIMENTIN is 
not specific for mesenchymal cells but is also found in migrating epithelial cells26 and cells 
experiencing mechanical stress27. Since VIMENTIN levels were substantially reduced when 
feeder-free hESC were maintained on Hydrogel, it is more likely that VIMENTIN expression 
results from growth on a rigid substrate rather than the initiation of differentiation due to the 
absence of feeder cells.
Conclusion
Combined, our MS data and complementary immunofluorescence evidence show that hESC 
grown for extensive periods without feeder cells uniformly exhibit an epithelial phenotype. 
This suggests that direct contact and communication with adjacent cells via cell-cell adhesion 
complexes is vital, as evidenced by their poor clonal survival. Furthermore, since VIMENTIN 
is essential for cell integrity, its abundant expression in feeder-free hESC might explain why 
these cells are relatively easy to handle and less delicate than hESC in colonies4.
Chapter 452
acknowledgements
We thank Dr. D.A. Melton for HUES-7 hESC, Dr. M.F. Pera and ES Cell International Pte. Ltd. 
for HES-2 hESC, Dr. A.L. Servin for anti-occludin, Dr. W.K. Peitsch for anti-desmoplakin 
(mixture of clones DP-2.15, DP-2.17 and DP-2.20), Dr. M.A.G. Van der Heyden for anti-
connexin 43, and Dr. K.J. Green for anti-desmoplakin (NW6). Dr. K. Parker is thanked for 
inspiring discussions on substrate induced cell stress. This work was financially supported 
by the Netherlands Proteomics Centre Bsik program (to D.V.H., W.D., A.J.R.H., J.K., and 
C.L.M.), the Bsik Dutch Platform for Tissue Engineering (to D.V.H. and S.R.B.), and the 
Bsik Stem Cells in Development and Disease (to D.V.H.). D.V.H. is currently affiliated 
with the Diabetes Center, University of California San Francisco, San Francisco, CA. 
 
References
Thomson, J.A., et al. Embryonic stem cell lines 1. 
derived from human blastocysts. Science 282, 
1145-1147 (1998).
Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, 2. 
A. & Bongso, A. Embryonic stem cell lines from 
human blastocysts: somatic differentiation in 
vitro. Nat Biotechnol 18, 399-404 (2000).
Cowan, C.A., et al. Derivation of embryonic 3. 
stem-cell lines from human blastocysts. N Engl J 
Med 350, 1353-1356 (2004).
Braam, S.R., et al. Improved genetic 4. 
manipulation of human embryonic stem cells. 
Nat Methods 5, 389-392 (2008).
Klimanskaya, I., et al. Human embryonic stem 5. 
cells derived without feeder cells. Lancet 365, 
1636-1641 (2005).
Ludwig, T.E., et al. Derivation of human 6. 
embryonic stem cells in defined conditions. Nat 
Biotech 24, 185-187 (2006).
Crook, J., et al. The Generation of Six Clinical-7. 
Grade Human Embryonic Stem Cell Lines. Cell 
Stem Cell 1, 490-494 (2007).
Rao, B.M. & Zandstra, P.W. Culture development 8. 
for human embryonic stem cell propagation: 
molecular aspects and challenges. Curr Opin 
Biotechnol 16, 568-576 (2005).
Sathananthan, H., Pera, M. & Trounson, A. The 9. 
fine structure of human embryonic stem cells. 
Reprod Biomed Online 4, 56-61 (2002).
Ginis, I., et al. Differences between human 10. 
and mouse embryonic stem cells. Dev Biol 269, 
360-380 (2004).
Raymond, C.B.W., Alice, P., Linh, T.V.N., Karen, 11. 
L.L.K. & Martin, F.P. Presence of Functional Gap 
Junctions in Human Embryonic Stem Cells. Stem 
Cells 22, 883-889 (2004).
Huettner, J.E., et al. Gap junctions and 12. 
connexon hemichannels in human embryonic 
stem cells. Stem Cells 24, 1654-1667 (2006).
Van Hoof, D., et al. A quest for human and 13. 
mouse embryonic stem cell-specific proteins. 
Mol Cell Proteomics 5, 1261-1273 (2006).
Baharvand, H., Hajheidari, M., Ashtiani, S.K. & 14. 
Salekdeh, G.H. Proteomic signature of human 
embryonic stem cells. Proteomics 6, 3544-3549 
(2006).
Carpenter, M.K., et al. Properties of four 15. 
human embryonic stem cell lines maintained 
in a feeder-free culture system. Dev Dyn 229, 
243-258 (2004).
Ullmann, U., et al. Epithelial-mesenchymal 16. 
transition process in human embryonic stem 
cells cultured in feeder-free conditions. Mol 
Hum Reprod 13, 21-32 (2007).
Dormeyer, W., et al. Plasma Membrane 17. 
Proteomics of Human Embryonic Stem Cells and 
hESC express an epithelial protein profile 53
Human Embryonal Carcinoma Cells. J Proteome 
Res 7, 2936-51 (2008).
Mummery, C., et al. Differentiation of human 18. 
embryonic stem cells to cardiomyocytes: role 
of coculture with visceral endoderm-like cells. 
Circulation 107, 2733-2740 (2003).
Denning, C., et al. Common culture conditions 19. 
for maintenance and cardiomyocyte 
differentiation of the human embryonic stem 
cell lines, BG01 and HUES-7. Int J Dev Biol 50, 
27-37 (2006).
Hartsock, A. & Nelson, W.J. Adherens and tight 20. 
junctions: structure, function and connections 
to the actin cytoskeleton. Biochim Biophys Acta 
1778, 660-669 (2008).
Pokutta, S. & Weis, W.I. Structure and 21. 
mechanism of cadherins and catenins in 
cell-cell contacts. Annu Rev Cell Dev Biol 23, 
237-261 (2007).
Schneeberger, E.E. & Lynch, R.D. The tight 22. 
junction: a multifunctional complex. Am J 
Physiol Cell Physiol 286, C1213-1228 (2004).
Stokes, D.L. Desmosomes from a structural 23. 
perspective. Curr Opin Cell Biol 19, 565-571 
(2007).
Giepmans, B.N. Gap junctions and connexin-24. 
interacting proteins. Cardiovasc Res 62, 
233-245 (2004).
Willecke, K., et al. Structural and functional 25. 
diversity of connexin genes in the mouse and 
human genome. Biol Chem 383, 725-737 
(2002).
Gilles, C., et al. Vimentin contributes to human 26. 
mammary epithelial cell migration. J Cell Sci 112 
( Pt 24), 4615-4625 (1999).
Goldman, R.D., Khuon, S., Chou, Y.H., Opal, P. 27. 
& Steinert, P.M. The function of intermediate 
filaments in cell shape and cytoskeletal 




vitronectin is a 
functionally  
defined substrate
Modified after Stem Cells 2008 Sep;26(9):2257-65
1 Hubrecht Institute, Developmental Biology and Stem Cell Research, Utrecht, The Netherlands
2  Netherlands Cancer Institute, Division of Cell Biology, Amsterdam, The Netherlands
3  University Medical Centre Utrecht, Heart and Lung Division, The Netherlands
4  University Medical Centre Utrecht, Department of Biomedical Genetics, The Netherlands
5  Leiden University Medical Centre, Dept Anatomy and Embryology, Leiden, The Netherlands 
that supports hESC self renewal via aVb5 integrin
Stefan R. Braam1,5, Laura M. Zeinstra1, Sandy H.M. Litjens1, Dorien Ward-van Oostwaard1,5, 
Stieneke van den Brink1, Linda W. van Laake1,3, Franck Lebrin1, Peter Kats4, Ron 
Hochstenbach4, Robert Passier1,5, Arnoud Sonnenberg2, Christine L. Mummery1,3,5
Integrins and hESC 55
Defined growth conditions are essential for 
many applications of human embryonic 
stem cells (hESC). Most defined media 
are presently used in combination with 
Matrigel™, a partially defined extracellular 
matrix (ECM) extract from mouse sarcoma. 
Here, we defined ECM requirements of hESC 
by analyzing integrin expression and ECM 
production and determined integrin function 
using blocking antibodies. hESC expressed 
all major ECM proteins and corresponding 
integrins. We then systematically replaced 
Matrigel™ by defined media supplements 
and ECM proteins. Cells attached efficiently to 
natural human vitronectin, fibronectin and 
Matrigel™ but poorly to laminin+entactin 
and collagen IV. Integrin blocking antibodies 
demonstrated that aVb5 integrins mediated 
adhesion to vitronectin, a5b1 to fibronectin 
and a6b1 to laminin+entactin. Fibronectin 
in feeder cell-conditioned medium partially 
supported growth on all natural matrices 
but in defined, non-conditioned medium 
only Matrigel™ or (natural and recombinant) 
vitronectin were effective. Recombinant 
vitronectin was the only defined functional 
alternative to Matrigel™, supporting 
sustained self-renewal and pluripotency in 




Human embryonic stem cells (hESC) are self-renewing, pluripotent cells with expected 
clinical applications in cell therapy, tissue repair and drug development because of their 
ability to differentiate to all cell types present in the adult body. Since the first derivation 
of hESC1, many lines have been generated under a wide variety of culture conditions. Most 
have included mouse or human feeder cells to inhibit differentiation2 but also to maintain 
karyotypic stability3,4. In addition, many studies have shown a consistent requirement for 
FGF2, either secreted by the feeders or added as recombinant protein5,6
Attempts to replace feeder cells have shown that hESC can be maintained on Matrigel™ 7, 
a laminin-111-rich, mouse sarcoma-derived commercial product also containing collagen 
IV, entactin, heparin sulfate proteoglycan and multiple other components including growth 
factors, but no vitronectin. More recently defined culture conditions that use a matrix of 
natural human collagen IV, fibronectin, laminin and vitronectin have been described8 but 
whether a specific matrix integrin interaction is essential is unclear. In addition, protein 
products from natural sources tend to show batch-to-batch variability. In a recent comparison 
of several commercial human laminin preparations, for example, both compositional and 
functional differences were found between batches, with highly fragmented proteins, 
mixtures of isoforms and/or contaminating fibronectin detected in variable amounts9. This 
is an important concern in attempts to understand the role of matrix-integrin interactions 
in pluripotency and self renewal. Therefore we aimed to establish culture conditions based 
entirely on recombinant / synthetic substrates. 
Integrins are the cell surface receptors that mediate cell-ECM adhesion and signaling10. 
Previously, a number of integrins were detected in hESC by RT-PCR. Among them were a6 
and b1 which mediate binding to matrigel™ 7. Integrins are heterodimeric transmembrane 
molecules with large extracellular domains and relatively small cytoplasmic domains 
formed by a and b subunits that can switch between inactive and active conformations. 
In the inactive state, integrins have a low affinity for ECM proteins. Intracellular signaling 
can prime the integrins, resulting in conformational changes that expose the ligand-binding 
site. Ligand binding activates signaling cascades that lead to the assembly of multiprotein 
focal adhesion signaling complexes at the site of cell adhesion to the ECM. This causes cells 
to assemble connections between the ECM and the actin cytoskeleton and induces many 
intracellular signaling pathways. The pathways that are activated depend on the particular 
ECM ligand-receptor interaction; they may give rise to cytoskeletal changes that result in 
different migratory behaviour or to changes in growth and/or differentiation10.
In nearly all cell types, integrin binding activates focal adhesion kinase (FAK)11. FAK disseminates 
integrin signals by forming complexes with signaling proteins that have numerous effects on 
cell function like proliferation, differentiation and apoptosis12. 
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While functional integrin-ECM interaction is clearly crucial for derivation, self renewal and 
maintenance of pluripotency by hESC, the ECM constituents and their role in signaling have 
not been systematically investigated. Here we have determined integrin and ECM protein 
expression profiles in three independently derived hESC lines (HES2, HUES1 and HESC-NL3), 
with a history of maintenance and culture under widely differing conditions. Functional 
analyses using integrin blocking antibodies showed that aVb5 integrins were responsible for 
adhesion to vitronectin, a5b1 to fibronectin and a6b1 to laminin+entactin in all three cell 
lines. Attachment of cells to recombinant vitronectin through aVb5 was demonstrated to be 
sufficient to support proliferation and self-renewal in chemically defined (mTeSR1) medium. 
Stem cell marker expression and pluripotency in vitro was retained over multiple passages 
without loss of karyotypic stability. Recombinant vitronectin matrix therefore represents a 
defined functional alternative for Matrigel™ in a chemically defined medium. 
Material & Methods
cell culture and matrices
HUES1 are routinely cultured13 on CD1 mouse embryonic fibroblast feeders (MEFs) (kind gift of Dr. 
C. Denning) in KO-DMEM (Invitrogen) containing 10% Plasmanate and 10% Knock Out-serum 
replacement (KSR) (Invitrogen), HES214 on 129SV MEFs as described previously 15 and HESC-NL3 
on human foreskin fibroblast feeders in Knockout DMEM/ KSR supplemented with bFGF16.
Furthermore HUES1 cells were cultured feeder-free as a monolayer on Matrix Growth Factor 
Reduced Matrigel (BD Biosciences) in MEF conditioned medium.  Trypsin/EDTA (Invitrogen) was 
used to release the cells which were then dissociated to a suspension of single cells and small 
clumps17,18. For the preparation of conditioned medium (CM), MEFs (mouse strain CD1) were 
mitotically inactivated by mitomycin C (MMC) (10 μg/ml, 2.5-3 hours) and seeded at 4,6 x 106 
cells per 75 cm2 flask. The next day, MEFs were incubated with 25 ml of hESC medium (Glutamax 
based DMEM-F12 supplemented with 15% KSR, 100 μM b-mercaptoethanol, 1% non-essential 
amino acids (all from Invitrogen) and 4ng/ml basic fibroblast growth factor (Peprotech). CM was 
harvested after 24 hours and supplemented with 4ng/ml bFGF. This procedure was repeated for 
7 consecutive days by replacing CM on MEFs with fresh hESC medium. 
The ECM protein concentrations for coating culture plates were determined in dose response 
curves (Figure 5.2A). ECM concentrations used for integrin blocking assays were: 10 ng/μl 
collagen IV (isolated from human placenta; Chemicon), 40 ng/μl fibronectin (isolated from 
human plasma; Harbor Bio-products, Norwood, MA), 10 ng/μl vitronectin (isolated from 
human plasma; Chemicon), 50 ng/μl laminin (laminin-111), 50 ng/μl mLaminin+entactin and 
Matrigel™ (84 ng/ul)  (all isolated from Engelbreth-Holm-Swarm mouse tumor; BD Biosciences). 
Throughout the manuscript the new nomenclature for laminins is used, i.e. indicating the three 
chains of each isoform 19.
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For feeder-free defined cultures all three lines were cultured in mTeSR1 (Stem Cell technologies) 
on recombinant vitronectin (5ng/μl) (R&D systems). Cells were grown in colonies as shown 
in Figure 5.4C-E. Once weekly, the colonies were dissected using glass needles into small 
pieces of 50-80 μM and transferred manually to new dishes without enzymes20. A minority 
of colonies contained some differentiated cells at the centre; these areas were omitted from 
transfer. Directed differentiations to meso- endo- and ectoderm were performed as described 
previously21.
facs analysis
hESC cells were trypsinized, and stained with specific integrin antibodies (supplementary 
data) and FITC-conjugated secondary antibody. Cells were analyzed on a FACSCalibur or a 
FACSCanto (BD Biosciences).
immunofluorecent staining
Cells on plastic coverslips (Sarstedt Inc, Newton, NC) were fixed with 2% paraformaldehyde and 
permeabilized with 0.5% Triton X-100. Cells were stained using specific primary antibodies 
(supplementary data) and fluorophore conjugated secondary antibodies; when applicable 
cells were co-stained with phalloidin-TRITC (Sigma). Nuclei were stained with TOPRO-3 
(Invitrogen) or DAPI. Cells were mounted using Mowiol or using Vectashield hard set with Dapi 
(Vectalabs). Plastic coverslips were immobilized on glass microscope slides and sandwiched 
with glass coverslips. Pictures were taken using Laser Confocal Scanning Microscopes TCS-SP2 
and TCS-SPE (Leica, Mannheim, Germany).
adhesion assay
Adhesion assays were essentially performed as described previously22. In brief, hESC were 
trypsinized, counted and incubated for 30 min. at 37oC in the presence or absence of integrin 
blocking antibodies in IMDM (Invitrogen) containing 0.35% bovine serum albumin (BSA). 
Purified antibodies were tested at 1 and 10 μg/ml concentrations and hybridoma supernatants 
at 1/5 and 1/50 dilutions. Dilutions appropriate for blocking were used in all subsequent 
assays.
They were subsequently seeded into 96-well flat-bottom plates, which were previously 
coated with various matrix components and blocked with 2% BSA, at 50,000-100,000 cells/
well, depending on the substrate. They were left to adhere for 30 min at 37oC. The non-
adherent cells were carefully washed away with IMDM/0.35% BSA three times, and finally 
once with PBS. The adherent cells were fixed with 100% ethanol for 5 min at RT and stained 
with 0.4% crystal violet in methanol for 5 min at RT. The wells were washed extensively 
with demi-water. The cells were solubilized by adding 40 μl 1% SDS and cell adhesion was 
determined by measuring OD
570
. Results are expressed as relative adhesion normalized to one. 
Blank controls were without cells but otherwise treated identically to controls
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integrin blocking assays
HUES1 from Matrigel™ were trypsinized and replated on the indicated matrix in the presence 
or absence of integrin blocking antibodies. For aVb5 antibody (Chemicon) a concentration of 
2 μg/ml was used, for AIIb2 (anti-b1 integrin) the supernatant was diluted 50 times. The cells 
were allowed to grow in MEF-CM for 4 days and the medium containing the antibodies was 
refreshed every day. Coverslips were stained for Tra-1-60, human nuclei and fibronectin or 
Tra-1-60, phalloidin and OCT4 as described above
cell expansion assays
HUES1 from Matrigel™ were trypsinized and replated on the indicated matrix. 4 hours 
later GoH3 1 μg/ml and / or Alpha5 blocking antibody (Chemicon) 1 μg/ml was added. Cell 
proliferation was assayed using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega) at 24, 48, 72 and 96h post plating. MEF-CM was refreshed daily. As required, 
integrin blocking antibodies were added freshly, daily.
karyotype analyses
hESC cultured on recombinant vitronectin in mTeSR1 were treated with 100 ng/ml colcemid 
(Karyomax) for 1 hr. hESC colonies were dissociated using TrypLE (Invitrogen). After hypotonic 
solution treatment (0,6 % citrate buffer), lysed cells were fixed in methanol/glacial acetic acid 
(5:1). G banding was performed for identification of chromosomes, 30 metaphase spreads 
were examined; full analysis involving band-by-band comparison between chromosome 
homologues was performed on 10 spreads, and the presence of gross abnormalities was 
visually examined in the remaining spreads.
Results
extracellular matrix expression in hESC cultures
Understanding the composition of ECM components in hESC cultures on feeder layers may 
provide clues on which substrates favor sustained undifferentiated proliferation of hESC. 
MEFs are most commonly used and produce a complex matrix of many structural ECM 
proteins including laminins, various collagens and fibronectin23. Detail is lacking on the 
exact composition of feeder derived matrix components making it difficult to predict which 
components are essential versus those that are redundant. In addition the exact interaction 
between hESC and feeder-derived ECM has not been investigated in detail. Therefore we first 
immuno-stained ECM proteins in three hESC lines that have all been derived and cultured 
under completely different culture conditions. HUES113, is cultured on MEFs in plasmanate/
KO-SR containing medium and passaged by trypsinization. HES214 is cultured on MEFs in 
FCS-containing medium and passaged mechanically using dispase. HESC-NL3 was derived in 
our lab on human foreskin feeders (HF), and is cultured in serum replacement medium and 
passaged mechanically without the use of enzymes. 
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Figure 5.1
Extracellular matrix and integrin protein expression in hESC cultures
HUES1, HES2 and HESC-NL3 stained 
for the ECM components fi bronectin, 
laminin-a1, collagenI and 
collagenIV. (A,E,I) polyclonal anti-
fi bronectin antibody recognizing 
both mouse and human fi bronectin 
is shown in green, human 
fi bronectin (mAb) is shown in red. 
(B,F,J) polyclonal anti laminin-a1 
recognizing both mouse and human 
is shown in green, with OCT4 shown 
in red. (C,G,K) polyclonal anti-
collagenI recognizing both mouse 
and human is shown in green, 
with OCT4 shown in red. (D,H,I) 
CollagenIV is shown in green, with 
human nuclei in red. In all pictures 
nuclei are counterstained in blue 
with TO-PRO (M) FACS analysis for 
the majority of integrin chains on 
the three hESC lines. All integrins 
tested were expressed at essentially 
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These diverse hESC lines were selected to address the question whether culture conditions 
themselves caused hESC to adapt with respect to their molecular mechanisms for cell-cell or 
cell substrate interactions.
As shown in Figure 5.1A, E and I large quantities of fibronectin were present in all three 
cultures under native conditions. There is abundant staining of fibronectin in the feeder 
areas, which is not recognized by the antibody specific for human fibronectin, and therefore 
appears to be of mouse origin. (Figure 5.1E and not shown). However, human fibronectin was 
found at the edges and at the center of the hESC colonies (Figure 5.1E and not shown). These 
are the areas that usually contain mostly differentiated hESC. It is most likely, therefore, that 
fibronectin is mainly secreted and assembled into bundles by the feeders and differentiated 
hESC, although we cannot exclude secretion by undifferentiated hESC. Importantly the human 
specific fibronectin antibody stained the human fibroblast feeders (HFs) exclusively (Figure 5.1I) 
but not the MEFs (Figure 5.1A,E). Both Laminin and collagen I were also found predominantly 
in the feeder area, again suggesting mouse origin (Figure 5.1B,F,J  and 5.1C,G,K). However 
there was some staining between hESC. Collagen IV was found exclusively in the feeder area, 
again suggesting mouse origin (Figure 5.1D,H,J). Immunolabeling with anti-vitronectin 
antibodies from multiple sources resulted in no obvious staining. Thus a number of major 
ECM components were present in the native cultures of three different hESC lines, primarily 
associated with the feeders or differentiated cells around the hESC, but independent of the 
type of feeder used and method of passage or culture medium.
integrin expression in hESC
Undifferentiated hESC need signaling factors from feeders for undifferentiated growth. 
This signaling may be mediated by growth factors but also ECM integrin interactions may 
contribute to signaling. Four major ECM components were present in hESC cultures, most of 
them secreted by the feeder cells, as described above. However, it is not known which ECM 
receptors on hESC mediate adhesion to the matrix present in the cultures. An important class 
of ECM receptors is the integrin family of proteins. In order to further investigate ECM-hESC 
interaction at the molecular level we determined cell surface expression of the majority of the 
a- and b-integrin chains by FACS analysis (Figure 5.1M). The three hESC lines tested exhibited 
comparable integrin expression profiles. Integrin chains a1, a4, a10, b3 and integrins a9b1 
and aVb6 were not detected or at very low levels (Figure 5.1M, left panels). Integrin chains 
a2, a3, a5, a6, a11, b1 and integrin aVb5 were expressed (Figure 5.1M, middle and right 
panels). These integrin chains can form the combinations a2b1 (binding collagen, laminin), 
a3b1 (binding nidogen, laminin, collagen I, fibronectin), a5b1 (binding fibronectin), a6b1 
(binding laminin-111, 211 and 411), a11b1 (binding collagen), aVb5 (binding vitronectin, 
fibronectin) and aVb1 (binding fibronectin). Thus hESC have cell surface receptors for all major 
ECM components, independent of their method of derivation or culture (Figure 5.1M). Even 
though a4 and a9b1, and sometimes a1 or b3, were detected at low levels by FACS analysis, 
immunofluorescent staining of these integrins showed only background levels (not shown) 
and are therefore unlikely to play a major functional role in adhesion. By contrast, integrin 
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chains a2, a3, a5, a6, a11, b1, and integrin aVb5 all showed distinct plasma membrane 
localization in the three hESC lines (Figure S1). Furthermore independent mass-spectroscopy 
analyses of membrane proteins from a fourth hESC line, HUES7, confirmed the presence of a2, 
a3, a5, a6, av, and b1 integrin peptides24 (Table S1). The peptides identified were blasted 
against reference databases, confirming their human origin. In summary, it is evident that the 
collagen receptor a2b1 and a11b1, the fibronectin receptor a5b1, the vitronectin receptor 
avb5 and the laminin receptor a6b1 are expressed on all three hESC lines.
Next we characterized the ability of hESC to attach to various ECM coated substrates. Since we 
observed no major differences in integrin expression profiles among the three tested lines, 
HUES1 was chosen for a detailed dose-response curve of their adhesion to laminin-111, 
laminin-111+entactin, Matrigel™, collagen IV, fibronectin and vitronectin (Figure 5.2A). 
Monolayer HUES1 cultures using Matrigel™-coated substrates in KSR-supplemented MEF 
conditioned medium (CM) have already been shown to be beneficial for cell manipulation. 
These conditions support undifferentiated proliferation of various hESC lines and to maintain 
their karyotype stably for at least 10 passages17. Since this system is based on trypsin passage 
it was clearly beneficial for attachment assays. Attachment was very efficient on vitronectin 
and Matrigel™ but poorer on fibronectin and collagen IV.  Attachment to pure laminin-111 
was extremely weak. Since laminin-111 and Matrigel™ are both isolated from the EHS tumor 
this suggests that the rigorous chemical purification of the commercial laminin product 
destroys its functionality. Indeed the less pure laminin+entactin combination from the same 
source rescued the binding to some extent (Figure 5.2A). Therefore throughout the manuscript 
laminin+entactin will be used when referring to laminin-111. 
functional validation of detected integrins
To investigate the functionality of these integrins in HUES1 further, we performed short 
term adhesion assays but now in the presence of specific integrin blocking antibodies. hESC 
were first incubated with the antibodies, then allowed to adhere mouse laminin+entactin, 
fibronectin, vitronectin or collagen IV (Figure 5.2B). 
Both anti-a6 and anti-b1 antibodies significantly reduced adhesion of hESC to 
laminin+entactin, indicating that a6b1 was indeed functional in binding its major ligand 
laminin-111 in hESC (Figure 5.2B). Blocking the integrin chains that make up the fibronectin 
receptor a5b1, as expected, significantly impaired adhesion to fibronectin, while blocking 
the vitronectin receptor aVb5 reduced binding to vitronectin (Figure 5.2B). The functionality 
of a2b1 and a11b1 could not be tested, as there where no specific blocking antibodies 
available. Taken together a6b1 was shown to mediate adhesion of hESC to laminin-111, 
a5b1 to fibronectin and aVb5 to vitronectin. 
the vitronectin receptor αvβ5 rescues the β1 integrin block
Since most functional integrin combinations rely on the b1 chain, we examined whether 
this chain was a specific signaling intermediate crucial for stem cell proliferation by adding 
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(A) HUES1 cell attachment dose 
response binding curve to various 
natural matrices, (B) Functional 
validation of integrin binding 
capacity on various matrices using 
integrin specifi c blocking antibodies. 
*** p≤0.01. Data from at least three 
independent experiments were 
collected and displayed as average 
+/- SEM.
hESC Integrin function in initial substrate adhesion
Figure 5.2






hESC expansion in various media is matrix dependent
HUES1 cells were trypsinized 
and replated in triplo in 96-
well plates on various matrices. 
Cell proliferation was measured 
quantitatively at different time-
points (A) HUES1 cell expansion on 
various substrates in MEF-CM, (B) 
HUES1 cell expansion on various 
substrates in mTeSR1, chemically 
defi ned medium. (C-F) HUES1 
cell expansion assays in the 
presence or absence of integrin 
a5 and a6 blocking antibodies 
which were added 4-hours post-
plating to circumvent differential 
attachment on (C), Ln+entactin 
(D), fi bronectin (E) collagen IV and 
(F) vitronectin. Experiments were 
repeated at least three times, 
one representative experiment 
is shown here. Each timepoint 
represents the mean absorbance 
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blocking b1 antibodies to HUES1 cultured on Matrigel™. This completely inhibited attachment/
proliferation, while blocking the vitronectin receptor aVb5 had as expected no effect (Figure 
S2). The combination of Matrigel™ with vitronectin but not fibronectin however, rescued the 
b1 block, whereas the combination of Matrigel™ and fibronectin had no effect (Figure S2). The 
rescue of vitronectin was mediated by the aVb5 integrin since a combination of b1 and aVb5 
blocking antibodies blocked the attachment and growth completely (Figure S2). These results 
indicated that the attachment and growth of hESC not necessarily require binding via the b1 
chain but that ligation of aVb5 to its ligand vitronectin could act as a functional substitute to 
mediate adhesion and support undifferentiated growth. 
matrigel™ and vitronectin support robust hESC proliferation in 
defined media
To test the functionality of hESC expressed integrins further, we examined the ability 
of purified ECM preparations to support proliferation of HUES1 in MEF conditioned media 
and mTeSR1. As expected, cells cultured in both media proliferated well when seeded on 
Matrigel™ coated plates, as reported previously7,25. However on all other matrices tested there 
was a clear difference between mTESR and MEF conditioned medium. Cells cultured in mTeSR1 
supported hESC growth exclusively on purified vitronectin but not on fibronectin, laminin and 
collagen IV while MEF conditioned medium supported hESC growth on any tested substrate 
(Figure 5.3A,B). To test these effects further, cells cultured in MEF-CM on various substrates 
were stained for OCT4 expression (Figure 5.3) and cultured for extended periods on the 
same ECM coated substrates. All cells retained OCT4 expression although we observed higher 
culture expansion rates of hESC on Matrigel™ and vitronectin (passage 7), than on laminin, 
fibronectin and collagen IV (passage 5) after one month of continuous culture. A possible 
explanation for the observed differences between MEF-CM and mTeSR1 would be the presence 
of additional factors present in KSR or secreted by the feeders that mediate binding of hESC to 
their substrate. FIBRONECTIN and LAMININ were selected as candidate proteins mediating the 
observed difference in culture expansion rates between the two media. This was based on 
extrapolation of the data in Figure 5.1 and a published secretome analyses of human fetal, 
human neonatal and mouse embryonic feeder fibroblast respectively26. We therefore carried 
out culture expansion assays in MEF conditioned media in the presence or absence of a6b1 
(laminin receptor) and a5b1 (fibronectin receptor) blocking antibodies on laminin+entactin, 
fibronectin, collagen IV and vitronectin (Figure 5.3C-F). Surprisingly, a5b1 reduced culture 
expansion on collagenIV and laminin+entactin, indicating that fibronectin secreted by the 
feeders is a major bioactive molecule in MEF conditioned medium. As expected, blocking 
a6b1 reduced culture expansion on laminin+entactin without a significant effect on the other 
matrices tested and blocking a5b1 reduced culture expansion on fibronectin as expected. 
Interestingly, culture expansion on vitronectin was not impaired by blocking fibronectin 
signaling. This confirmed the suitability of vitronectin as replacement for Matrigel™.
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hESC culture on a completely defined substrate
The aim of this study was to find defined synthetic ECM substrates for sustained self 
renewal of hESC without loss of pluripotency or changes in karyotype. We identified purified 
vitronectin as a candidate ECM protein for this purpose. Since human recombinant vitronectin 
is commercially available, we next tested whether this would be as effective as purified 
human vitronectin from plasma, preferably in combination with defined medium rather 
than medium conditioned by MEFs or HFs. HUES1 grown on plasma vitronectin expanded 
at the same rate as cells grown on recombinant vitronectin (Figure 5.4A) and used integrin 
aVb5 for cell attachment (Figure 5.4B). Next we tested the ability of recombinant vitronectin 
to support long term self-renewal in defined (mTeSR1) medium. For this we used all three 
lines used at the outset (HUES1, HES2 and HESC-NL3) to examine the general applicability of 
this culture method.  Each of the lines proliferated robustly in a ‘cut and paste’ culture in 
continuous culture for up to 12 weeks, the maximum presently tested. Under these culture 
conditions hESC had a similar growth rate to conventional cultures grown on feeders cells and 
were passaged once a week. After minimally 5 weeks of culture (5 passages) on recombinant 
vitronectin in mTeSR1 medium cells were analyzed in detail for karyotypic abnormalities and 
pluripotency in culture. 
Under these defined conditions cells grew in compact colonies (Figure 5.4B-D) without obvious 
morphological differentiation. Karyotypic analyses of HESC-NL3 and cultured on recombinant 
vitronectin showed a normal 46xy karyotype in all cells analyzed (Figure 5.4E). Maintenance 
of stemness was demonstrated by staining for the stem cell markers E-CADHERIN, GCTM2, OCT4, 
SOX2, SSEA-3 and SSEA-4 (Figure 5.4F-K). To examine their differentiation potential, hESC 
cultures on recombinant vitronectin in mTeSR1 were treated with growth factor supplemented 
N2/B27 medium as described previously 21. Cell types derived from each of the three germ 
layers were present for each of the line. Endoderm differentiation was confirmed using 
antibodies against alpha-fetoprotein (AFP), ectoderm using antibodies against betaIII-tublin, 
a neuronal protein and mesoderm differentiation was confirmed using antibodies recognizing 
alpha-actinin, a cardiac protein (Figure 5.4L-N). These results confirmed the potency of our 
fully defined hESC culture system. 
Discussion
For both clinical applications as well as addressing fundamental questions regarding hESC 
biology and the molecular nature of `stemness’. it is clearly beneficial to culture with fully 
defined culture substrates and media based on recombinant (or clinical grade) proteins27. 
We demonstrated here that hESC express integrin receptors for laminin, fibronectin, collagen 
and vitronectin and that all of these receptors are functional in mediating adhesion. MEFs 
and HFs secrete large quantities of at least laminin, collagen I, collagen IV and fibronectin. 
Although all cell lines attached and proliferated well on the major ECM proteins if grown in 
MEF-CM. However if the fully defined mTeSR1 medium was used, only vitronectin supported 
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(A) HUES1 cell expansion assay 
on plasma Vitronectin (pVN) and 
recombinant vitronectin. (B) HUES1 
cell attachment in the presence 
and absence of integrin avb5 
blocking antibodies on both plasma 
vitronectin and recombinant 
vitronectin (C-E) representative 
brightfi eld pictures of HUES1, 
HES2 and HESC-NL3 cultured for 8 
passages on recombinant vitronectin 
in mTeSR1 (F) Karyogram of HESC-
NL3 cultured for 7 passages on 
recombinant vitronectin in mTeSR1 
showing a normal diploid 46,xy 
karyotype (G-L) Immunostaining for 
stem cell markers and DNA for HESC-
NL3 (overlay). (G) E-cadherin, (H) 
GCTM2, (I) OCT4, (J) SOX2, (K) SSEA3 
(L) SSEA4. (M-O) Immunostaining for 
HESC-NL3 differentiation markers 
representing the three germ layers 
(M) AFP, endoderm (N) beta III 
tubulin, ectoderm and (O) a-actinin, 
mesoderm. Scale bars, 50 μm.  














hESC growth as well as Matrigel™. We identified recombinant vitronectin as a suitable and 
functional alternative for Matrigel™. Three independently derived cell lines (HUES1, HES2 and 
HESC-NL3) were cultured long term on recombinant vitronectin in mTeSR1 medium and all 
maintained their characteristic compact morphology, expression of stem cell markers, normal 
karyotype and differentiation potential, demonstrating the general applicability of these 
conditions.
Most of the >400 hESC lines derived to date have been traditionally cultured on a feeder 
layer of MEFs to maintain self renewal and pluripotency.  It was of interest to note in our 
study that MEF conditioned medium reduced the stringent ECM requirements for hESC i.e. 
fibronectin, collagen IV and laminin could replace Matrigel™ as well as vitronectin. We 
showed that feeder cells produce a highly complex matrix consistent of several ECM molecules 
and that secreted fibronectin is likely responsible for this loss of matrix stringency. However, 
it is of interest that FGF2 signaling, the primary signaling pathway for hESC self-renewal, 
is highly dependent upon the ECM. FGF family members bind to the extracellular matrix 
(ECM) becoming concentrated in specific regions where they are protected from proteolytic 
degradation28. FGF receptor activation is dependent upon heparan sulphate side chains on 
either ECM or cell surface proteoglycans29. Many of the growth factor signaling pathways are 
shared with integrin pathways30. ECM modulated signals may convergence with FGF signaling 
and be involved in the maintenance of “stemness”. 
Indeed, it has been suggested that integrin signaling in mouse ES cells converges with growth 
factor signaling to maintain stemness. Recently is has been shown that cells cultured on type 
I and IV collagen or poly-d-lysine remained undifferentiated while laminin or fibronectin 
induced differentiation31. Unfortunately vitronectin was not investigated in this study. 
However, as many studies have shown, results obtained in mouse ES cannot always easily be 
translated to hESC, particularly with respect to cell surface proteins and signal transduction. 
This is likely related to their different state of differentiation32,33. Nevertheless it might be 
interesting to study the relationship between integrin signaling in differentiation and self-
renewal of hESC in more depth in the future.
Almost all of our knowledge related to hESC is based on studies carried out under the 
influence of feeder cells and/or serum. This might explain several inconsistencies in the 
literature, for example; the debated role of Activin A in hESC self-renewal6,21. Over recent 
years, a number of papers have described defined media for hESC but the majority made 
use of Matrigel™ 6,21,25,34-37 which is still incompletely defined.  Apart from laminin, entactin, 
collagen and heparin sulfate proteoglycan Matrigel™ contains several growth factors, even in 
its growth factor reduced variant. Among these is TGF-b which might contribute to hESC self-
renewal38. Therefore, under Matrigel™ culture conditions it is difficult to define growth factor 
requirements for undifferentiated growth or directed differentiation. Furthermore, Matrigel is 
derived from a tumour of mouse origin, a potential xenorisk, since it contains the non human 
sialic acid Neu5Gc, an immunogenic molecule that might be transferable to hESC39. 
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Based on the work of Xu et al (ref 7) in which a6b1 integrin was detected on the cell surface 
of hESC and feeder-free culture of hESC on Matrigel™ in MEF-CM was described, it has been 
generally assumed that laminin is the most important ECM protein for hESC in culture. Indeed 
hESC culture on purified laminin has been reported7,40. Both studies were however performed 
in MEF-CM. It is likely that these results were influenced by ECM proteins secreted by MEFs. 
Since feeders secrete fibronectin26 and blocking the fibronectin receptor a5b1 reduced hESC 
expansion on laminin and collagen IV it is likely that fibronectin is the major bioactive protein 
in MEF-CM in this respect. In fact, it has been reported that purified fibronectin supports hESC 
growth even in semi-defined hESC medium41. Here we observed even better cell growth and 
attachment on purified vitronectin. Furthermore, on vitronectin we observed no delay in cell 
expansion by blocking fibronectin signaling indicating that ligation of hESC through avb5 is 
sufficient for hESC growth.
The recombinant vitronectin, used was produced in the mouse myeloma cell line, NS0 and 
therefore could potentially contain Neu5Gc. However, biotechnological innovations may and 
should overcome this problem. Previously, yeast was successfully genetically engineered 
to produce humanized glycosylated proteins42. Another possibility could be to use human 
protein expression platforms, such as the PER.C6 cell line43
Concurrent with the present study, two papers reported defined media for hESC culture. 
Gerecht et al. (2007) described a defined hydrogel based on hyaluronic acid. For routine use 
however, this approach has certain drawbacks: cells are difficult to access for subsequent 
analysis and use and encapsulation of cells depends on UV photoactivation. This might cause 
point mutations in the DNA. Furthermore the authors did not demonstrate serial passage, 
prolonged culture and karyotypic stability in this system44. Derda et al. used SAM surface 
arrays to detect peptides derived from laminin suitable for hESC-self-renewal45. The biological 
relevance of that study might be limited by the fact that surface arrays were coated with 
serum which contains high levels of fibronectin and the use of MEF-CM. As shown in our study 
fibronectin from MEF-CM mediated binding on several substrates that were not supportive 
in defined media. This illustrates the importance of media and substrate development 
progressing in parallel.
In conclusion; we defined a culture system for hESC based entirely on human/recombinant 
proteins that can be used for long-term self-renewal and selected differentiation of hESC. 
This will be essential for both basic research on hESC pluripotency and clinical applications.
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Pluripotent stem cells self-renew indefinitely 
and possess characteristic protein-protein 
networks that remodel during differentiation. 
How this occurs is poorly understood. Using 
quantitative mass spectrometry, we analyzed 
the (phospho)proteome of human embryonic 
stem cells (hESC) during differentiation 
induced by bone morphogenetic protein 
(BMP) and removal of hESC growth factors. 
Of 5222 proteins identified, 1399 were 
phosphorylated on 3067 residues. 
Approximately 50% of these phosphosites 
were regulated within 1 hr of differentiation 
induction, revealing a complex interplay 
of phosphorylation networks spanning 
different signaling pathways and kinase 
activities. Among the phosphorylated 
proteins was the pluripotency-associated 
protein SOX2, which was SUMOylated as a 
result of phosphorylation. Using the data 
to predict kinase-substrate relationships, 
we reconstructed the hESC kinome; CDK1/2 
emerged as central in controlling self- 
renewal and lineage specification. The 
findings provide new insights into how 
hESC exit the pluripotent state and present 
the hESC (phospho)proteome resource as a 





All future applications of pluripotent cells depend on exquisite control of their developmental 
fate. An essential first step for differentiation is to exit the pluripotent state but exactly how 
this is regulated is unclear. Recent evidence for a core transcriptional machinery regulating 
pluripotency1 has indicated the most important pathways for functional interrogation, 
but information on the activation state of component proteins is largely unknown. Here, 
we analyzed the proteome and phosphoproteome of human embryonic stem cells (hESC), 
prototype pluripotent cells, for this purpose and compared this profile globally with that 
immediately after induction of differentiation.
ESC are derived from preimplantation embryos, self-renew indefinitely, and can undergo 
multilineage differentiation2. Although mouse ESC (mESC) and hESC have a similar core 
transcriptional regulatory network, involving OCT43, SOX24,5, and NANOG6, they differ in their 
growth requirements. BMP and leukemia inhibitory factor sustain self-renewal of mESC7, but 
hESC require basic fibroblast growth factor (bFGF) and transforming growth factor-b (TGF-b)/
Activin A signaling8,9. In fact, BMPs rapidly induce differentiation of hESC10. In all pluripotent 
cells however, the pluripotency genes, OCT4, SOX2, and NANOG collaborate by co-occupying 
the promoters of many genes, including their own, thereby promoting expression of ESC-
associated genes and repressing lineage specification genes11,12.
Recent studies have shown that SOX2 can act synergistically with OCT4 in vitro to activate 
OCT-SOX enhancers, and that SOX2 is necessary for regulating multiple transcription factors 
affecting OCT4 expression13. Exactly how differentiating cells downregulate the transcription 
factors controlling self-renewal is unclear. Transcriptional regulation of NANOG by TGF-b/
Activin A and BMP-responsive SMADs has been demonstrated recently. In undifferentiated 
hESC, SMAD2/3 dominates through TGF-b signaling, whereas SMAD1/5/8 becomes activated 
upon BMP-induced differentiation. These SMADs bind the proximal promoter of NANOG with 
opposing effects; SMAD2/3 promotes but SMAD1/5/8 inhibits its expression14. Furthermore, 
NANOG activity is regulated post-translationally by caspase-mediated proteolytic cleavage, 
which is associated with differentiation15. Although mESC lacking NANOG are prone to 
differentiate, they still self-renew, suggesting that downregulation of NANOG alone is not 
sufficient to induce differentiation16.
Mass spectrometry (MS)-based proteomics is presently the most powerful tool for dissecting 
stimulus-dependent dynamics of phosphorylation events in living cells17,18. We used stable 
isotope labeling by amino acids in cell culture (SILAC)-based quantitative MS19 to study early 
phosphorylation and dephosphorylation events in hESC upon BMP-induced differentiation. 
Metabolically-labeled hESC were compared quantitatively with unlabeled differentiating 
cells exposed for various times to BMP. TiO
2
-based phosphopeptide enrichment followed 
by MS identified a large set of proteins phosphorylated in hESC, including SOX2. Mutational 
analysis suggested that phosphorylation of one or more consecutive serine residues induced 
Phosphorylation dynamics in hESC 77
SUMOylation. This post-translational modification (PTM) has been described as inhibiting its 
transcriptional activity20. Using the NetworKIN algorithm21 we linked the phosphorylation 
sites to their cognate kinases. This showed that of the multiple active kinases, CDK1/2 had 
the largest number of substrates, including SOX2. Furthermore, comparison of cells before and 
after BMP exposure provided a global map of protein phosphorylation dynamics as hESC exit 
the pluripotent state.
Results
silac analysis of hESC and the effect of bmp-induced differentiation









]-lysine (Figure 6.1). Rapid differentiation of unlabeled hESC was 
induced by BMP4 addition10; cells were harvested at various times thereafter (Figure 6.1). 
Western blot analysis shows that BMP4-induced differentiation, as previously, resulted in 
downregulation of OCT4 and SOX2 (Figure S1). Phosphorylation dynamics were studied using 
an automated approach to enrich for phosphopeptides based on SCX and TiO
2
22 combined 
with SILAC technology19 for accurate relative quantitation. Proteins from undifferentiated hESC 
(0 min) and differentiated cells (30, 60, and 240 min after BMP4 addition) were extracted, 
combined, and processed for quantitative MS analysis (Figure 6.1). MS intensities of the 
“light” and “heavy” peaks reflect the relative changes in protein phosphorylation between 
the two samples analyzed. Collectively, the three SILAC mixtures provided a four-time-point 
profile of phosphorylation events during early differentiation of hESC (Figure 6.1).
the hESC proteome and phosphoproteome
From 800,000 spectra collected over 144 LC-MS/MS runs, 5,222 proteins were identified 
with high confidence using a highly conservative Mascot Score of 35 at the peptide level 
(false discovery rate<1%) (Tables S1 and S2). Because protein abundance cannot be 
predicted accurately from mRNA levels 23, these data corroborated protein presence for many 
transcripts, and additionally demonstrated the existence of proteins for which there was 
no direct evidence at the transcriptional level. Of the proteins identified, 1399 (27%) were 
phosphorylated on one or multiple residues (Figure S2, Table S3 and File S1), making these 
proteome and phosphoproteome data sets the largest reported to date for hESC. In total, 3090 
unique phosphopeptides were detected, carrying 3067 phosphorylation sites localized on 
2431 serines, 582 threonines and 54 tyrosines. These proteome profiles represent a unique 
opportunity to gain insights into the functional protein content and identify active signaling 
pathways involving these proteins.
The proteins identified were first classified by molecular function, biological function, and 
subcellular localization (Figure S3). The two most abundant categories (molecular function) 
consisted of nucleic acid binding proteins (941 proteins, 18.0%) and transcription factors 
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Changes in phosphorylation levels 
are shown for those proteins cited 
in the text. (A) Specifi c regulation 
of four different phosphorylation 
sites from TP53BP1. S1114 shows 
a delayed phosphorylation 
whereas S500 and S552 belong to 
intermittent profi le. S379 is not 
regulated during differentiation. 
(B) Two phosphopeptides were 
identifi ed for JUN, only one (S73, 
temporal phosphorylation) was 
quantifi ed in the three time 
points. (C) Y216 from GSK3b shows 
a sustained phosphorylation 
profi le. Error bars are shown if the 
phosphopeptide was quantifi ed 
more than two times. See Figure 
S10 for confi rmatory western 
blot and immuno-fl uorescence 
analyses.
Figure 6.2
Temporal profi les of phosphorylation during differentiation.
Figure 6.1
(1) Two populations of hESC were used, 










Differentiation of unlabeled hESC was 
induced by BMP4 and samples collected 
at 30, 60 and 240 min. Differentiated 
cells and SILAC labeled-hESC were 
combined, lysed and enzymatically 
digested. (2) The three mixtures 
were subjected to phosphopeptide 
enrichment based on TiO
2
 and SCX prior 
to high-resolution LC-MS/MS analysis. 
The peak intensities of the identifi ed 
phosphopeptides are proportional 
to their relative abundance. (3) The 
three SILAC mixtures provide a profi le 
of phosphorylation events over 4 time 
points after the onset of differentiation. 
Phosphorylation networks were 
reconstructed by predicting potential 
kinases for every phosphosite identifi ed. 
SUMOylation of the pluripotency 
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are highly active in hESC. Gene ontology (GO) analyses confirmed enrichment of several GO 
terms related to these categories in our hESC proteome (P<0.001, Hypergeometric test) (Table 
S4) compared to the entire human genome. To evaluate whether this overrepresentation 
was specific for pluripotent cells, we also classified two proteomes previously reported by 
our group24, hESC (HES-2) and their differentiated derivatives (12 days in the absence of 
feeder cells) (Figure S4). Interestingly, we found a reduction (P<0.05, Chi-square test) in the 
abundance of transcription factors and nucleic acid binding as ESC differentiated indicating 
that this class of transcriptional and translational proteins is highly represented in ESC. 
Next we assessed whether proteins identified originated from genomic regions predicted to 
be active, as indicated by K4 trimethylation of histone 3 (H3K4me3), or silent, marked by 
trimethylation on K27 (H3K27me3)25,26. Our proteome notably correlated with whole-genome 
analysis of histone 3 methylation in hESC27 since 2848 proteins in our catalogue carried the 
activating H3K4me3 mark on their corresponding genes, 279 proteins had both H3K4me3 
and H3K27me3 marks, 240 proteins with neither H3K4me3 nor H3K27me3, whereas only 9 
were reported as silenced genes (Figure S5 and Table S5).
phosphorylation dynamics during differentiation
Of the 3090 unique phosphopeptides identified, 1987 were quantified in at least one of 
the three SILAC mixtures (Figure S6, Table S3 and File S1). We achieved a relative standard 
deviation (RSD) of 7% (data not shown) by measuring modified variants of the reported 
phosphopeptides resulting from trypsin missed cleavages or methionine oxidations. On this 
basis, we found that 1091 phosphopeptides (50% of the quantified phosphoproteome) were 
regulated during differentiation (Table S3 and Data Set S1). Next, we examined the relationship 
between protein abundance and its regulation status (i.e. differentially regulated or not), 
applying total peptide count (including multiple observations of the same peptide within a 
single experiment). We observed an inverse correlation between frequency and regulation 
status (Figure S6B), indicating that low-abundant peptides tended to be more regulated than 
high-abundant peptides. Thirty minutes after BMP4 addition, the level of phosphorylation 
of 407 proteins was increased, whereas only 25 decreased. Changes of similar magnitude 
were found at 60 min (506 upregulated, 51 downregulated), and 240 min (622 upregulated, 
42 downregulated), suggesting an overall increase in kinase activity. The time course 
showed a trend in most of the phosphopeptide profiles, showing up- or downregulation at 
minimally two consecutive time points, suggesting the robust- ness of the data set. Second, 
we confirmed phosphorylation profiles for GSK3b and 4EIFEBP1 by immunofluorescence 
and western blotting, the method of choice being dictated by the properties of available 
antibodies (Figure S10).
To gain insight into temporal regulation during differentiation, phosphopeptides quantified 
at all time points and significantly differing in phosphorylation in at least one of the four 
time points were grouped by k-means clustering (Figure S7 and Table S6). Two phenomena 
become apparent from these data. First, the most dramatic phosphorylation changes took 
place during the first hour, coincident with SMAD1/5/8 phosphorylation in hESC10 and no 
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phosphopeptides were regulated after 4 h only, indicating that events are initiated by BMP4 
within this time frame. Second, apart from a small group of dephosphorylation events (cluster 
“dephosphorylation” in Figure S7), most changes represent an increase in phosphorylation 
level. In several cases, the same proteins occupied more than one cluster, indicating that 
regulation of phosphorylation is site-specific, and that individual sites may be affiliated with 
different functions. This is congruent with the idea that proteins can serve as platforms for 
integrating signals from various kinases/cascades28. One example is tumor suppressor p53-
binding protein 1 (TP53BP1), a hyper-phosphorylated transcription activator engaged in the 
response to DNA damage29, checkpoint signaling during mitosis (Swiss-Prot by similarity) and 
hESC differentiation27. Three phosphopeptides identified for TP53BP1 were regulated with 
different kinetics since they belonged to different profile clusters (delayed and intermittent) 
(Figure 6.2, Table S6).
signaling pathways activated by bmp4
The coverage of signaling pathways was assessed by projecting protein identification and 
quantitative phosphorylation on 130 signaling pathways in Panther30. Components of nearly 
all pathways were represented in our data (Figure 6.3A and Figure S8), 86 of which contained 
between 1 and 79 phosphorylated proteins. Seventy pathways were represented by proteins 
with dynamic phosphorylation. (Table S7). This suggests the activation of a protein network 
composed of multiple signaling cascades. To investigate this in more detail, we considered 
key components of individual pathways and looked at whether observed phosphorylation 
sites were those known to be involved in protein activation. Activation of the BMP-pathway 
was indicated by phosphorylation of receptor-SMADs, SMAD5 and SMAD8 at S465 and S467, 
respectively, confirming activation of the BMP4-SMAD signaling cascade in hESC (Figure S9A,B) 
as previously10.  
Several components of PI3K signaling were identified (Figure 6.3 and Figure S10). Increased 
phosphorylation of PDPK1 at S241 indicated activation of this kinase for subsequent 
phosphorylate of its target AKT1 (PKB). Additionally, an increase in phosphorylation of various 
proteins with confirmed AKT1 target sites was observed, including S166 of MDM2, S280 of 
CHK1 (both of which lead to inhibition of p53-mediated apoptosis) and S341 and S588 of 
TBC1D4 (also known as AS160). These all point to activation of AKT1.
c-Jun, which forms the heterodimeric activator protein 1 transcription factor complex 
with c-Fos, was phosphorylated at S63 and S73, suggesting activation of the JNK pathway. 
Interestingly, the immediate phosphorylation of c-Jun after BMP activation at 30 min was 
followed by a decrease over the next hours (Figure 6.2B), indicated that JNK activation was 
transient. Wnt signaling is one of the best-covered pathways in our dataset and included 
multiple proteins with phosphorylation changes (Figure S9C). Amongst these was an activating 
phosphorylation at Y216 of GSK3B that was induced within 30 min of BMP addition (Figure 
6.2B). Phosphorylation of this tyrosine over time was confirmed in a biological repeat on 
cell lysates using western blotting and at the single-cell level using immunofluorescent 
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(A) Nonphosphorylated proteins, 
nonregulated phosphoproteins, 
and regulated phosphoproteins 
were mapped to 130 pathways 
with Panther classifi cation system 
30. Only those pathways with a 
relative high coverage are shown. 
The complete analysis can be 
found in Table S7 and Figure 
S8. (B) Graphical representation 
of PI3K/Akt signaling pathway. 
Identifi ed proteins by MS are 
represented in blue color. 
Identifi ed phosphosites are 
also shown when applicable 
(red, upregulated site; green, 
downregulated; grey, not 
regulated or not quantifi ed). Some 
examples of other pathways can 




antibody staining (Figure S10). Furthermore, several peptides of the key Wnt signaling 
protein, b-catenin, were identified. However, the N-terminal peptide marking activity when 
phosphorylated was not detected so that activation status of b-catenin cannot be determined 
from our data directly. However, several co-activators (BCL9, BCL9L, PYGO2) and repressors 
(TLE1, TLE3)31 of b-catenin were differentially phosphorylated at several positions, indicating 
some level of regulation of Wnt signaling. Moreover, phosphorylation of casein kinase I, which 
phosphorylates b-catenin, was increased on at least two sites. Combined, these data implied 
rapid activation of the Wnt pathway at the onset of BMP-induced differentiation. 
Many other phosphorylation events were observed, but their effect on the activation of the 
proteins affected are largely unknown. Nonetheless, their multitude and diversity, as well 
as the fact that some of them are shared by several pathways (e.g. G3BP1 and 2)32 indicated 
that induction of differentiation by BMP4 initiates signaling via an intricate network that 
vigorously alters the behavior of hESC. 
additional effects of bmp4
To investigate the effects of BMP4 induction beyond kinase signaling, proteins with altered 
phosphorylation levels (>0.5 fold, log
2
 scale) were mapped to GO terms with respect to 
molecular function (Table S8) and biological process (Table S9). These analyses showed the 
broad range of protein classes affected by BMP4, indicating that its effects extended well 
beyond those proteins participating in established signal transduction cascades. Some of the 
processes are related to differentiation (e.g. alteration of cell cycle kinetics or cell cycle exit and 
initiation of development); however, it was unclear exactly how the individual components 
were affected. To address this, the same set of phosphoproteins was subjected to an unbiased 
analysis using Anni33, an ontology-based interface that applies text mining to retrieve 
associations between proteins by co-occurrence in the literature. This tool classifies proteins 
by a term or “concept” they have in common, which is not necessarily a GO term. Although 
some of the 39 clusters identified in this manner (Figure S11 and Table S10) were also defined 
by GO analysis (e.g. cell cycle, cytoskeleton), many additional “concepts” emerged, such as 
transcriptional repression, transcriptional elongation factors, translation initiation factors, 
and SWI/SNF chromatin remodeling34. This implies that established mechanisms associated 
with differentiation, like genome remodeling, silencing of the pluripotency network, and 
activation of differentiation inducing genes, are initiated rapidly after induction. Additionally, 
the presence of a protein SUMOylation cluster indicated active post-translational processing 
of proteins. Furthermore, clusters containing Rab11 family-interacting proteins, microtubule 
associated proteins, VIMENTIN, GTPase-activating proteins, tight junctions and focal adhesions 
strongly suggested remodeling of the cellular matrix.
phosphorylation of pluripotency-associated proteins
To determine the phosphorylation status of proteins associated with pluripotency, we mapped 
MS identification to ESC-associated genes defined by the International Stem Cell Initiative35. From 
the top 20 genes with a NANOG pairwise correlation coefficient >0.5, we detected the protein 
Phosphorylation dynamics in hESC 83
Venn diagram representing 
the overlap of OCT4, SOX2 and 
NANOG target genes differentially 
phosphorylated during 
differentiation. Examples of 
regulated phosphosites are shown 
for every section of the diagram. 
The full list of proteins can be 
found in Table S11.
Figure 6.4
Downstream targets of the core transcriptional regulatory circuitry regulated by phosphorylation
IPI Number Gene Symbol (Protein Name) Phosphosites
IPI00002948 LIN28 (Lin-28 homolog A) S3, S200, T202
IPI00012593 DNMT3B (Isoform 1 of DNA(cytosine-5)-methyltransferase 3B) S82, S136, S202, S209, 
T383, S387
IPI00300620 IFITM1 (Interferon-induced transmembrane protein 1)
IPI00219089 POU5F1 (Isoform A of POU domain, class 5, transcription factor 
1; OCT4) 
IPI00009703 SOX2 (Transcription Factor SOX2) S249, S250, S251
IPI00026637 GAL (Galanin precursor) S116
IPI00020668 UTF (Undifferentiated embryonic cell transcription factor 1) S18, T35, S245
IPI00007164 FOXD3 (Forkhead box protein D3)
IPI00299659 GDF3 (Growth/differentiation factor 3 precursor)
IPI00045497 NODAL (Nodal homolog precursor)
IPI00299116 PDXL (Podocalyxin-like protein 1 precursor)
IPI00434539 NANOG (Isoform 1 of Homeobox protein NANOG)
table 6.1 hESC markers and phosphosites (regulated sites in bold)
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products of 12, including the three core transcription factors OCT4, SOX2, and NANOG (Table 1). 
Sixteen novel phosphosites were identifi ed in fi ve of these proteins; among these were three 
residues of UTF1, three residues of LIN28, seven residues of DNMT3B, and three consecutive 
residues of SOX2. During differentiation, the phosphorylation state changed for 6 of the sites 
identifi ed, suggesting that the ESC-associated proteins to which they belong are regulated 
post-translationally. To fi nd differential phosphorylation sites of downstream targets for OCT4, 
SOX2, and NANOG, we mapped the phosphoproteomes to chromatin immunoprecipitation 
data sets published for OCT4, SOX2 and NANOG11. Of the 2,260 genes reported, we found 586 
products, 100 of which were phosphoproteins regulated during differentiation, including 
19 transcriptional regulators (Figure 6.4 and Table S11). Interestingly, these phosphorylated 
proteins are predominantly components of the RNA post-transcriptional modifi cation (e.g. 
SFPQ, DDX20, ADAR, ACIN1, SFRS7) and the gene expression machinery (e.g. POU2F1, SFPQ, 
PAK1, STAT3, SUMO1, SOX2, HIST1H1). These results suggested that many components of the 
hESC core transcriptional circuitry are regulated by phosphorylation, and that differentiation 
is accompanied by active modulation of these processes.
HeLa cells stably expressing His
6
-
SUMO2 (HeLaSUMO2) were transfected 
with pCAG expression constructs 






Cells were lysed and His
6
-SUMO2 
conjugates were enriched on 
nickel-nitrilotriacetic acid-
agarose beads. Purifi ed fractions 
were subjected to SDS-PAGE, and 
immunoblotted using antibodies 
to detect Sox2 or SUMO2/3. 
These results indicate that 
SUMOylation of SOX2 depends on 
phosphorylation at S249-251).
Figure 6.5
Phosphorylation-dependent SUMOylation of SOX2. 
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phosphorylation-dependent sumoylation of sox2
Our MS results showed that SOX2 can be phosphorylated at three consecutive serine 
residues: S249, S250, and S251 (Table S3 and File S1). This serine triplet flanks an upstream 
SUMOylation site of SOX220, the combination of which resembles the phosphorylation-
dependent SUMOylation motif (PDSM), YKxExxSP, described in other SOX family members36. 
We hypothesized that SUMOylation of SOX2 depends on phosphorylation of one or more 
of these serine residues in a similar manner. To address whether crosstalk occurs between 
these phosphorylation and SUMOylation sites, a set of SOX2 mutants was created, and their 
SUMOylation state investigated using HeLa cells stably expressing SUMO237 (Figures 6.5, S12A 
and S12B). Expression of wt human SOX2 in these cells showed a low basal level of SUMOylated 
SOX2 compared with free SOX2 (Figure 6.5 and S12B). However, when the serine residues were 
replaced by aspartic acid (SOX2
S249-251D
) to mimic constitutive phosphorylation, high levels of 
the SUMOylated SOX2 mutant were observed; including double and triple SUMOylated forms 
(Figure 6.5 and S11B). On the other hand, replacing the serine residues by alanine (SOX2
S249-
251A
) showed a ratio between the free and SUMOylated form similar to that of wt SOX2 (Figure 
6.5 and S12B). Furthermore, replacing K245 of the PDSM by alanine (SOX2
K245A
) completely 
prevented SUMOylation of the transcription factor (Figure S11B), indicating that this lysine 
residue is the only target for SUMOylation under these conditions. Notably, none of these 
mutations affected the nuclear localization of SOX2 in HUES-7 cells (Figure S11C), which 
suggested that phosphorylation of these serine residues did not initiate immediate export of 
SOX2 from the nucleus.
the hESC kinome network
Consensus motifs of phosphorylation sites are inappropriate for systematic matching with 
their corresponding kinases as specificity is largely determined by context21. Linding et al. 
addressed this issue by developing an algorithm (NetworKIN) which introduces the novel 
concept of combining probabilistic modeled network context with linear motifs recognized by 
the catalytic domain of kinases21. Relationships between kinases and all the phosphorylation 
sites defined here were predicted, creating for the first time a kinase-substrate database for 
hESC (Table S12). This was used to create an in vivo kinome for hESC (Figure 6.6A), comprising 
107 kinases, representing most of the known kinase families38. Interestingly, CDK1/2 appeared 
to play a prominent role, since it was predicted to phosphorylate ~1,200 peptides in our 
assay. To investigate this further, all kinases were predicted for Phospho.ELM39 and PhoshoSite 
(www.phosphosite.org), two publically available repositories of human phosphorylation sites, 
with >23,000 unique phosphosites. By comparing this hypothetical absolute kinome with the 
hESC-specific kinome, kinases that are under- or over-represented in hESC, based on the 
incidence of specific phosphorylations, could be identified (Figure S13). For instance, CDK1/2 
was found to mediate 26% of the phosphorylation events in hESC, which is significantly more 
(P<0.0001, Chi-square test) than the 12% of all theoretical phosphorylation sites in humans. 
Additional kinases with activities over-represented in hESC were MAPK8, MAPK11, MAPK14, 
TGFBR2, GSK3B, and NEK2, the latter being a known modulator of the cell cycle, just as CDK1/2. 
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Figure 6.6
Phosphorylation networks during hESC differentiation
The NetworKIN algorithm was 
used to predict kinases for every 
phosphorylation site identifi ed. 
(A) In total, 107 kinases were 
predicted to regulate the hESC 
phosphoproteome; the number 
of substrates is indicated in the 
pie chart. Kinases predicted to 
phosphorylate <30 substrates are 
shown combined in “others”. 
(B) By linking regulated kinases 
(blue boxes) to their predicted 
upstream kinases (red boxes), 
kinase cascades during hESC 
differentiation were modeled. 
Kinases regulated at only one time 
point are depicted as dark blue 
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S12). These findings suggest that prevalent kinases control cell cycle processes as well as the 
activity of pluripotency-associated transcription factors, both of which are characteristic of ESC. 
The MS data indicated that CDK2 is phosphorylated progressively at Y15, marking a decrease 
in its activity40. Linking site-specific kinases that were found regulated over the investigated 
time course with their corresponding upstream kinases, generated a temporal kinase-cascade 
model that illustrates the dynamics in kinase relationships during differentiation (Figure 
6.6B). This overview suggested that the initial signal that disturbs the ESC-associated network 
expands over time by activating an increasing number of kinases, resembling the model 
proposed previously41.
Discussion
Self-renewal in pluripotent hESC is highly sensitive to factors that trigger differentiation through 
transmission of signals to the nucleus. Activation and inactivation of intracellular proteins 
by phosphorylation and dephosphorylation are among the earliest events following binding 
of a ligand to its receptor. In addition to regulating protein activity, phosphorylation also 
contributes to controlling cell identity by fine-tuning protein expression. We used MS-based 
quantitative proteomics here to monitor dynamic changes in the phosphoproteome of hESC at 
the onset of BMP4-induced differentiation. We probed the hESC proteome to a depth of 5222 
proteins, 586 of which are thought to be regulated by the core transcriptional network. Since 
this core transcriptional network was postulated on the basis of ChIP data and transcription 
factor binding does not necessarily mean that the particular gene is regulated by that factor; 
our dataset provides high quality confirmation of the involvement of many proposed players. 
GO annotation of the hESC proteome resulted in prominent subclasses consisting of proteins 
associated with epigenetic modification27, transcription11,42, and translation43, suggesting that 
these processes are prominent in hESC. Among the 1399 proteins phosphorylated on a total 
of 3067 residues, more than 1200 sites had not been reported previously to our knowledge, 
430 belonging to the class of proteins that participate in the core transcriptional regulatory 
circuitry11. This implies that the activity of many proteins involved in the pluripotency and 
self-renewal network is regulated by a selection of kinases and phosphatases. 
Interruption of self-renewal by exogenous factors has major effects on signaling networks that 
sustain the undifferentiated state. Changing the identity of hESC by exposure to extracellular 
stimuli is immediately followed by a complete reconstitution of signaling pathways. This was 
exemplified by the observation that half of the phosphoproteome was modulated within the 
first hour of BMP4 exposure. In addition to the expected phosphorylation of receptor SMADs, 
increased phosphorylation of several substrates of AKT1 were detected, indicating activation of 
the PI3K/AKT pathway. This might have resulted from signaling through the insulin receptor44, 
as hESC differentiated in medium containing insulin as a survival factor. In addition, S63 and 
S73 of c-Jun were phosphorylated, though temporarily, suggesting transient activity of JNKs. 
Although cross-talk between intracellular pathways cannot be deduced from the present data, 
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there is evidence for reciprocal interactions between JNKs and AKT. JNKs can phosphorylate 
AKT1 at T450, thus priming this protein for activation through phosphorylation by PDK145. 
Conversely, AKT1 can inhibit the JNK pathway by phosphorylating ASK1 (MAPKKK5), which lies 
upstream of JNKs. This apparent dichotomy is in agreement with our data, as phosphorylation 
of c-Jun was early and transient, whereas phosphorylation of AKT substrates was sustained. 
This would tip the balance of pro-apoptotic (JNKs) and anti-apoptotic signaling (AKT) in favor 
of the latter.
In addition to changes in signaling pathways, we also found alterations in established 
and proposed regulators of pluripotency. For instance, a novel acetylation and three novel 
phosphorylation sites on LIN28 were identified. Ectopic expression of LIN28 contributes to 
formation of iPS cells, illustrating the importance of this pathway in regulating the pluripotent 
state46. Furthermore, LIN28 is known to block maturation of primary pri-Let-7g transcripts 
to mature Let-7g transcripts47. This led to the hypothesis that Let-7 and LIN28 participate 
in an incoherent feed-forward loop that contributes to rapid differentiation48. Another 
example is the detection of three novel phosphorylation sites on the transcription factor 
UTF1, a chromatin-associated transcriptional repressor crucial for differentiation of mESC49; 
two of the phosphorylation sites were regulated upon differentiation. For DNMT3B, six novel 
phosphorylation sites were identified, two of which were regulated. Upon differentiation, 
methyltransferases DNMT3A and DNMT3B are recruited to the OCT4 promoter, thereby repressing 
its transcription through CpG methylation50. We also identified three novel consecutive 
phosphosites on SOX2, which we investigated in more depth.
The transcription factor SOX2 is one of the three core transcription factors that play essential 
roles in embryonic development4,5 and self-renewal of ESC13,51. However, little is known 
about how the activity of SOX2 itself is regulated. Whereas SUMO-conjugation was found 
to inhibit binding of mouse Sox2 to DNA20, the PDSM defined initially in Sox3, Sox8, and 
Sox9 amongst other transcriptional regulators, had not been identified in Sox236. This can 
be explained by a surplus residue between E247 and S251, which does not match the 
established consensus sequence36. Combined, our findings indicated that the consensus of 
this PDSM is rather flexible and suggested that the three adjacent serine residues immediately 
upstream of P252 have redundant functions. Moreover, they imply that transcriptional activity 
of SOX2 is regulated by SUMOylation that results from phosphorylation. Interestingly, all 
phosphorylated forms of SOX2 were identified in hESC, but none increased significantly upon 
differentiation, suggesting that transcriptional activity of SOX2 is controlled stringently both 
in differentiating and undifferentiated ESC. A critical level of functional SOX2, essential for 
self-renewal52,53, is probably maintained by a fine balance between de novo synthesis, PTMs 
that alter its activity, and translocation from the nucleus followed by degradation. Of note 
is that all SOX2 mutants were localized predominantly in the nuclei of HUES-7 transfectants. 
This implies that phosphorylation of SOX2, as mimicked by the S249-251D mutation, and 
the consequent SUMOylation at K245, does not immediately lead to massive nuclear export 
and subsequent targeting for degradation. Presumably, the SUMOylation pathway is saturated 
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when SOX2 is overexpressed in HUES-7 cells, requiring concomitant overexpression of SUMO in 
order to detect SUMOylated forms of SOX2, as observed for SUMO2 overexpressing HeLa cells. 
Further investigation is needed to determine the balance between de novo synthesis versus 
degradation of SOX2, and the role of PTMs during its life span.
Using the NetworKIN algorithm to predict the kinases responsible for phosphorylation during 
differentiation, we reconstructed a hESC kinome composed of 107 kinases, 26 of which were 
regulated by phosphorylation upon BMP4 stimulation. Because of their low abundance, only 
54 phosphotyrosine peptides were identified, consequently receptor Tyr Kinases (e.g. INSR, 
EPHA4 and IGFIR) seem under represented. In contrast, 2,431 phosphoserine peptides were 
identified, pointing to a central role for CDK1/2. In addition to CDK1/2 and GSK3B, MAPK8 (a 
JNK protein), as well as MAPK11 and MAPK14 (p38 MAPK proteins) of the CMGC Ser/Thr protein 
kinase family38, have well-documented functions in differentiation. p38 MAPKs are inhibitory 
during cell commitment and are anti-apoptotic during late stages of differentiation, whereas 
the pro-apoptotic JNKs are involved in ectoderm and primitive endoderm differentiation54. 
However, protein phosphorylation is regulated by a precise control of protein kinase (PKs) and 
protein phosphatase (PPs) activities. The latter are regulated, in the same way as kinases, by 
an array of targeting and regulatory subunits, PTMs and by specific inhibitors. A total of 43 
PPs (30% of all phosphatases reported in SwissProt) were identified in our data set, 4 of them 
presented differentially regulated phosphosites: PPMH1 (Ser/Thr PPs), DUSP19 (Dual Specificity 
PPs) and, PTPN13 and PTPN14 (Tyr PPs). Both PKs and PPs possess basal activities; therefore 
we should take into account that some of the up-regulated phosphopeptides observed in our 
study could result from an inhibition of their specific PPs, and not because of an increase of 
the kinase activity. The same applies for down-regulated phosphopeptides.
It is not surprising that most dynamic phosphorylation of signaling cascade components 
occurred within 30 min of BMP4 exposure since similar kinetics had been observed by others 
studying EGF stimulation in HeLa cells28. The multiplicity of components of the network in 
hESC, and their initiation upon differentiation is far too complex to be covered in entirety 
here. Nevertheless, the multitude and variety of proteins that undergo phosphorylation 
changes during the first hours of differentiation suggests rapid and dramatic reorganization of 
the proteome that extends far beyond signaling alone. Proteins affected were classified based 
on GO-annotation and contextual co-occurrence in literature. These included methylation, 
transcription initiation, and transcriptional elongation, indicating that silent developmental 
genes controlled by OCT4, SOX2, and NANOG experience complex transcriptional regulation55. 
These genes are occupied by nucleosomes with histone H3K4me3 and histone H3K27me3. 
Although transcription is initiated, there is no productive elongation because of repression 
by PcG proteins56,57. Transcriptional repression of ESC-associated genes and SWI/SNF chromatin 
remodeling are also concepts associated with differentiation. Furthermore, the emergence 
of a protein SUMOylation cluster (consisting of E3 ligases, hydrolase and SUMO-isopeptidase) 
suggests that this type of PTM is a concept linked to differentiation that extends beyond the 
effects on SOX2 described above. Finally, the presence of clusters containing Rab11 family-
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interacting proteins, microtubule-associated proteins, VIMENTIN, GTPase-activating proteins, 
tight junctions, and focal adhesion proteins suggested that initiation of differentiation leads 
to remodeling of cell shape. We had shown previously that hESC grown as monolayer cultures 
under feeder-free conditions (i.e. identical to those used in this study) have an epithelial 
phenotype, evidenced by the expression of proteins belonging to adherence junctions, tight 
junctions, gap junctions, and desmosomes58. The observation that proteins forming these 
structures experience increased phosphorylation strongly suggests that their biogenesis 
changes 59 during a process that is initiated at the onset of differentiation.
Concluding remarks
In addition to an extensive profile of the hESC proteome, our approach generated a dynamic 
map of protein phosphorylation during differentiation of hESC showing concordance over time, 
which we used to define a wide spectrum of novel kinase substrates. These data provide a rich 
resource for further investigation of the function of individual proteins, as exemplified by the 
phosphorylation sites of SOX2 that regulate its transcriptional activity through SUMOylation. 
Linking genomic, epigenomic, transcriptomic, and proteomic approaches will improve our 
knowledge of stem cell biology and (human) development and, thereby, our ability to control 
self-renewal versus differentiation fate decisions by pluripotent cells.
Experimental Procedures
SILAC labeling of hESC and differentiation
HUES-7 hESC were cultured as previously60 on Matrigel without MEFs and differentiation 
induced by 50 ng/ml of BMP4. For details see Supplementary Experimental Procedures.
western blotting 
Western blotting was carried out as previously24. For details see Supplemental Methods.
phosphopeptide enrichment and mass spectrometric analysis
1 mg of protein was first reduced/ alkylated and digested with Lys-C. The mixture was then 
diluted 4-fold to 2 M urea and digested further with trypsin. Strong cation exchange was 
performed as before22; 24 fractions (1 min each, i.e. 50 μl elution volume) were collected 
by hand. The online TiO
2
 chromatography was set using a triple stage precolumn and both 
TiO
2
 eluate and Flow-Through fractions were chromatographically resolved using a 100 min 
linear gradient in the analytical column. The LTQ-Orbitrap was operated in data-dependent 
mode, automatically switching between MS and MS/MS. Full scan MS spectra (m/z 400-1,500) 
were acquired in the Orbitrap with a resolution of 60,000 while the two most intense ions 
were selected for MS/MS fragmentation in the linear ion trap. Further details can be found in 
Supplemental Experimental Procedures.
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peptide identification and quantitative analysis
Raw data were converted to single DTA files using Bioworks 3.2 and merged into Mascot 
Generic Format files which were searched using an in-house licensed Mascot v2.2 search 
engine against IPI human 3.28 database (containing 68,020 sequences). Carbamidomethyl 
cysteine was set as fixed modification; protein N-acetylation, oxidized methionines, serine, 









]-lysine) were set as variable modifications. The mass tolerance of the precursor 
ion was 10 ppm, and 0.9 Da for fragments ions. The false discovery rate was determined as 
<1% (Mascot score threshold of 35) using the decoy database approach. MSQuant (http://
msquant.sourceforge.net) was used to quantitate the levels of the identified phosphopeptides 
and determine the exact phosphorylation site within the peptide28. Every phosphopeptide 
quantitation was manually validated; peptides with low signal/noise ratios, low number of 
MS scans or overlapping peaks were not included for quantitative purposes. StatQuant, an 
in-house developed java software was used to correct for the arginine to proline conversion 
artifacts61, statistical analysis, comparison and normalization.
construction of human sox2 mutants
Wild-type human SOX2 was amplified by PCR using 5’-GGAATTCTCGGCGGCCGCCGGCGG-3’ in 
combination with5’-GGAATTCTCACAGATCCTCTTCTGAGATGAGTTTTTGTTCCATGTGTGAGAGGGGCAGTGTG
C-3’ (EcoRI site underlined; myc-tag sequence italicized), and pcDNA3.1/Zeo-hSOX2 (a gift 
from Dr. N.A. Hanley) as template. The myc-tagged human SOX2 PCR fragment was ligated 
into pGEM-T, and sequenced to check for errors. Mutations were introduced by digestion of 
this pGEM-hSOX2-myc plasmid with BplI, followed by ligation of synthetic double-stranded 
oligos outlined in Table S13, and sequencing to verify the mutations. Each human SOX2 
construct was isolated from the different pGEM-hSOX2-myc variants by digestion with EcoRI, 
and ligated into pCAG-GFP-IRES-Puror 60 linearized using EcoRI, thus replacing the existing 
GFP open reading frame. The resulting pCAG-hSOX2-myc mutants were sequenced to confirm 
correct orientation behind the pCAG promoter.
transfection and immunofluorescent analysis of hues-7 cells
HUES-7 cells were transfected as described previously60 with the pCAG-hSOX2-myc variants, 
and fixed after 48 h. Fixed cells were stained using specific antibodies. For details see 
Supplementary Experimental Procedures. 
Culture and transfection of HeLa cells, and purification of His
6
-SUMO2-conjugated proteins 
HeLa cells, stably expressing His
6
-SUMO2 were cultured as described previously62, and 
transfected with the pCAG-hSOX2-myc variants using polyethyleneimine. The following day, 
cells were lysed and His
6
-SUMO2 conjugates purified on nickel-nitrilotriacetic acid-agarose 
beads (Qiagen) as described previously63.
supplemental data
Supplemental Data contains Supplemental Experimental Procedures, 13 Supplemental Figures, 
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13 Supplemental Tables, one Supplemental File and Supplemental references which can be 
found on-line at http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00230-
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Cardiac progenitor cells give rise to the 
major cellular components of the heart. 
Understanding how they form and what 
they can become has important implications 
for elucidating the mechanisms underlying 
(abnormal) heart development. In addition, 
the ability to isolate these cells from 
pluripotent stem cells allows characterization 
of their properties and possibly expansion in 
culture, a crucial step  for advancing cardiac 
translational medicine. Functional analysis of 
these cells has been hampered by the paucity 
of lineage specific markers and inefficient, 
undefined differentiation procedures. Here 
we describe the targeted modification of 
two independent human embryonic stem 
cell (hESC) lines in which EGFP was inserted 
into the locus of NKX2-5, one of the earliest 
transcription factors expressed in heart 
development. EGFP fluorescence driven by 
the endogenous NKX2-5 promoter faithfully 
reported cardiovascular lineage commitment 
of differentiating hESC under defined culture 
conditions. The early NKX2-5 positive cell 
population contained multipotent progenitor 
cells capable of directed differentiation to 
cardiomyocytes, endothelial and vascular 
smooth muscle cells. NKX2.5 overlapped only 
partially with previously reported selection 
markers for the cardiovascular lineage. These 
data are compatible with expectations from 
heart development and identify a progenitor 
that can give rise to the three major cell types 
of the heart or through fine temporal fine 
tuning, almost exclusively cardiomyocytes. 
Taken together, these experiments 
demonstrate the utility of hESC for analyzing 
the previously inaccessible events of human 




The ability to generate functional cardiovascular (progenitor) cells from human pluripotent stem 
cells is beginning to offer unprecedented opportunities for translational research in cardiac 
medicine. Applications range from the use of cells to study early human cardiac development, 
the development of disease models, predictive cardiotoxicity assays, drug development and 
ultimately the development of cell therapy for degenerative diseases1. Advance of all of 
these applications depends on robust differentiation procedures underpinned by detailed 
knowledge of the signaling mechanisms regulating cell fate. 
Over the previous decade methods for expansion and directed differentiation of human 
embryonic stem cells (hESC) has improved considerably. One recurring theme is that most 
successful differentiation protocols recapitulate the regulatory circuits that control normal 
development. Initially, protocols supporting cardiomyocyte differentiation relied on poorly 
defined reagents and inefficient cell culture methods. This resulted in cultures with only 
a very small percentage of beating cells (<1%)2. Later it was shown that co-culture with 
endoderm-like cells, mimicking signaling from endoderm in normal development3 resulted in 
a relatively efficient and robust cardiomyocyte differentiation4. More recently, several groups 
have shown that the cytokines Bone Morphogenetic Protein 4 (BMP4) and Activin A induce 
mesendoderm in differentiating hESC cultures5,6,7. However, the exact timing, concentration 
and spectrum of growth factor requirements for the initiation of cardiogenesis, formation of 
cardiac progenitors and further maturation remain to be defined. 
In mouse the earliest cardiac progenitor identified, arises in the primitive streak and 
expresses Flk-1/KDR8. Later in development at least two progenitor populations are present. 
The first population expresses the transcription factor Nkx2-5 and is present in the cardiac 
crescent or the first heart field (FHF).  Nkx2-5 is one of the earliest cardiac progenitor markers 
and continues to be expressed in the adult myocardium9. The committed FHF progenitors 
contribute to left and right ventricles, both atria and AV canal10,11. The second population, 
known as the second heart field (SHF) is characterized by the expression of the transcription 
factor Isl1 in addition to Nkx2-5. These cells give rise mainly to the outflow tract and right 
ventricle but also contribute to all other regions of the heart except the left ventricle10. In the 
developing SHF, multipotent Isl1+/Nkx2-5+ progenitors can differentiate to endothelial cells, 
vascular smooth muscle and cardiomyocytes12. 
Two studies to date have used a human pluripotent stem cell model for identification, selection 
and characterization of cardiac progenitors6,13. An antibody mediated cell sorting method 
developed in mice and based on cell surface expression of the VEGF-receptor FLK-1/KDR was 
instrumental in the first isolation human cardiovascular progenitors from hESC6. Later, genetic 
tagging of Isl1 allowed the isolation of another population of human cardiac progenitor 
cells from hESC. Although both methods worked effectively neither was an exclusive cardiac 
progenitor marker. Flk-1/KDR is not specific for cardiac mesoderm14,15 and ISL1 is broadly 
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expressed in multiple non-cardiac lineages during early development. 
Here we report targeted modification of NKX2-5 with EGFP in hESC. The activity of the 
reporter faithfully recapitulated the process of cardiac development and allowed purification 
of cardiomyocytes from a heterogeneous cell population. The transgenic line permitted 
development of a cytokine screening strategy in defined medium that ultimately resulted in 
an optimized cardiac differentiation protocol. FACS based purification of early NKX2-5 positive 
cells revealed a multipotent progenitor population capable of directed differentiation to the 
cardiac, endothelial and vascular smooth muscle cell lineages.
Materials and methods
hESC culture and differentiation
hESC culture and gene targeting were performed as previously described7. Differentiation was 
induced by forced aggregation in APEL media16, with the following cytokines: 20 ng/ml of 
BMP4 (R&D) and Activin A (R&D), 30 ng/ml VEGF (R&D) and 40 ng/ml SCF (R&D). hESC-CMs were 
also derived using the END2 co-culture system, as previously described4.
flow cytometry
Embryoid bodies (EBs) were dissociated using TrypLE Selectä (Invitrogen), and intracellular 
flow cytometry carried out on cells fixed and stained with anti-ISL1 (DSHB, clone 39.4D5), 
anti-OCT4 (Santa Cruz Biotechnology) and anti-NKX2.5 (Abcam) antibodies as previously 
described17. Mouse anti-human primary antibodies reacting with cell surface antigens for live 
cell sorting included unconjugated anti-E-CADHERIN (Zymed), anti-TRA-1-60 (Chemicon), anti-
SSEA4 (Chemicon), FITC-conjugated anti-CD9 (BD Biosciences), anti-PDGFRa (BD Biosciences), 
anti-VCAM (BD Biosciences) and phycoerythrin (PE) conjugated anti-CXCR4. Non-conjugated 
antibodies were detected with allophycocyanin (APC)-conjugated goat anti-mouse IgG (BD 
Biosciences). Flow cytometric gates were set using control cells labeled with the appropriate 
isotype control antibody. Single cell cloning was performed using the single cell deposition 
function of a FACSaria FACS station as previously described7.
imaging
Cells were cultured on glass coverslips, fixed in 4% PFA for 30 min, permeabilized for 5 min. 
with 0.1% Triton X-100 in PBS and blocked with 4% normal goat serum. Cells were incubated 
with primary antibodies and labeled with alexa405, Cy3, Cy5 and/or alexa647 conjugated 
secondary antibodies. Primary antibodies used in this study were against a-actinin (clone 
EA53, Sigma), PECAM (DAKO), smooth muscle actin (Abcam), NKX2-5 (Santa Cruz) MLC2V (Synaptic 
Systems), MLC2A (Synaptic Systems), MYH6 (Chemicon), GATA4 (Santa Cruz), c-KIT(Dako), and 
PDGRa BD) Nuclei were counter stained with DAPI. Confocal scanning was performed on a 
Leica SP5 confocal laser scanning microscope (40x and 63x oil immersion objectives). For live 
cell imaging, cells were cultured on MatTek dishes (MatTek Corp. Amsterdam) and imaged 
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on a Leica SP5 using the resonance scanner at a resolution of 512x256 (30fps). For calcium 
imaging, cells were loaded with Fura Red (Molecular Probes, Invitrogen). The 488nm laser 
was used to excite EGFP and Fura Red (calcium free). Two PMTs were used simultaneously 
for detecting EGFP and Fura Red specific photons respectively. ImageJ imaging processing 
software was used for normalization of Fura Red fluorescence to EGFP and for further data 
analyses.
electrophysiology
Patch clamp electrophysiology was carried out essentially as described previously, with minor 
modifications18. Briefly, beating clumps of cardiomyocytes were dissociated using Tryp.Le, 
replated on gelatin-coated coverslips and measured in current clamp mode between 7 and 
14 days after plating.
For MEA electrophysiology, hESC-CM clusters were microdissected and replated on plasma 
cleaned fibronectin coated 60 electrode MEAs. Extracellular recording was performed using 
a MEA1060INV MEA amplifier (Multi Channel Systems, Reutlingen, Germany) at 37oC. Output 
signals were digitized at 10 kHz by use of a PC equipped with a MC-card data acquisition 
board (Multi Channel Systems, Reutlingen, Germany).
force measurements
A beating region within an embryoid body was selected and viewed through a Nikon Eclipse 
TS100 inverted microscope with Hoffman modulation contrast optics, coupled to a Basler 
(model A602f) camera. Quick Caliper (SDR Clinical Technologies) enabled the acquisition of 
a 10 second capture (80 frames/second).  Prior to the addition of agonists/activators a 10 
second capture was obtained to establish baseline conditions. Following this, either forskolin 
(1μM), endothelin-1 (ET-1; 10nM) or vehicle controls were added to the well, and the plate 
placed back in a humidified incubator (37oC, 5% CO
2
).  A second 10 second capture was then 
taken 2 and 5 minutes post forskolin or ET-1.
ET-1 was dissolved in physiological salt solution (PSS) buffer consisting of (in mM) NaCl 140, 
KCl 6, CaCl
2
 2, MgCl2 1, HEPES 20 and glucose 10, supplemented with 1.4 % (w/v) BSA (pH 7.4, 
37ºC). Forskolin was dissolved in ethanol and the final ethanol concentration did not exceed 
0.01% of the media volume in the well.
The video captures were analysed using the Metamorph® Imaging System (Molecular Devices 
Ltd). For each image stack constituting a 10 second capture, an intensity threshold was set for 
the beating image. The Metamorph® software was then used to track the intensity centroid 
of a selected particle throughout the 10 second image stack. The amplitude of contraction 
of the selected particle (in pixels) was plotted against time for each time point (See Figure 
7.3C). The number of peaks within the 10 second capture was converted to beats per minute 
to represent the contraction frequency.  The frequency recorded in response to an agonist was 
reported as a percentage of the basal spontaneous rate (i.e. prior to agonist addition). 
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As previously reported hESC-derived cardiomyocytes, not all beating aggregates responded 
to agonist stimulation. Responding and non-responding aggreagtes were identified using 
a repeated measures ANOVA test of the time interval between beats in each 10 second 
capture.  Differences between means were tested using the Student’s t-test and values of p< 
0.05 were considered statistically significant.
Results
nkx2-5egfp/w hesc line facilitates identifaction and purifaction of 
human cardiac progenitor cells
To investigate early differentiation events in human cardiogenesis we introduced sequences 
encoding the green fluorescent protein (EGFP) into the NKX2-5 locus of hESC (Figure 7.1). The 
targeting vector contained a PGK promoter driving expression of neomycin acetyltransferase 
flanked by loxP sequences, the recognition sites of bacteriophage Cre recombinase. Correctly 
targeted hESC clones were identified by polymerase chain reaction (PCR) amplification (Figures 
7.1A & data not shown) and sequencing of the resultant PCR products. The selection cassette 
was removed by transient transfection of hESC with a Cre recombinase expression vector and 
subsequent single cell deposition by FACS7. Cassette deletion was validated by PCR (data not 
shown). Southern blotting with an EGFP probe confirmed that the identified NKX2-5EGFP/w 
clones contained only a single integration event (Figure 7.1B). Two hESC lines, HES319 and 
MEL1 (Millipore) were targeted in this manner to generate H3 NKX2-5EGFP/w and M1 NKX2-
5EGFP/w, respectively. All NKX2-5EGFP/w clones expressed markers of undifferentiated HESC, 
were karyotypically normal and formed teratomas (data not shown). To derive cardiomyocytes 
NKX2-5EGFP/w cells were initially differentiated20 in the END-2 co-culture system. As expected, 
this protocol resulted in reproducible and robust cardiac differentiation. Importantly, eGPF 
driven by the NKX2-5 promoter was specifically activated in beating foci. Beating areas could 
be readily identified based on bright green fluorescence and all green beating foci stained 
positive for cardiac a-actinin (Figure 7.1C). To verify that EGFP expression recapitulates 
endogenous NKX2-5 expression, dissociated EGFP+ cells were stained with anti-NKX2-5 
antibody. All EGFP+ cells showed prominent nuclear NKX2-5 staining, as well as expression of 
the cardiac protein a-actinin (Figure 7.1D). Furthermore, dissociated cardiomyocytes stained 
positive for the cardiac structural proteins MLC2a, MLC2v and beta myosin heavy chain as 
well as transcription factors NKX2-5, ISL1 and GATA4 (data not shown). EGFP cardiomyocytes 
displayed a similar fetal sarcomeric organization as cardiomyocytes from control hESC lines21.
optimized differentiation in defined media
Having validated the integrity of the GFP reporter cell lines and retention of the ability to form 
cardiomyocytes robustly, we designed a cytokine screening strategy based on the fluorescent 
reporter as a read-out. The aim was to develop a method for directed cardiovascular 
differentiation of hESC under chemically defined culture conditions. To screen and cross titrate 



















(A) Design of the gene targeting 
vector to insert sequences 
encoding EGFP into exon 1 of the 
NKX2-5 locus. NeoR is the PGK-
Neo cassette encoding neomycin 
acetyltransferase, fl anked by LoxP 
sites (black triangles) (B) Southern 
blot with a GFP probe to confi rm a 
single integration in the genome. 
(C) a-actinin staining on cardiac 
differentiated H3 NKX2-5EGFP/w 
(D) co-staining for NKX2-5 and 
a-actinin on dissociated H3 NKX2-
5EGFP/w.
(A) Optimized differentiation 
protocol based on temporal 
addition of BMP, SCF, Activin A and 
SCF for three days. (B) Temporal 
expression pattern of NKX2-5 
during EB differentiation by fl ow 
cytometry for EGFP+ cells (C) 
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used a forced aggregation (or “spin EB”) protocol in a chemically defined media (APEL)16,17 
supplemented with BMP 4 and Activin A5,6. Since cardiac mesoderm derives from a cell 
population expressing the VEGF receptor, KDR6, and stem cell factor (SCF) has been shown 
to improve cell viability in spin EBs22 both VEGF and SCF were included in the differentiation 
medium (Figure 7.2A).
Optimal cytokine concentrations were determined by cross titration of the growth factors 
mentioned above, examination of EBs for eGFP expression and scoring for the appearance 
of spontaneous contractile foci. The optimized protocol presented here consists of two 
initial steps performed in suspension culture; i) mesendoderm induction by a combination 
of BMP4 and Activin A until day 3 of differentiation and ii) further specification of cardiac 
mesoderm relying on endogenous signaling networks established by the primitive 
streak-like population generated in step I (Figures 7.2A & S7.2). Removal of growth 
factors on day 3 leads to a significant increase in the production of NKX2-5EGFP+ cells 
(Figure 7.2). This suggests that by day 3 EBs contain sufficient patterning information for 
cardiomyogenesis to proceed autonomously without the addition of exogenous factors. 
 
The temporal expression pattern of NKX2-5 during EB differentiation was established 
by flow cytometry for EGFP+ cells. Control experiments using FGF2 demonstrated a 
requirement for mesendoderm induction to allow cardiac differentiation to proceed 
(Figure 7.2B). EGFP+ cells emerged on days 6-7 of differentiation and increased as 
a percentage of the culture until day 12 (Figure 7.2B). After transfer to adherent culture 
beating foci appeared within EBs. NKX2-5EGFP/w EBs maintained for 90 days continue to 
contract; however, after day 12 little increase was observed in percentage of EGFP+ cells. 
To confirm that EGFP expression recapitulated NKX2-5 expression, sorted EGFP+ cells 
were stained with anti-NKX2-5 antibody. All EGFP+ cells examined showed significant 
nuclear NKX2-5 staining, as well as expression of cardiac a-actinin (data not shown). 
nkx2-5egfp/w cells can differentiate to functional cardiomyocytes
For many future applications requiring human cardiomyocytes derived from stem or progenitor 
cells, it will be important to know their electrical and functional properties. We therefore 
analyzed the action potentials of cardiomyocytes generated from the H3 NKX2-5EGFP/w line. 
Cells were classified as atrial-like, ventricular-like or pacemaker-like based on the profiles of 
the action potentials, as previously. As in cardiomyocytes from the parent HES3 line induced 
by END2 cell co-culture, the majority of cardiomyocytes from the NKX2-5EGFP/w cell line 
displayed a ventricular-like action potential; only a minority of cells displayed characteristics 
of pacemaker- or atrial cells18. The average upstroke velocity was 6,4±2,3 V/s , the 90% 
repolarization 522,8±199,6 ms, the amplitude 88,8±6,6 mV and the resting potential was 
-43,5±5,7 mV in 18 independent measurements, A representative ventricular like action 
potential is shown in Figure 7.3A. Next the cells were analyzed using Multielectrode array 
(MEA) field potential analyses. As expected the cells showed a trace typical for hESC-CM (Figure 



































































Characterization of NKX2-5EGFP/w cardiomyocytes
(A) Patch clamp electrophysiology 
showing a representative 
ventricular like action potential 
from H3 NKX2-5EGFP/w, (B)
Field potential from a cluster 
contracting cardiomyocytes 
measured on a multi electrode 
array (recording from one 
electrode). (C) Fura red calcium 
imaging using confocal microscopy 
from a beating cluster. 
(D) Contraction force 
measurements of beating EBs in 
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hESC-CM with respect to their electrical phenotype. To investigate properties of the cells 
in more detail, they were labeled with Fura Red to visualize the calcium homeostasis. As 
expected the cells showed typical calcium traces that accompanied contraction of the cells, 
indicating normal calcium homeostasis (Figure 7.3C, movie S7.2). Finally the cells were 
tested functionally by adding the ionotropic/chronotrophic agents endothelin-1 (ET-1) and 
Forskolin. Both compounds exert similar effects on cardiomyocytes but the mechanisms are 
different: ET-1 increases the concentration of cytosolic Ca2+ while Forskolin activates adenylyl 
cyclase resulting in elevated cAMP levels. Approximately 57% (4/7) of the spontaneously 
beating cardiomyocyte aggregates responded to ET-1 (10nM) addition, whereas 66% (2/3) 
responded to forskolin (1μM) addition. In the responding aggregates, ET-1 (10nM) increased 
contraction frequency by 58 ± 11% (p<0.05, students t-test, n=4). Preliminary investigations 
with forskolin indicated that it, also, increases contraction frequency (by 43±7%; n=2). 
Although the responses were not homogeneous, the hESC-CM do contain functional endothelin 
receptors, as well as intact cAMP signalling pathways, both of which are involved in the 
modulation of spontaneous contraction frequency. 
isolation and characterization of multipotent nkx2-5+ cardiac 
progenitor cells (CPCs)
Having demonstrated the cardiomyogenic potential, the validity of the reporter and the 
functionality of cardiomyocytes generated from H3 NKX2-5EGFP/w we used the line to 
investigate the temporal dynamics of the appearance of NKX2-5 positive cells in greater 
detail. Studies in mouse embryos and mESC have shown that early Nkx2-5 positive cells co-
express Flk-1 and c-kit. These cells have the potential to differentiate into cardiomyocytes, 
vascular smooth muscle and endothelial cells23. To determine whether this is also the case for 
early NKX2-5+ cells from hESC we analyzed the NKX2-5+ cells at day 7 of END-2 co-culture for 
the membrane markers c-Kit, PDGFRa and Flk-1/KDR by confocal imaging (Figure 7.4A). While 
PDGRa was expressed at low levels we could find no evidence for c-Kit expression or Flk-1/
KDR (Fig 7.4A and data not shown). Many cells that expressed high levels of PDGFRa did not 
express NKX2-5 (Figure 7.4A, see insert), thus did not correspond with a cardiac progenitor 
population. Furthermore, it was clear that none of these markers segregated exclusively with 
the NKX2-5 population. Analyses of day7 cells derived from spin EB indicated the presence 
of a comparable population. PDGFRa was expressed at low levels and Flk-KDR expression did 
not exceeded background levels. We next sorted day 7 NKX2-5+ cells from H3 NKX2-5EGFP/w 
differentiated in End-2 co-culture using flow cytometry (Figure 7.4C). Cells were re-plated 
on fibronectin coated substrates in defined culture medium supplemented with selected 
recombinant growth factors. To date, most CPC differentiation protocols have not used defined 
media; as a result, the signaling pathways required for cardiovascular lineage specification 
have not been precisely defined. Addition of bFGF plus BMP4 resulted in the appearance 
of SMA and PECAM positive cells as well as a-actinin positive cells (Figure 7.4D), suggesting 
that the sorted NKX2-5+ cell population contained multi-lineage cardiovascular progenitors. 
The NKX2-5- cells did not form these cells under the same conditions indicating the NKX2-5 
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(A) Confocal microscopic imaging 
of END-2 co-cultures at day 7 of 
differentiation. NKX2-5+ areas 
stained for PDGFRa and c-Kit. 
(B) FACS analyses of day 7 spin-
EB differentiations stained for 
PDGFRa and Flk-1/KDR (gated on 
NKX2-5+ cells) (C) experimental 
flowchart describing FACS sorting 
NKX2-5 progenitors (D) directed 
differentiation of END-2 derived 
CPCs to endothelial lineages (positive 
for PECAM), vascular smooth muscle 
(a-smooth muscle actin) and 
cardiomyocytes (a-actinin)
Figure 7.4 
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the other markers tested.  Interestingly, the balance between FGF and BMP signaling has 
been described as a fate regulator of pericardial chick mesoderm, determining the choice 
between the epicardial and myocardial lineages24,25. We therefore cross-titrated these two 
growth factors in the sorted NKX2.5-GFP cells and determined their cardiac differentiation 
potential. Preliminary results indicated that BMP alone gives rise to cultures highly enriched 
for contracting cardiac a-actinin positive cells. Addition of bFGF led to a clear dose dependent 
lineage shift to non-myocardial cells, suggesting that the balance between BMP and FGF 
regulates the fate of the NKX2-5+ CPC population from hESC as in the chick.
Discussion
The origin and fates of human cardiovascular progenitor cells are still largely unknown. Here 
we show that the combined use of pluripotent stem cells and gene targeting allows dissection 
of previously inaccessible events during human cardiac progenitor development. Insertion 
of eGFP in the NKX2-5 gene resulted in two independent hESC lines that captured cells with 
cardiovascular developmental potential from the heterogenous mixtures of hESC derivatives. 
Beating foci were brightly fluorescent and eGFP positive areas stained positive for both cardiac 
a-actinin and NKX2-5 proteins. Electrophysiological analysis, calcium imaging and force 
measurements confirmed their phenotype as functional cardiomyocytes, indistinguishable 
from cardiomyocytes generated from wild type hESC. The bright eGFP reporter activity driven 
by the endogenous NKX2-5 promoter line permitted development of a cytokine screening 
strategy that ultimately resulted in an optimized cardiac differentiation protocol. This new 
protocol makes use of defined medium supplemented with the cytokines BMP, Activin A, 
SCF and VEGF. Notably, removal of the growth factors at day 3 led to a significant increase in 
the production of NKX2-5EGFP+ cells (up to 35%), suggesting that by day 3 the EB contains 
sufficient patterning information for cardiomyogenesis to proceed without further addition 
of exogenous factors. Recent work on mESC suggests that EBs can be polarized in an anterior-
posterior direction and form a structure that resembles the primitive streak. Local activation of 
the Wnt pathway resulted in an epithelial-to-mesenchymal transition and differentiation into 
mesendodermal structures. This process required exogenous factors but was self-reinforcing 
after initiation26. A similar process seemed to occur in our protocol despite the absence of 
exogenous Wnt signals.  Addition of fresh cytokines at later time-points never enhanced 
differentiation outcome. This suggested that the auto- and endocrine signaling between the 
different cell types is so balanced that alteration of exogenous signaling mainly disturbs their 
differentiation potential. 
Isolation of human cardiac progenitors based on NKX2-5 expression could be a good approach 
to dissect cardiac progenitor lineage decisions without interference of cells not associated 
with this lineage. In the mouse, Nkx-2.5 transcripts are first detected at early headfold 
stages in myocardiogenic progenitor cells. Expression precedes the onset of myogenic 
differentiation, and continues during  lifetime of a cardiomyocyte9. NKX2-5 is one the earliest 
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genes that control cardiac differentiation and is present in both the progenitors of the FHF 
and SHF. Transcripts are mainly expressed in the heart although expression is also detected 
in the cardiac associated pharyngeal endoderm, lingual muscle, spleen and stomach9. In 
the mouse several cardiac progenitor populations have been described and the majority of 
them expressed Nkx2-5. Only the Flk-1 progenitor described by Kattman et al emerges at 
such an early developmental stage that Nkx2-5 is not yet expressed8. However according 
to fate mapping experiments performed in mouse embryos, Flk1+ progenitors contribute 
only to a subset of cardiac muscle cells15. Moreover Flk-1 is not expressed in all cells of the 
cardiac crescent during development, nor is it cardiac specific. Two independent groups have 
described the isolation of putative primordial / FHF specific progenitors in the mouse23,27. Both 
of these studies made use of a Nkx2-5 reporter construct for the isolation of CPCs. However 
there were differences between the cell populations. The cells identified by Wu and colleagues 
co-expressed c-Kit, were bi-potent, indicated by their differentiation to cardiomyocytes and 
smooth muscle cells27. The cells identified by Christoforou and colleagues co-expressed c-kit 
and Flk-1/KDR and were reported to be multipotent: besides cardiomyocytes and vascular 
smooth muscle cells they were also capable of forming endothelial cells23. Whether the cells 
from these two studies represent the same population remains to be investigated. In the 
developing SHF a similar multipotent cell can be identified. This progenitor expresses Isl1+/
Nkx2-5+ and is capable of directed differentiation to endothelial, vascular smooth muscle 
and cardiomyocyte lineages12. 
Isolation of NKX2-5+ cells from the H3 NKX2-5EGFP line at day 7 of differentiation resulted in 
multi-lineage differentiation to cardiomyocytes, endothelial cells and vascular smooth muscle 
cells. These findings indicate a differentiation potential comparable to the mouse multipotent 
progenitors found in the SHF, and the Nkx2-5 progenitors described by Christoforou et al. 
However, in contrast to the mouse Nkx2-5 CPCs our cells do not express c-KIT, and FLK-1 is 
only expressed at low levels, which suggests a difference to the mouse cells described by 
Christoforou. Furthermore the relationship to ISL1 remains largely unclear. According to Bu et 
al (2009) the expression of ISL1 in human cardiac development precedes NKX2-5 expression, 
however this was not investigated in detail. Although some of our NKX2-5+ cells do express 
ISL1 it is certainly not co-expressed in all cells. In general, from studies in the mouse it seems 
that ISL1 and NKX2-5 mark a distinct but overlapping population of cardiac progenitors. 
However it is of note that ISL1 is expressed in multiple organs and tissues in the developing 
embryo, including motor neurons and pancreas progenitors28,29. In accordance with this, only 
4.2% of the human Isl1 clones gave rise to cells expressing cardiac genes, 3.1% to endothelial 
and 44.1% to smooth muscle13.  
Further follow up studies including clonal assays on human NKX2-5 positive cells, will be 
required to confirm the multipotency of our cells and their relationship with ISL1. Finally, it 
should be mentioned that analyses of the ISL1 family of cardiac progenitors suggests clear 
differences in mouse and human cardiac development. In the mouse, a rapid transition 
from an Isl1 progenitor to migration and conversion to cells of the SHF is observed. 
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Consequently, later in development relatively few Isl1-expressing cells can be found in the 
heart. Furthermore, Isl1-progenitors generally co-express the transcription factors Nkx2-5 
and Flk-1/KDR; indicative of a rapid fate restriction. In the first trimester of cardiac human 
development relatively large numbers of ISL1 expressing cells are present that do not co-
express KDR or Smooth muscle myosin heavy chain or cardiac Troponin, perhaps reflecting the 
fact that heart development in humans is a much longer process than rodents. It has been 
suggested that these cells represent the upstream precursor for the multipotent progenitors in 
the SHF lineage13. Therefore the presence of a family of ISl1 expressing intermediate, lineage-
restricted progenitors could reflect the requirement for the more extensive cell expansion 
necessary to produce cell numbers orders of magnitude greater in adult human hearts than 
in mice30.
In summary, the findings reported here demonstrate the combined potential of the pluripotent 
stem cell model with genetic manipulation of these cells. Targeted modification of NKX2-5 with 
EGFP resulted in a highly specific reporter line that can be used for the isolation and lineage 
dissection of human cardiac progenitors. Specifically we show that day 7 CPCs are capable 
of directed differentiation to cardiomyocytes, vascular smooth muscle and endothelial cells. 
Interestingly it seems that the ratio of exogenous bFGF to BMP determines the differentiation 
fate of the NKX2.5 marked CPCs. BMP2 is a known cardiogenic factor expressed in lateral 
plate mesoderm and cardiac-associated pharyngeal endoderm31. Our data suggests that this 
signaling might be a driver of CPC specification to cardiomyocytes. It is expected that further 
studies on CPCs will eventually lead to optimized culture conditions for self-renewal and 
directed differentiation to various cardiovascular lineages of the heart.
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Recent withdrawals of prescription drugs 
from clinical use because of unexpected 
side effects on the heart have highlighted 
the need for more reliable cardiac safety 
pharmacology assays. Block of the human 
Ether-a-go go Related Gene (hERG) ion 
channel in particular is associated with life-
threatening arrhythmias, such as Torsade de 
Pointes (TdP). Here we investigated human 
cardiomyocytes derived from pluripotent 
(embryonic) stem cells (hESC) as a renewable, 
scalable and reproducible system on which 
to base cardiac safety pharmacology assays. 
Analyses of extracellular field potentials 
in hESC-derived cardiomyocytes (hESC-CM) 
and generation of derivative field potential 
duration (FPD) values showed dose-
dependent responses for 12 cardiac and 
non-cardiac drugs.  Serum levels in patients 
of drugs with known effects on QT interval 
overlapped with prolonged FPD values 
derived from hESC-CM, as predicted. We 
thus propose hESC-CM FPD prolongation as a 
safety criterion for pre-clinical evaluation of 
new drugs in development. This is the first 
study in which dose responses of such a wide 
range of compounds on hESC-CM have been 
generated and shown to be predictive of 
clinical effects. We propose that assays based 
on hESC-CM could complement or potentially 
replace some of the preclinical cardiac 
toxicity screening tests currently used for 





The pharmaceutical industry presently generates large libraries of “new chemical entities” 
(NCEs) with the aim of selecting those most promising for clinical trials. Distinguishing specific 
from detrimental off-target effects at an early stage has the potential to accelerate clinical 
introduction, improve drug safety and reduce drug development costs. The heart has proven 
to be particularly sensitive to off-target, life threatening toxic effects of non-cardiac drugs. 
Over the last several years, reports of unexpected drug-induced ventricular arrhythmias 
associated with sudden cardiac death, have led to the withdrawal of a number of drugs from 
the market, while for many others, additional safety labels have been required to warn of 
potential risk1.
An important determinant for development of Torsade de Pointes (TdP), is prolongation of 
the QT interval indicating delayed ventricular repolarization. This is defined as the period 
between the beginning of the QRS complex (depolarization of the ventricles) and the end of 
the T-wave (repolarization of the ventricles) on an electrocardiogram (ECG). In 1998 the Food 
and Drug Administration (FDA) defined prolongation of the QT interval on an ECG as a major 
drug safety issue. Currently, assessing risk for QT interval prolongation is part of the standard 
pre-clinical evaluation of NCEs as defined by the International Conference of Harmonization 
(ICH) Expert Working Group in topic S7B for all drugs in development2,3.  
Drug-induced long QT is most commonly induced by affecting the rapid potassium current 
I
kr
 by binding to the hERG ion channel4,5. Both for cardiac and non-cardiac drugs, primary 
canine or rabbit Purkinje fibers, or cell lines ectopically expressing the hERG ion channel 
are the preclinical in vitro test systems presently available. Species differences or the lack of 
complex ion channel interactions in transgenic cell lines reduce the predictive value of these 
systems. For example, determination of the IC
50
 value for a drug compound in transgenic 
cell lines over-simplifies a complex process that is state-, time- and voltage dependent. 
Some drugs like dofetilide require channel activation to reduce the hERG current6 while 
others, like fluvoxamine, interact exclusively with a closed channel. Finally, not all drugs 
that block hERG channels in these cell systems carry an arrhythmogenic risk; one well known 
example is verapamil 1. Also of note: many anti-arrhythmics can interact with multiple ion-
channels simultaneously. In addition to potassium channels, the activity of a heart cell is 
largely dependent on sodium and calcium channels. Whereas activation of sodium channels 
is required for the generation of an action potential, inward Ca2+ currents through (L-type) 
calcium channels counterbalance outward potassium currents in the repolarization phase. 
To illustrate the complexity of predicting QT prolongation, a recent comparison of 10 drugs 
on dog Purkinje fibers demonstrated a wide range of effects on QT time, ranging from 158% 
prolongation to 16% shortening, while all compounds blocked hERG channels by more than 
50%7. 
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Together, these findings emphasize the importance of assessing pre-clinical cardiotoxic 
responses to drugs on cells that closely resemble functional cardiomyocytes of the human 
heart.  Moreover, any alternatives to the current models must be scalable, reproducible and 
preferably from an inexhaustible source. Human embryonic stem cell-derived cardiomyocytes 
(hESC-CMs) have this potential8. Embryonic stem cells can differentiate to all somatic cell 
types including cardiomyocytes and in recent years, much effort has been put into developing 
efficient and reproducible differentiation protocols9 and methods for cardiomyocyte 
enrichment from differentiated cell populations10-12. Here, we describe the use of hESC-CM 
in a medium-throughput screening system using microelectrode arrays (MEAs) to determine 
action potential duration or QT interval by measuring extracellular field potentials. We provide 
a first validation of the system, using a selection of drugs previously associated with QT 
prolongation and/or TdP during clinical use in humans. We show that hESC-CM, as used here, 
can recapitulate drug toxicity mediated through human ion-channels and therefore represent 
an opportunity for pre-clinical NCE evaluation.
Results
validation of hESC-CM
Co-culture of HES2 and HES3 cells with visceral endoderm-like END-2 cells is among the most 
efficient ways to produce enriched cultures of hESC-CM9,13. Using an optimized serum- and 
insulin free protocol, cultures containing ~25% cardiomyocytes can be reproducibly obtained 
within 12 days of initiating differentiation14-16. 
To test the cardioactivity of drugs, it is important that the electrical properties of the target 
cell are known. We therefore first analyzed action potentials of HES3 derived cardiomyocytes 
using patch clamp electrophysiology, as described previously13. Cells were designated as 
ventricle-like, atrial-like, or pacemaker-like based on the shape of the action potential (AP) 
defined by the following parameters: amplitude, maximal repolarization, maximum increase 
in AP (dV/dtmax), AP duration (APD90), and the overall pattern of the AP compared to those 
recorded in cells from 16 week human fetal hearts13,17. Ventricular-like APs characteristically 
show a plateau phase that results in longer repolarization compared to the more triangular 
shaped, atrial-like APs. Pacemaker-like cells are characterized by slow upstroke velocities and 
smaller amplitudes. As described previously for the HES2 cell line13, cardiomyocytes generated 
from the HES3- END-2 co-cultures were almost exclusively ventricular-like (Figure 8.1A). An 
example of a typical action potential is shown in Figure 8.1B. We therefore concluded that 
these relatively homogeneous populations of cardiac ventricular cells may be particularly 
suitable for drug cardiotoxicity screening.
Traditional patch clamp electrophysiology, the most accurate measure of the properties 
of electrically excitable cells, requires precise positioning of the electrode on the plasma 
membrane to enable gigaOhm seals to form between the electrode and the cell. However, 
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Figure 8.2
Validation of hESC-CM fi eld potential responses
(A) Sodium peak amplitude-dose 
relationship for hESC-CM in the 
presence of increasing amounts 
of lidocaine. (B) Example of fi eld 
potential raw data; note the 
reduction of amplitude at higher 
concentrations. (C) FPD–dose 
relationship for hESC-CM in the 
presence of increasing amounts 
of nifi dipine. (D) Example of 
fi eld potential raw data; note 
the reduction of fi eld potential 
duration at higher concentrations 
of nifi dipine. (E) FPD-dose 
relationship for hESC-CM in the 
presence of increasing amounts 
of E-4031. (F) Example of fi eld 
potential raw data; note the 
prolongation of fi eld potential 
duration in response to E-4031
Figure 8.1
(A) Patch clamp analyses of 
cardiac differentiated HES3 cells. 
(B) Example of a ventricular-like 
action potential measured by 
patch clamp electrophysiology. 
(C) Multichannel electrode 
chip with culture chamber. (D) 
6-Well multichannel electrode 
chip for higher throughput. 
(E) Example of hESC derived 
cardiomyocytes attached and 
cultured on a MEA chip. (F) 
Amplifi er used for digitizing 
electrical signals recorded by one 
of the electrodes. (G) Example of 
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this is labor intensive, limited to individual cells and therefore unsuitable for medium/high 
throughput drug screens. The more sophisticated planar patch clamp systems are potentially 
suitable but are difficult to implement since they require purified single cell suspensions. 
Measurement of external field potentials generated by clumps of beating cardiomyocytes 
derived from hESC, rather as an electrocardiogram on patients, represents an attractive 
alternative to conventional patch clamp analyses of APs that is amenable to medium 
throughput modalities. The signal recorded with one of the extracellular electrodes integrated 
into the substrate reflects local changes of the membrane potential in a cluster of electrically 
connected cardiomyocytes (Figure 8.1C-F). An example of a field potential is shown in Figure 
8.1G. Parameters such as the field potential duration (FPD) are easy to define and measure 
and are directly linked to the action potential duration. 
drug effects on hESC-derived cardiomyocytes
To determine whether hESC-CM would be a useful model to detect drug-induced QT elongation 
we first profiled field potential duration in response to selective ion channel blockers. Lidocaine 
was used to block I
Na
, nifidipine to block I
CaL
 and E-4031 for I
Kr
. As expected, Lidocaine did 
not affect the FPD in three independent experiments; however it caused cessation of beating 





 for lidocaine of 61 μM18 and with a study of Satin et al, who described 
initiation of the spontaneous action potentials in hESC-CM by the sodium current19. 
Nifidipine, a typical L-type calcium channel blocker, reproducibly induced a dose dependent 
shortening of the FPD, which was initiated at 10 nM and saturated at 1 μM in three 
independent experiments (Figure 8.2C,D). In 3 out of 4 independent experiments loss of 
spontaneous activity was observed between 300 nM and 1 μM, indicating the importance of 
a strong inward calcium current for cyclic contraction.  Concomitant with decreased FPD, we 
observed a higher beating frequency but no arrhythmic behavior. 
E-4031 is a specific blocker of the hERG channel. In four independent experiments E-4031 
induced sustained prolongation of the FPD at concentrations of 30nM and higher (Figure 
8.2E,F). At concentrations of 1-3 μM, early after-depolarizations (EADs), which indicate 
an increased tendency for arrhythmia, were observed in 3 out of 4 experiments (data not 
shown). Beating frequency was not affected at nanomolar concentrations; however, at higher 
concentrations it was reduced, indicating a concomitant non-specific ion-channel block. 
responses to repolarization prolonging anti-arrhythmic drugs
A large class of cardioactive drugs is used clinically to treat arrhythmias. These drugs are 
classified in four categories and, except for category II (beta-adrenergic receptor-blocking), 
their mechanism of action is related to ion-channel block. We tested two compounds, quinidine 
(class Ia) and D,L-sotalol (Class II, III) for their effects on field potential profiles. Quinidine 
administration to patients is strongly associated with TdP (1-8.8%)1. In hESC-CM it induced 
a dose dependent FPD prolongation (Figure 8.3A). At the estimated unbound therapeutic 
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plasma concentration (ETPC unbound) which is 0.9-3.2 μM, we observed a 20-50% increase 
in QT time which was further prolonged at higher concentrations. D,L-sotalol administration 
to patients is also strongly associated with TdP (1.8-4.8%); it also induced a dose dependent 
FDP prolongation in hESC-CM. At the ETPC unbound (1.8 – 14 μM) we observed a 15 – 20% 
FPD prolongation, which increased at higher concentrations (Figure 8.3B). In summary, both 
drugs prolonged the FPD at physiologically relevant plasma concentrations, as expected. 
FPD–dose relationship for hESC-
CM in the presence of increasing 
amounts of (A) Quinidine, (B) D,L-
sotalol. (C) cisapride (D) sparfloxacin, 
(E) terfenadine, (F) domperidone, 
(G) sertindole. (H) ketoconazole (I) 
verapamil. The blue areas indicate 
the ETPC unbound measured in 
patients and the black line indicates 
hERG IC
50
. Dotted lines indicate the 
95% confidence interval of the fitted 
curve. ETPC unbound and hERG IC50 
data are adapted from reference 1. 
Figure 8.3
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responses to non-cardiac drugs associated with TdP or QT prolongation
In addition to repolarization-prolonging anti-arrhythmic drugs, where QT prolongation is the 
desired effect, a large class of (non-cardiac) drugs prolongs the QT interval as a detrimental 
side effect. These drugs derive from various therapeutic areas and include but are not limited 
to antihistamines, antipsychotics and anti-microbial agents. Here we tested cisapride, 
sparfloxin, terfenadine, domperidone and sertindole, all of which are associated with QT 
prolongation and/or TdP as a side effect. Although the clinical incidence of TdP for all of 
these drugs is low, cisapride and terfenadine have been withdrawn from the market because 
of negative risk/benefit analyses. Cisapride is a serotonin 5-HT4 agonist which increases 
acetylcholine release in the enteric nervous system and was used for the treatment of a 
number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults 
and children. In a market span of 12 years, 384 cases of ventricular arrhythmias due to TdP 
were reported, giving a TdP incidence of 1/120,00020. The ETPC unbound is 2.6-4.9 nM 1. 
At this concentration we observed no effects on the FPD (Figure 8.3C). However, at higher 
concentrations sustained prolongation of the FDP was observed (Figure 8.3C). 
Sparfloxacin is an antibiotic used for the treatment of bacterial infections. The ETPC unbound 
is 0.19 - 1.76 μM which overlaps with published IC
50
 values (0.23 – 34.4 μM). This would 
classify sparfloxacin with repolarization prolonging anti-arrhythmics in a conventional hERG 
assay. However in integrated safety analysis of data from 6 multicenter phase III trials, QTc 
(heart rate corrected QT interval) prolongation (10 +/- 24 milliseconds) occurred in 1.1% of 
the patients. There were no ventricular arrhythmias related to QTc prolongation in any of 
these patients21. In hESC-CM we found no FDP prolongation at the ETPC unbound but only 
at higher concentrations (Figure 8.3D), thus supporting the toxicity screening potential of 
the hESC-CM model as used here. Terfenadine, an antihistamine used for the treatment 
of allergies, is a “prodrug” and generally metabolized to the active form Fexofenadine by 
intestinal CYP3A4. The association with TdP is low with an occurrence of once in 10,000 
person years. Nevertheless the compound has been withdrawn from market due to perceived 
risks. The ETPC unbound is 0.1-0.29 nM. However in cases of genetic deficiencies or induced 
CYP3A4 inhibition (e.g grapefruit juice or erythromycin) Terfenadine concentrations in human 
plasma may reach 100 nM22. At this higher concentration, we observed 10% FPD prolongation 
(Figure 8.3E). At even higher concentrations, we observed a further increase, followed by a 
dose dependent reduction of FPD at micromolar concentrations. The shortening is most likely 
a result of calcium channel block23. Domperidone is an anti-dopaminergic drug administrated 
either orally, rectally and intravenously to suppress nausea and vomiting. TdP has been 
reported sporadically and solely with intravenous use24,25. The ETPC unbound is 5-19 nM; 
at this concentration there is only a minor prolongation of the FPD (Figure 8.3F). At higher 
concentrations, however, there is a biphasic dose dependent FPD prolongation that suggests 
block of multiple channels (Figure 8.3F). 
Finally we tested the effects of sertindole. Sertindole is a drug used for the treatment of 
schizophrenia but was withdrawn from the market in 1998 after concern on the high rate of 
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proven or suspected TdP. After re-evaluation of existing data and new clinical data, Sertindole 
was reintroduced to the European market in 200226. We did not observe FDP prolongation at 
the ETPC unbound (0.02-1.59 nM) and even at higher concentrations, only a relatively weak 
FPD prolongation was observed (Figure 8.3G). In summary, all of these compounds showed 
effects on the FPD interval, although in general, this was at concentrations higher than the 
ETPC unbound. This correlates well with the overall very low incidence of TdP induced by 
these drugs. In general, for these drugs a wide safety margin between plasma concentrations 
and side effects on cardiomyocytes would be advisable. Induction of TdP due to overdosing 
or disturbed metabolism (see for example terfenadine) is not acceptable and has led to 
numerous drug failures.  
responses to drugs not associated with TdP in man
Next we investigated two drugs not clinically associated with QT prolongation or TdP (as 
negative controls). Ketoconazole is a drug used to treat a variety of fungal infections and 
there is no evidence that it causes TdP or QT prolongation. However ketoconazaole is a strong 
inhibitor of cyp34a and may therefore be involved in drug-drug interactions associated 
with TdP (for example terfenadine). We observed no FPD prolongation in hESC-CM in the 
concentration range of 0.3 nM- 30 μM, as expected (Figure 8.3H). Verapamil is a class IV anti-
arrhythmic used clinically to treat atrial tachyarrhythmias. The compound exerts its action by 
blocking calcium channels but is also a potent hERG blocker. In fact the narrow safety margin 
between the ETPC unbound (25-81 nM) and the hERG IC
50
 (140 – 830 nM) would make this 
compound a false positive in conventional hERG assays (Redfern et al). 
At the ETPC unbound concentration (25-81 nM) we observed a minor FPD shortening which 
was amplified at higher concentrations (Figure 8.3I). Neither of the negative controls in the 
assay, caused any FPD prolongation.
Discussion 
Efficient, reproducible differentiation of hESC to ventricular cardiomyocytes, preferably 
phenotypically similar to adult human cardiomyocytes, is of critical importance for 
implementing hESC-CM technologies in drug cardiotoxicity screening. Previously we have 
shown that the hESC-END-2 co-culture system is a very efficient and reproducible method for 
cardiac lineage differentiation, in particular to ventricular-like cells. Here we show that these 
cardiomyocyte populations are phenotypically homogeneous, have strong electrophysiological 
responses and are suitable for drug safety pharmacology. 
Previously, we and others have discussed the immaturity of hESC-CM compared to the 
human adult heart8,13,19,27. In a previous study we disaggregated beating areas that had 
formed during 12 days of differentiation and found by patch clamp electrophysiology that 
the cells were comparable to 16-week fetal ventricular cardiomyocytes13. One of the major 
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differences between hESC-CM and mature cardiomyocytes is their relatively low resting 
potential. This means that Na
v
1.5 sodium channels can be spontaneously activated resulting 
in AP generation19. Finally, the initial upstroke velocity of the AP is relatively small due to a 
lower I
Na
 current compared to adult cardiomyocytes. Importantly, chronotropic responses of 
dissociated hESC-CM are comparable to human fetal ventricular cells. This was demonstrated 
by decreased beating frequency following treatment with the cholinergic agonist carbachol, 
whereas adrenergic agonists Phenylephrine and Isoprenaline increased beating frequency13. 
Interestingly, despite the relatively immature phenotype of hESC-CM, we found the drug 
responses highly predictive of clinically observed cardiotoxic effects. To validate hESC-CM as 
a potentially useful new in vitro test system for QT prolongation and TdP, we performed dose 
escalation studies for a number of drugs known to prolong the QT interval as a therapeutic- 
or side effect. Two previous studies also used hESC-CM in combination with the MEA system 
to measure drug responses28,29 but none of them compared a number of compounds 
systematically over a wide concentration range in dose dependent manner. As a starting point, 
we used three drugs that block sodium, calcium and hERG potassium channels. As expected 
lidocaine, a classical sodium channel blocker, caused dose –dependent cessation of beating 
at 30 μM - 100 μM. Nifidipine, a classical calcium channel blocker, reduced the FPD in a dose 
dependent fashion and E-4031 increased the FPD by blocking the hERG channel. Interestingly 
we observed arrhythmic behavior in 3 of 4 independent beating areas in response to high 
E-4031 concentrations. E-4031 was developed as novel class III anti-arrhythmic but this 
development was stopped for reasons that have remained undisclosed. Most importantly, 
hESC-CM behavior was reproducible although a wide variety of field potential shapes were 
observed. This illustrates that hESC-CM as a model can be used to investigate the effects of 
drugs on various ion channels present in cardiomyocytes.
Having validated the different ion channel responses, we then profiled a series of drugs 
that fell into one of three categories: 1) repolarization prolonging anti-arrhythmics, 2) drugs 
associated with QT prolongation or with TdP as clinical side effect and 3) drugs not associated 
with QT prolongation or TdP (negative controls). Quinidine and D,L-sotalol are both used 
therapeutically to prolong the QT interval, but are also strongly associated with arrhythmias. 
Both D,L-sotalol and quinidine induced prolongation at concentrations relatively close to the 
ETPC unbound. D,L-sotalol is especially interesting since the hERG IC
50
 data (74 μM) is clearly 
distinct from the ETPC unbound (1.8 – 14 μM). Therefore, despite the strong association with 
QT prolongation and TdP, a conventional hERG assay would predict no effect QT effect of the 
compound at therapeutic plasma concentrations. Quinidine, showed a massive prolongation 
of the field potential at concentrations higher than the ETPC unbound.  Quinidine ion channel 
interactions are known to be complex. In addition to its blocking effect on hERG, Quinidine 
blocks inward calcium current (I
Ca
), the rapid (I
Kr
) and slow (I
Ks
) components of the delayed 
potassium rectifier current, the inward potassium rectifier current (I
KI





30. Furthermore, quinidine-induced I
Na
 block has been shown 
to increase at higher beating frequencies, dependent on the ion channel state. It has a low 
affinity for the resting state, avidly blocks open channels but does not bind significantly 
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to inactivated sodium channels31,32. Nevertheless its net effect is prolongation of the AP in 
normal and diseased hearts, which was clearly shown in the hESC-CM.  
Addition of drugs from the second category, domperidone, sparfloxacin and cisapride to 
hESC-CM had a clear effect on the FPD interval. Interestingly in contrast to the repolarization 
prolonging drugs tested here, the effective concentration triggering FDP prolongation was 
always higher than the ETPC unbound, which might explain the low incidence of TdP in 
patients taking these drugs. Although both sertindole and terfenadine, drugs from the same 
category, had only minor effects on the FPD interval this may nevertheless indicate functional 
interactions with ion channels. Terfenadine caused a minor prolongation of the FPD interval 
followed by a shortening at higher concentrations. This is in agreement with guinea-pig 
ventricular myocyte data where terfenadine has also been described as causing a small, but 
significant, prolongation of APD90 at 100 nM and 1 μM at 1 Hz stimulation frequency, while 
at higher concentrations, AP duration was shortened33. In the same study, dog Purkinje fibers 
showed no significant effects after Terfenadine administration33. In conclusion; we observed 
FPD changes for all tested drugs without exception but always at a higher concentration 
that the ETPC unbound. This was distinct from the repolarization prolonging drugs where 
we observed FPD changes at the ETPC unbound. We therefore hypothesize that drugs with 
a low pro-arrhythmic potential (ability to induce TdP) can act synergistically with known 
pro-arrhythmic risk factors such as silent mutations, drug-drug interactions, heart failure, 
ventricular hypertrophy, hypomagnesemia, hypokalemia, hypocalcemia, hypoxia or acidosis. 
The combination of any of these factors can induce TdP in patients taking these medicines5,34. 
Finally, addition of the negative control drugs verapamil and ketoconazole to hESC-CM did 
not result in FPD prolongation, as expected. The fact that verapamil did not prolong the FP 
interval is of interest since the close margin between the ETPC unbound (25-81 nM) and the 
hERG IC
50
 (140 – 830 nM) would suggest differently. Therefore verapamil is a classic “false 
positive” in a conventional hERG assay.
Previously, an association of 1.93 (95% CI: 1.89–1.98) between the anti-hERG activity of 
drugs, measured as log10 (ETCP unbound/IC
50
), and reports of serious ventricular arrhythmias 
and sudden death to the WHO-UMC database was found35. In another study, a 30-fold 
safety margin (between the hERG IC
50
 and the ETPC unbound) was established as providing 
an acceptable degree of safety1. Using hERG IC
50 
as criteria, both verapamil and sparfloxacin 
would be classified incorrectly. Verapamil was introduced to the market in 1982 and has 
not been associated with TdP. This is likely the result of multiple channel blocks, which 
compensate the hERG blocking effect. In fact we observed a shortening of the FPD in hESC-CM, 
which is in agreement with clinical data36. Sparfloxacin has a low pro-arrhythmic potential. 
However, the hERG IC
50
 and the ETPC unbound values are in the same concentration range.  This 
would suggest a strong association with QT prolongation and TdP, as anti-arrhythmic drugs 
prolonging repolarization. The hESC-CM model as used here would have accurately predicted 
the risk by showing drug induced QT prolongation but only at concentrations higher than the 
ETPC unbound. The data for both verapamil and sparfloxacin underscore the necessity of a 
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human model system that displays the full complexity of the human cardiomyocyte. 
In conclusion, our results indicate that electrophysiological properties and drug responses of 
hESC-CM match clinical observations on QT prolongation/shortening and arrhythmia at similar 
concentrations. We showed here that by using FPD prolongation as a read out hESC-CM flag 
up adverse drug effects with greater confidence than standard hERG in vitro assays. Screening 
a wider variety of drugs under defined conditions would further validate and identify the 
strengths and weaknesses of the system. Ultimately this should lead to the definition of a 
safety margin which can be instrumental for improving pre-clinical decision making and 
reducing drug development costs.
Materials and Methods
cell culture and differentiation
HES3 cells37 were routinely cultured on 129SV Mouse embryonic fibroblast (MEFs) to maintain 
pluripotency and induced to differentiate to cardiomyocytes as described previously13,14. Large 
numbers of contracting areas are obtained within 12 days that routinely consist of 20-25% 
cardiomyocytes and 75-80% endodermal cells and other mesodermal derivatives but no 
neural cells. 
patch clamp electrophysiology
Patch clamp electrophysiology was essentially done as described previously38,39. Briefly, 
beating clumps of cardiomyocytes were dissociated using a collagenase-based method. 
Cardiomyocytes were plated on gelatin-coated glass and measured between 7 and 14 
days after plating. Microelectrodes with a resistance between 1 and 3 MΩ were made from 
Borosilicate glass (Clark electrical instruments, GC-150 T) with Flaming/Brown Micropipette 
Puller Model 80 (Sutter Instruments, CA). During electrophysiological measurements were kept 
in a DMEM/F12 based medium without serum or Phenol red. The pipette contained buffer 
consisting of 145 mM KCl, 5 mM NaCl, 2 mM CaCl
2
, 4 mM EGTA, 2 mM MgCl
2
, and 10 mM HEPES, 
adjusted to pH 7.30 with KOH.
mea electrophysiology
MEA chips were plasma cleaned and coated with fibronectin for 1 hour at 37oC. Clumps of 
beating hESC-CM clusters were microdissected and replated on standard 60 electrode MEAs 
or alternatively 6-well MEAs. Extracellular recording was performed using a MEA1060INV MEA 
amplifier (Multi Channel Systems, Reutlingen, Germany). Output signals were digitized at 10 
kHz by use of a PC equipped with a MC-card data acquisition board (Multi Channel Systems, 
Reutlingen, Germany).  Standard measurements were performed in DMEM supplemented with 
5% FCS. During recordings, temperature was kept at 37oC. Data were recorded using QT-screen 
(Multi Channel Systems, Reutlingen, Germany) and analyzed off-line with QT-analyzer (Multi 
Channel Systems, Reutlingen, Germany).
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data processing
Field potential duration or sodium amplitude data from at least three independent beating 
areas were averaged using GraphPad Prism software. Datapoints are displayed as mean +/- 
SEM. Curves were fitted using the one phase decay algorithm, 95% confidence intervals are 
plotted as dashed lines.
compounds
Lidocaine, nifedipine, E-4031, cisapride monohydrate, quinidine and verapamil hydrochloride, 
D-L-Sotalol, sparfloxacin, sertindole, terfenadine, domperidone and ketoconazole were 
obtained from Sigma-Aldrich. The substances were dissolved DMSO at 10 mM and serial 
dilutions were made in medium. The highest concentration of DMSO is reached at 30μM drug 
which represents 0.3% DMSO. Measurements were started after a wash-in time of 2 min. 
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Abstract
Stem cells derived from either preimplantation 
human embryos or from somatic cells by 
reprogramming are pluripotent and self-
renew indefinitely in culture. Pluripotent 
stem cells are unique in being able to 
differentiate to any cell type of the human 
body. Differentiation towards the cardiac 
lineage has always attracted significant 
attention, initially with a strong focus 
on regenerative medicine. Although an 
important research area the heart has proven 
challenging to repair by cardiomyocyte 
replacement. However, the ability to 
reprogram adult cells to pluripotent stem 
cells and genetically manipulate stem cells 
presented opportunities to develop human 
disease models. The availability of human 
cardiomyocytes from stem cell sources is 
expected to accelerate cardiac drug discovery 
and safety pharmacology by offering more 
clinically relevant human culture models 
than presently available. Here we review 
the state of the art using stem cell-derived 
human cardiomyocytes in drug discovery, 




The first derivation of human embryonic stem cells (hESC) in 1998 led to great excitement 
in the field of regenerative medicine1. For the first time there were opportunities to treat 
a multiplicity of diseases with cell therapy. Restoration of heart function by replacing 
damaged cardiomyocytes by cardiomyocytes from stem cells was among the most appealing 
applications. However, issues like effective transplantation techniques, proper functional 
integration, safety related to introduction of electrically active cells in the heart and teratoma 
formation by residual undifferentiated cells as well as immune rejection of transplanted cells 
are now considered to represent significant hurdles to clinical introduction. For other tissues, 
these issues may be less significant obstacles for clinical trials. For example, Geron, a US stem-
cell based company, recently received FDA approval for the first trial to evaluate the safety of 
transplanting hESC-derived oligodendrocytes into the spinal cords of patients suffering from 
acute crush lesions. In addition, clinical trials planned to transplant hESC-derived retinal 
epithelial cells intraoccularly in patients with macular degeneration are likely to receive 
regulatory approval shortly. However, apart from these exceptions, it is generally accepted 
that cell therapy based on pluripotent stem cell derivatives is a long-term perspective. By 
contrast, largely as a result of refinements to culture and differentiation protocols over the 
past 10 years, short-term applications of pluripotent human stem cells are expected in the 
area of drug discovery and safety pharmacology. 
The pharmaceutical industry has been developing and marketing small molecule drugs to 
treat various diseases successfully for decades. Factors that have shaped the industry include 
the search for ‘best in class’ drugs with unquestionable benefit versus risk profiles and highest 
predicted return-on-investment. This research and development (R&D) strategy has resulted 
in multiple drugs with revenues exceeding $1 billion annually. However, this R&D strategy also 
led to a steady decline in R&D productivity from 53 new molecular entities (NMEs) approved in 
1996 to only 21 in 20082. In addition, the recent withdrawal of the anti-inflammatory drug 
Vioxx from the market due to unforeseen cardiotoxic effects has forced regulatory bodies to 
review their approval policy, which will most likely lead to tighter registration requirements 
and subsequently to higher costs of drug development. As a consequence, focus is on more 
personalized, predictive and preventive medicine3. 
Most R&D expenditures are presently incurred during late stages of clinical development, and 
therefore companies are focusing on cost reductions at these stages. Whilst difficult to speed 
up regulatory processes or reduce the size of clinical trials, historical perspectives indicate 
that clinical attrition can be minimized if the principle causes are identified. In 1990 >40% 
of drug attrition was the result of pharmacokinetic and bioavailability issues; in 2000 this 
was reduced to <10%3. Unforeseen (cardio)toxicity and lack of efficacy are at present the 
most common cause of clinical attrition4,5.  This may in part be because much pre-clinical 
drug discovery-related R&D is carried out initially on cell lines with low clinical relevance and 
only much later in costly animal models. The tumour cell lines or primary cells used are not 
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always representative for the end point of interest. Implementation of model systems based 
on normal human cells could reduce the incidence of unexpected toxicology and lack of 
efficacy by offering specific human targets in a cost effective way rather than less physiological 
non-human biological environments. Pluripotent stem cells in combination with specific 
differentiation protocols offer the opportunity to create appropriate human test models with 
high biological relevance. Indeed, at least 70% of the top 20 pharmaceutical companies are 
working with stem cells, 64% of them now investigating the use of hESC6. In addition, 50% of 
the top 10 biotech companies make use of stem cells, 20% of them makes use of hESC6. 
In this review we will discuss the opportunities for cardiomyocytes derived from human 
pluripotent stem cells with respect to cell therapy, safety pharmacology and drug development 
(Figure 9.1). In addition, we will comment on the hurdles in bringing these cells from the 
research bench to the pharmaceutical R&D laboratory and clinical practice. 
Human pluripotent stem cells
hESC were first derived from blastocyst stage embryos surplus to assisted reproduction 
requirement in 19981. Since then it has been estimated that >800 normal and genetic disease-
bearing lines have been generated under various culture conditions. Because of their ability 
to self-renew indefinitely and differentiate to all cell types of the body, hESC were initially 
of great interest for developing clinically relevant cell replacement therapies. In addition, 
they presented opportunities for studying differentiation in early human development, 
genetic disorders and screening new drug and compound libraries. However, progress has 
lagged behind expectations, in part because of: (1) labour intensive non-defined culture 
protocols for self-renewal, (2) few efficient directed differentiation protocols (see below), (3) 
poor transfection efficiencies which have limited functional analysis of signalling pathways 
controlling fate choices and cell selection, and (4) low single cell cloning efficiencies compared 
with, for example, mouse ESCs. The first hESC lines were derived on mouse embryonic 
feeder cells (MEFs) in medium containing fetal calf serum (FCS)1,7 . In contrast to mouse ESCs, 
leukemia inhibitory factor (LIF) was unable to replace MEFs in supporting self-renewal of 
hESC. hESC instead required basic fibroblast growth factor (bFGF) for self-renewal under 
(semi) defined conditions8.  Multiple “defined” culture condtions for hESC, based on slightly 
different basal media and supplements have since been described9-13. The International Stem 
Cell Initiative14 is presently comparing these different conditions on different hESC lines with 
view to identifying the most robust and ubiquitously applicable. Both mechanical “cut-and-
paste” and enzymatic (trysin, dispase, collagenase, Tryp.LE) passaging methods are being 
compared for their ability to sustain self renewal without loss of developmental potency and 
karyotypic stability. Defined growth conditions for hESC are not only important for therapeutic 
application but are also essential for developing robust and reproducible in vitro assays. 
The first fully defined medium for hESC was called mTeSR. Initially mTeSR only worked in 
combination with a complex mixture of purified human collagen IV, fibronectin, laminin and 
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vitronectin matrix components 11. Later it was shown that Matrigel™ a laminin-111-rich, 
mouse sarcoma-derived commercial product also containing collagen IV, entactin, heparin 
sulfate proteoglycan and multiple other (growth factor) components also supported hESC self 
renewal 15. Recently we showed that mTeSR1 in combination only with recombinant vitronectin 
was sufficient to support sustained self-renewal in three independently derived hESC lines, 
retaining karyotypic stability and pluripotency16. Recently the first hESC lines were derived 
under conditions compliant with Good Manufacturing Practice (GMP), although co-culture 
with human feeder cells pre-cultured in FCS-containing medium and bovine serum albumin 
supplement was still required. Whether these culture conditions will be generally accepted as 
best practice for GMP remains to be established17. Methods for efficient gene transfection using 
chemical, viral and electroporation based methods have now been developed for multiple cell 
lines using trypsin based monolayer culture18-21 . The issue of low cloning efficiency (which 
limits selecting genetically modified clones and demonstrating pluripotency at the single cell 
rather than population level) has been partly solved by addition of a selective inhibitor of 
p160-Rho-associated coiled-coil kinase (ROCK) to the culture medium22. Finally, for scaling 
up stem cell production, it was recently shown that the CompacT SelecT™ robotics system 
could be used for serial propagation of hESC cells on Matrigel™ without loss of pluripotency or 
differentiation potential23. This widely used system can manage 90 T175 flasks simultaneously 
which facilitates scaling to >109 cells in one batch. Together, these improvements in hESC 
culture techniques have set the stage for medium to high throughput robotics and production 
scale up that would be essential for both in vitro and therapeutic use. 
induced pluipotent (iPS) cells
One of the most remarkable discoveries of the last few years is that adult somatic cells can 
be reprogrammed to a pluripotent stem cell state by the transient expression of just a few 
key transcription factors. In 2006, Yamanaka showed that four genes (c-Myc, Klf4, Oct4 and 
Sox2) could convert adult mouse fibroblasts to cells virtually indistinguishable from mouse 
ESCs24. In 2007 Yamanaka and Thomson independently described the ability to derive induced 
pluripotent stem (iPS) cells from human somatic cells25,26. Human iPS cells, like their mouse 
counterparts are very similar to hESC but do not require embryo use for derivation. In addition, 
they can be derived from patients with complex genetic defects to create disease models that 
would otherwise only be available through derivation of hESC lines from embryos.  Today, 
iPS cell lines can be generated without integration of transgenes, as required in the original 
method27,28. Although there is accumulating evidence that iPS cells differ from ESCs based on 
analysis of methylation state and gene (mRNA) and miRNA expression29,30 it seems most likely 
that the cells can be used to study disease processes. However, some disease-associated 
mutations might interfere with iPS cell generation as recently shown for mutations in the 
Fanconi Anaemia pathway31. Nevertheless, studies have shown that iPS cell lines from patients 
with neurodegenerative disorders like spinal muscular atrophy32 and amyotrophic lateral 
sclerosis (ALS)33 recapitulate the disease phenotype. IPS cells thus represent an opportunity 
to study disease development “in a dish” and hence can serve as models to test methods of 
delaying its advance or reversing its phenotype. 
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Cardiac differentiation of  
pluripotent stem cells
Various methods have been described to induce differentiation in pluripotent cell lines. Most 
widely used is the growth of undifferentiated cells as aggregates in suspension which causes 
them to form structures called embryoid bodies34. Within the embryoid body, derivatives of 
the three primary germ layers, ectoderm, endoderm and mesoderm develop spontaneously. 
Cardiomyogenic mesodermal progenitors are normally formed in the embryo during 
gastrulation as cells of the epiblast pass through the primitive streak35. Many although not all 
protocols for directed differentiation (to cardiomyocytes) are based on these developmental 
principles. In general two different directed differentiation strategies have been applied: 
(1) co-culture of hESC with cardio-inductive cell types and (2) induction of gastrulation by 
specific growth factors. Both approaches have made considerable progress over the last few 
years with respect to cardiomyocyte differentiation efficiencies.
co-culture of hESC with cardio-inductive cell types
The discovery of cardio-inductive signals originating from the visceral endoderm represents 
a key step in the directed differentation of pluripotent stem cells to cardiomyocytes. Co-
culture of pluripotent stem cells with END-2 an endodermal cell line, is a very robust and 
efficient method for cardiac differentiation36,37. Although the exact mechanism of END-2 
cardiac induction is still unclear, the transcriptome and secretome of END-2 cells have been 
described38,39. Cardiac induction by END-2 conditioned medium can be (partly) mimicked by 
insulin depletion40, inhibition of p38 MAPK41  and addition of prostaglandin E42.  Interestingly, 
high concentrations of insulin appear to favor differentiation to neuroectoderm and blocking 
p38 MAPK further enhances cardiac differentiation. P38 MAPK signaling is highly active in 
neuroectoderm and blocking of this pathway may favor meso-/endoderm differentiation. 
induction of gastrulation and cardiac commitment by 
specific growth factors
The heart is the first organ to develop in the embryo and its development has been studied 
extensively in various animal models. As gastrulation proceeds, cardiac progenitors form in 
the posterior primitive streak. These cells express genes like Brachyury T, MIXL and MESP1. 
MESP1 is thought to induce an epithelial-mesenchyme transition in the epiblast and to bind 
directly to regulatory DNA sequences located in the promoters of many members of the core 
cardiac regulatory network, including NKX2-5. This promotes development of mesoderm 
precursors of the cardiovascular lineage43,44. MESP1 also directly represses the expression 
of key genes regulating other early mesoderm derivates. These signaling pathways can be 
recapitulated in cell culture by the addition of specific recombinant growth factors like bFGFs, 
bone morphogenetic proteins (BMPs) and WNTs. Several studies have shown that various 
combinations of BMP4, WNT3a and ACTIVIN A induce gastrulation-like events and meso- /



















Applications of cardiomyocytes from pluripotent stem cells
Human pluripotent stem cells can 
be obtained from preimplantation 
human embryos or from somatic 
cells by reprogramming. These 
stem cells can be kept in culture 
indefi nitely and can differentiate 
towards all cell types present in 
the human body. Differentiation 
towards the cardiac lineage has 
always been of great interest, 
initially with the focus on cell 
therapy. However, it is widely 
believed that cell therapy based 
on pluripotent stem cell derived 
cardiomyocytes is a long term 
perspective. Instead, focus is on 
applications in drug discovery and 
cardiac safety pharmacology.
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based on temporal stimulation with BMP4, bFGF and Activin A, followed by VEGF and WNT 
inhibition through DKK was descibed. By day 6 of differentiation, a KDRlowC-Kitneg population 
had emerged which was primed for cardiac differentiation48. Recently it was shown that 
Isl1 heart progenitors are capable of self-renewal and expansion before differentiation to 
cardiomyocytes, endothelial or smooth muscle cells49. 
The availability of reporter cell lines expressing fluorescent proteins under the control of 
lineage specific promoters can be a highly instructive tool for identifying factors that improve 
the efficiency of directed differentiation. Recently eGFP was inserted downstream of the 
endogenous MIXL promoter in two different hESC lines, thereby marking cells undergoing 
gastrulation50. Similar strategies can now be used in high content differentiation screens 
whereby several growth factors can be cross-titrated in 96- or 384 well plates followed by 
automatic imaging. Screening for small molecules that enhance differentiation in a similar 
high content screen could directly activate appropriate signaling pathways in a ligand 
independent way. This concept has been successfully applied to cardiac differentiation of 
pluripotent mouse stem cells and recently on hESC differentiating to pancreas cells51-53.
Functionality of hESC-derived 
cardiomyocytes
Differentiation of pluripotent stem cells to cardiomyocytes generally results in mixtures of 
ventricular-like, atrial-like and pacemaker-like cells defined by patch-clamp electrophysiology 
of action potentials (APs). Ventricular-like action potentials are defined by a relatively fast 
upstroke velocity and a plateau phase that results in longer repolarization compared with 
the more triangular shaped atrial-like APs (Figure 9.2). Relative slow upstroke velocities and 
much smaller amplitudes characterize pacemaker-like cells (Figure 9.2). Interestingly, specific 
differentiation protocols seem to affect the ratios of the different cardiac cell types formed 
in culture. While most differentiation protocols based on embryoid bodies/cell aggregates 
lead to equal numbers of ventricular and atrial like cells, cardiac induction by END-2 co-
culture results largely in homogenous populations of ventricular-like cells36. Comparison of 
these cells with the human fetal heart shows that hESC-derived cardiomyocytes (hESC-CM) are 
morphologically still relatively immature with irregular sarcomere structures but contain the 
proper ion channels coupled to downstream signaling pathways, which have been shown to 
be modified by specific cardiac drugs54 . Nevertheless the auto-arrhythmic behaviour and 
small sodium currents indicate electrical-, in addition to morphological, immaturity. During 
fetal development, the electrophysiology of the heart changes dramatically. For example, the 
resting potential of the ventricular cells in early embryos is low (e.g. -40/-50 mV) and this 
changes progressively during development towards that of adult cells (e.g. -75/-85 mV). 
The maximum rate of rise of the action potential upstroke velocity (dV/dtmax) also increases 
dramatically during development, from about 20 V/sec to about 200 V/sec in the late embryonic 
stage. This increase is the result of a much greater number (density) of TTX-sensitive fast 
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The normal electrophysiological 
behaviour of the heart is determined 
by ordered propagation of 
excitatory stimuli that result in 
rapid depolarization and slow 
repolarization of various excitable 
cell types 51. The electrical activity 
of the heart is initiated in the 
sinoatrial node (not visible in the 
picture) and initiates depolarization 
of atrial myocytes which can be 
seen as the P wave on an ECG. The 
electrical activity is then slowed 
down by the atrioventricular node 
(not visible in the picture) and 
spreads via the common bundle and 
bundle branches to the ventricular 
muscle. The QRS complex results 
from ventricular depolarization, 
while the T wave is indicative of 
ventricular repolarization. The 
human ventricular action potential 
can be subdivided into five phases. 
Phase 0 is the fast depolarization 
of the membrane potential due to 
sodium channel (SCN5a) activation 
and a rapid increase in membrane 
permeability to Na+, followed by a 
rapid repolarization (phase 1). This is 
followed by a plateau phase (phase 
2), where Ca2+ ions enter the cell 
through L-type calcium channels. 
The slow gating kinetics of the 
L-type Calcium channel results in 
long lasting inward flow of Ca2+ that 
supports optimal contraction of the 
ventricles. Repolarization, or phase 
3, results from the inactivation of 
calcium channels and an increase 
in net outward potassium currents 





) components of the delayed 
rectifier potassium channels. Inward 
rectifying potassium channels (I
Ki
) 
contribute to phase 3 repolarization 
and to the maintenance of the 
resting potential (phase 4).
Figure 9.2
Electrical activity of the heart
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Na+ channels. In hESC-CM, membrane potentials and upstroke velocities are comparable to 
16-week fetal hearts36. The major difference between hESC-CM and adult heart cells is the 
absence of I
K1
 in hESC-CM55. In adult heart cells this inward rectifier K+ channels (Kir) clamps 
the membrane potential to a value near the K+ reversal potential. At such hyperpolarized 
potentials the probability of the Na
V
1.5 channels opening approaches 0.  The absence of this 
current leads to a slightly depolarized membrane potential, which can lead to spontaneous 
activation of Na
V
1.5 thereby driving the spontaneous action potential. Absence of physical 
work and the haemodynamics of blood flow56 might underlie the relatively immature 
phenotype of hESC-CM. Advanced tissue engineering in combination with cyclic stretch and 
strain might enhance maturation of the cells in culture. 
Cardiomyocytes from pluripotent  
stem cells to regenerate the heart
Restoring function of failing hearts by replacing damaged cardiomyocytes is straightforward 
in principle but probably among the most challenging paradigms of regenerative medicine. 
Any transplanted cells would have to be immunomatched, integrate into the (hypertrophic) 
host myocardium, receive a blood supply via the vasculature and cardiomyocytes should 
couple with residual host cardiomyocytes to contract synchronously in response to the cardiac 
conduction system. 
Bone marrow cells (BMCs) were amongst the first non-cardiomyocyte sources of regenerative 
cells described for the heart. Initially transdifferentiation of BMCs to cardiomyocytes 
was thought to take place, explaining functional improvement, but this later turned out 
to be autofluorescence from scar tissue57-59. Nevertheless, these early results evoked an 
unprecedented progression to completion of the first randomized clinical trials within 5 years. 
Early reports of non-controlled pilot studies were unanimously positive but the results of 
recent randomized (placebo-) controlled trials were somewhat disappointing, especially after 
longer follow-up times. Most researchers now agree that if BMCs improve cardiac function, it 
is more likely to result from early salvage of ischemic myocardium by some kind of paracrine 
action from the transplanted cells (reviewed in 60). 
Cell therapy for the heart would ideally require replacement of cardiomyocytes, vascular 
endothelial (EC) and smooth muscle cells (SMCs); hESC and hiPS cells are therefore promising 
candidates because of their ability to form not only bona fide cardiomyocytes but also 
supportive ECs and SMCs in vitro with high efficiency. Transplantation of hESC-derived cells 
would likely be heterologous and sensitive to immune rejection whereas iPS could theoretically 
be patient-derived and hence immunologically matched. However, aside from safety issues, 
it remains to be seen whether this degree of “personalized medicine” would be financially 
viable for health and insurance services. 
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The first transplantation of hESC-CM demonstrated their potential to act as biological 
pacemakers in electrically silenced or AV-blocked hearts61,62. This was rapidly extended to 
studies investigating their ability to regenerate the working myocardium. When hESC-CM were 
transplanted into the healthy myocardium of immunodeficient rats or mice, they survived45, 
63,64 and matured63,64 for at least 12 weeks after transplantation63. In all studies, mixtures 
of cardiomyocytes and other differentiated hESC-derived cells were injected. All reported 
preferential survival of cardiomyocytes, while non-cardiac elements were lost over time. 
Although grafted human cells formed a syncytium with each other, they were largely separated 
from the rodent myocardium by a layer of fibrotic tissue. When transplanted into infarcted 
hearts in rodents, hESC-CM were the only cells that formed considerable grafts, although in 
one study, the addition of a pro-survival cocktail resulted in larger grafts45. Cardiac function 
in animals receiving hESC-CM was better than in animals receiving non-cardiomyocyte 
derivatives45,63. Notably, rodents receiving non-cardiac hESC-derived cells also showed some 
improvement compared the vehicle-injected animals. Hence, there were cardiomyocyte-
specific benefits additional to an enhancement of cardiac function by hESC-derived cells in 
general. This was correlated in one study quantitatively with the degree of neovasculature 
derived from the host in the border zone of the infarct65. Only one study so far has, however, 
extended functional follow up to 12 weeks after transplantation63. In mice analyzed at this 
time-point the advantage of hESC-CM over hESC-non-CM was no longer present63 even when 
the number of cells transplanted or the number of injections was increased65, 66. Of interest, 
the grafts in mice in these studies often contained human ECs and SMCs at later time points 
(6 months)65 suggesting that either these cells or cardiac progenitors67 were present in the 
cell populations injected65. “Priming” hESC with BMP to differentiate hESC to the cardiac 
progenitor stage only has been suggested as an alternative therapeutic option68. 
Primary fetal human cardiac progenitors, although difficult to obtain routinely, have also 
been described to differentiate in the rodent heart after MI and improve cardiac function, 
perhaps for even longer periods than hESC-CM69. Overall, though, functional enhancement 
by hESC-CM with the current strategies may generally be limited to mid-term at most. The 
therapeutic benefit of the cell therapy may be prolonged when using a pro-survival cocktail 
or different timing of injection, for example after the initial inflammatory phase when the 
environment may be hostile to the donor cells, but this remains to be proven. A fibrotic layer 
can develop between injected and host cells65 that may or may not impede transduction of 
electrophysiological signals. The question rises whether rodents are the most useful model 
animals to address potential safety issues in humans. Rodent hearts beat at 400-600 times 
per minute, humans at 60-100 times per minute. Injection of human cardiomyocytes with 
intrinsic different electrical properties into rodent hearts is therefore unlikely to contribute 
to cardiac function. Secondly, transplantation in the rodent myocardium is less likely to 
create arrhythmic substrates than the same procedure in humans. Transplantation of new 
cardiomyocytes into the human heart is thus likely to be fraught with safety and efficacy 
issues at the outset. It might be better to use iPS cells or ESCs from larger animal species 
(pigs, goats, sheep, non-human primates) preferably from the same species. This would also 
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provide the opportunity to assess the risk of tumor/teratoma formation, a recognized risk of 
ESCs and iPS cells, without crossing xeno barriers. Grafts may also provide passive support only 
sufficient to prevent dilatation and retain cardiac function temporarily, but inadequate for 
sustained improvement. Similarly, if paracrine mechanisms were the main modus of action 
for hESC-CM, as thought to be the case for BMCs70, these may provide a transient protection 
only. Finally, the host immune response to grafted cells is poorly understood. Unless a cell 
transplant is derived from the patient’s own cells, which might be feasible using iPS cell 
technology, the cells will be targeted for rejection by the immune system. An emerging 
approach to address this issue is ‘re-educating’ the immune system to induce tolerance to 
foreign cells71. Taken together, the clinical use of cardiovascular derivatives from pluripotent 
stem cells would appear challenging, since safety issues are likely to be a significant hurdle 
to the broader repair of damaged myocardium in the near future. Although beyond the scope 
of this review, options including tissue engineering may present better strategies for moving 
forward into clinical therapy60 .
Applications of cardiac differentiated 
stem cells in safety toxicology
Cardiomyocytes, especially from the adult heart, have a very limited proliferation capacity and 
can not be propagated as a cell-line. Repeated isolation of primary tissue is therefore necessary 
for in vitro functional analyses. Primary canine cardiomyocytes are currently the most widely 
used preclinical model for cardiac safety pharmacology. The strongest arguments for using 
canine cardiomyocytes (or Purkinje fibres) are their physiological similarity to humans and 
availability in large numbers. However their use is costly and has ethical issues associated 
with euthanasia of hundreds of dogs annually. Alternatives are cell lines expressing specific 
ion channels ectopically but these have the disadvantage that over-expressed human single 
ion channels function in isolation from the complex ion channel interactions normally present 
in cardiomyocytes. Their advantage, however, is scalability that allows automatic screening 
in 384 wells for potential safety issues. The number of cases where unforeseen drug induced 
cardiotoxicity occurs and the number of drug withdrawals from the market clearly indicates 
the need for better reliable test systems. 
One of the most recent and well-known cases of unexpected cardiotoxicity is Vioxx. Vioxx 
is a COX-2 inhibitor prescribed to patients with arthritis and other conditions causing acute 
and chronic pain. On September 30, 2004, Merck voluntarily withdrew Vioxx from the market 
because of concerns about increased risk of cardiotoxicity and stroke associated with long-
term, high-dosage use. Vioxx was one of the most widely used drugs ever to be withdrawn 
from the market, over 80 million people were prescribed Vioxx at some time. In the year before 
withdrawal, Merck had sales revenues of US$2.5 billion from Vioxx Worldwide72. Although 
the exact mechanism is still unclear it has recently been shown that selective deletion of 
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COX-2 in cardiomyocytes depressed cardiac output and enhanced susceptibility to induced 
arrhythmogenesis73. 
One of the most appealing successes of the biotechnology industry is the development of 
Herceptin (trastuzumab). Herceptin binds a membrane protein HER-2 which is overexpressed 
at 20-30% of early stage breast cancers and is used to treat these cancers. However, also 
in the case of herceptin heart failure is observed in 1 to 4% of patients treated with the 
antibody, while 10% have a decreased cardiac function74. The combination of herceptin with 
chemotherapy has been shown to increase both survival and response rate, in comparison 
to Trastuzumab alone. However, when herceptin is co-applied with anthracycline based 
chemotherapy cardiac failure is severely increased75. These effects were not known prior to 
clinical trials and today every single patient is screened for heart failure before herceptin 
treatment. The fact that drugs like herceptin, which are clearly not harmless, are still used 
in the clinic has to do with their risk/reward profile. In general, the safety evaluation of 
biologicals is further complicated by the fact they are designed to act on a human target. 
Traditionally widely used animal models might therefore be a less relevant choice. In order to 
detect potential safety issues associated with this class of drugs, human cell models have to 
be developed that detect parameters like cell viability and force of contraction.  
drug indication market span reason for withdrawal
Astemizole 
(Hismanal)
Antihistamine 1983-1999 Withdrawn from the market due to TdP
Cisapride 
(Propulsid)
Prokinetic 1988-2000 Withdrawn from the market due to TdP
Droperidol Antipsychotic/antiemetic 1970-2001 Withdrawn from the market due to TdP
Grepafloxacin Antibiotic 1997-1999 Withdrawn from the market due to TdP
Levomethadyl Opioid agonist 1993-2001 Withdrawn from use in EU due to TdP; use 
restricted in US
Prenylamine Anti-anginal 1960s-1988 Withdrawn from the market due to TdP
Rofecoxib 
(Vioxx)
Nonsterodial 1999-2004 Withdrawn because of risk of myocardial 
infarction
Sertindole Antipsychotic 1996-1998 Withdrawn from the market due to TdP
Terodiline Bladder incontinence 1986-1991 Withdrawn from the market due to TdP
Tegaserod 
(Zelnorm)
5-HT4 agonist 2002-2007 Withdrawn because of imbalance of 
cardiovascular ischemic events, including heart 
attack and stroke. Was available through a 
restricted access program until April 2008
Terfenadine 
(Seldane)
Antihistamine 1982-1997 Withdrawn because of risk of cardiac 
arrhythmias; superseded by fexofenadine
table 9.1 
Drugs withdrawn from the market due to cardiotoxicity
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Besides cardiac toxicity due to modulation of signaling pathways in cardiomyocytes there is 
actually a more profound reason for cardiotoxicity. The hERG channel, which produces the I
Kr
 
current, is robustly blocked by a large class of drugs. Since this current has a major function 
in cardiac repolarization it affects the length of the action potential and the QT interval on a 
surface electrocardiogram. In 1998, the Food and Drug Administration (FDA) recognized that 
prolongation of the QT interval on a surface electrocardiogram formed a major drug safety 
issue. The QT interval represents the duration of ventricular depolarization and subsequent 
drug indication black box warning?





Sunitinib RTK inhibitor (anticancer drug) None, but case reports of cardiotoxicity81
Rosiglitazone 
(avandia)




Anti-inflammatory Yes, cardiovascular risk 
Mitoxantrone Anti-neoplastic agent Yes, cardiotoxicity
Thioridazine Anti-psychotic Yes, QTc prolongation, TdP, sudden death
Mesoridazine Anti-psychotic Yes, QTc prolongation, TdP, sudden death
Muromonab Immunosuppressant Yes, cardiotoxicity, cardiac arrest
Nilotinib BCR-ABL inhibitor, anticancer drug Yes, QTc prolongation, TdP, sudden death
Itraconazole Antifungal agent Yes, congestive heart failure
Flecainide Class Ic anti-arrhythmic agent Yes, ventricular pro-arrhythmic effects
Cetuximab EGFR inhibitor, metatatic colon 
cancer
Yes, cardiopulmonary arrest
Clozapine Anti-psychotic Yes, myocarditis
Alglucosidase alfa Enzyme replacement therapy, 
pompe disease
Yes, cardiorespiratory failure
Amiodarone Class III Anti-arrhythmic Yes, pro arrhythmic affects
Arsenic trioxide Chemotherapeutic Yes, QTc prolongation, TdP, sudden death
Tocaininde Class Ib anti-arrythmic agent Yes, ventricular pro-arrhythmic effects
Imatinib BCR/ABL inhibitor, anticancer drug None, but case reports of cardiotoxicity82
table 9.2 
Drugs associated with cardiotoxicity
Chapter 9142
repolarization, and is measured from the beginning of the QRS complex to the end of the 
T wave. A prolongation to more than 440 to 460 milliseconds may allow life threatening 
arythmias, e.g. torsade de pointes (TdP) to occur. Identification of QT prolongation and 
torsade de pointes has led to the removal of several drugs from the market in the United 
States, including terfenadine, cisapride and grepafloxacin (Table 1), while many others have 
been required by the FDA to carry additional black box safety labeling warning of the potential 
risk (table 2). Today, risk assessment for delayed ventricular repolarization and QT interval 
prolongation is part of the standard pre-clinical evaluation of novel drug candidates as 
defined by the International Conference of Harmonization (ICH) Expert Working Group (topic 
S7B) for drugs in development76. Several compounds with known hERG liability have already 
been tested on hESC cardiomyocytes54.  
In conclusion, both small molecules and biologic drugs may affect human cardiomyocyte 
biology thereby significantly reducing cardiac function (Table 1 and 2). In addition, a large 
class of small molecules can interfere with hERG channel function, thereby increasing the 
arrhythmogenic risk. Therefore there is a great need for novel model systems that recapitulate 
human biology, are scalable, reproducible and preferably from an inexhaustible source. Human 
pluripotent stem cell-derived cardiomyocytes may have this potential. However their relatively 
immature phenotype might affect their drug responses. It therefore remains to be seen if drug 
responses on these cells recapitulate drug responses of the adult myocardium. Given the 
recent interest of the pharmaceutical industry and advances in cell tissue engineering, it is 
highly likely that human pluripotent cardiac models will be implemented in standard safety 
evaluation of novel drug candidates. One of the most promising tools will be the creation of a 
library of stem cell lines of different genetic origin, so that drug response and toxicity can be 
specified against a specific genetic background, enabling personalized treatment solutions, 
in combination with the FDA-required companion diagnostics.
Applications of cardiomyocytes from 
pluripotent stem cells in drug discovery
Human pluripotent stem cell lines, either hESC or hiPS cells, are considered promising novel 
tools for drug target discovery, in part because they may be derived as “healthy controls” 
but also because of the opportunities they represent for creating cardiac disease models. 
Clinically relevant mutations can be introduced by gene targeting in hESC or hiPS cell lines 
can be derived from cells of patients with a particular genetic disease of choice. This should 
facilitate the creation of innovative human disease models caused by simple as well as 
complex genetic abnormalities. This could be dependent on selected genetic backgrounds 
with specific predisposition factors affected the phenotype. In addition, non-genetic organ 
diseases can be mimicked in disease models using advanced tissue engineering and culture 
conditions. 
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Although cardiac drug discovery using pluripotent stem cells is a relatively novel concept, 
there are a few encouraging reports in the literature to suggest that it might work. A screen 
with P19cl6 pluripotent stem cells for Nkx2.5 gene activation led to the identification of a 
family of sulfonylhydrazone small molecules can trigger cardiac differentiation in adult stem/
progenitor cells. Human mobilized peripheral blood mononuclear cells treated with this small 
molecule engraft in an infarcted rat heart and improve cardiac recovery51. Another example 
is the isolation of mouse multipotent ISL1+/NKX2-5+ cardiac progenitors77. These cells are 
present in the fetal heart and can give rise to cardiomyocytes, endothelial cells and vascular 
smooth muscle. Automatic high content screening with 15.000 compounds resulted in 25 
compounds that increased ISL1+ self-renewal78. A secondary screen confirmed the activity of 
three compounds, two of these compounds were unknown the third 6-bromoindirubin-3’-
oxime (BIO) has been previously described as an inhibitor of GSK-3b.  Further experiments 
confirmed self-renewal of ISL1+ cardiovascular progenitors via the by the WNT/ß-catenin 
pathway. These experiments may be a starting point for further drug development. 
Challenges to be overcome before hESC-CM can be successfully implemented in the drug 
discovery pipeline are scaled differentiation and purification of cell fractions of interest. 
High content screens usually require >108 purified cells, which is still a significant challenge. 
Genetic enrichment at present seems to be the most promising strategy. At least two studies 
indicated that transgenic enrichment of hESC-CM by genetic selection is a feasible approach. 
In one study the [alpha]MHC promoter was used to drive expression of GFP-IRES-Puror while 
another used the same promoter driving expression of Neor 79, 80.
Conclusions and future perspectives
In recent years, it has become clear that transplantation of heart cells derived from pluripotent 
stem cells has faced several major obstacles.  This makes it unlikely that these cells will be 
used in clinical trials for the treatment of heart disease in the near future. It is thought that a 
combination of different cell-types, such as endothelial cells, smooth muscle cells, fibroblasts 
and cardiomyocytes seeded on a (pre-formed) biodegradable matrix mimicking the in vivo 
environment (e.g. stretch or electrical fields) followed by transplantation will be necessary for 
long-term beneficial effects. Besides the common hurdles that are encountered when only 
one cell-type is transplanted in the heart, the diversity of disciplines needed for generating 
a multi-cellular tissue-engineered bio-construct capable of integrating and communicating 
with the host tissue, indicates the complexity of this issue and the need for further basic 
research. 
Recent developments in defined culture conditions, genetic manipulation, directed 
differentiation and derivation of (disease-specific) pluripotent stem cells prompted academic 
researchers and pharmaceutical industry to change their focus to pre-clinical drug discovery. 
Human cardiomyocytes derived from pluripotent stem cells have unique properties and a 
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In this thesis various aspects of human 
embryonic stem cell (hESC) biology and 
technology development were studied with 
the aim of enhancing reproducibility and 
efficiency of their growth, differentiation and 
genetic manipulation. All future applications 
of human embryonic stem cells depend on 
the robustness of these procedures, exquisite 
knowledge of their biology and control of 
their signaling and fate choices.  
Culture methods for efficient genetic 
manipulation and completely defined 
conditions for expansion on a defined 
substrate were developed. Quantitative 
phosphoproteomics provided new insights 
on maintenance of pluripotency but more 
importantly exit from the pluripotent state, 
an essential first step in differentiation but 
rather neglected compared with the focus on 
fate control. Genetic manipulation of hESC 
and targeting of the cardiac transcription 
factor Nkx2.5 with EGFP, resulted in a 
cardiac reporter cell line that was used to 
optimize cardiac differentiation in defined 
conditions, isolate progenitor cells and 
study human cardiac fate choices. Finally 
hESC cardiomyocytes were used to develop 
and validate an assay for cardiac safety 
pharmacology of QT prolonging drugs. The 
major implications of these findings are 
discussed in this chapter. This includes future 
perspectives of hESC in safety pharmacology, 
disease modeling, drug discovery and 
personalized medicine. 
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The human embryonic stem cell model
For decades (bio) medical researchers have used model systems to study human biology, 
development and disease. In particular, model organisms are widely used to investigate 
treatments and potential causes of human disease when experiments directly on humans are 
not feasible or become unsafe and thus unethical. Examples of commonly used laboratory 
model systems include the yeast Schizosaccharomyces pompe, the nematode Caenorhabditis 
elegans, the fruit fly Drosophila melanogaster, the zebrafish Danio rerio and the mouse Mus 
musculus. Largely because of the ability to perform reverse genetics, the mouse has evolved 
as the favorite model to study human genes and disease processes1.  Although all of these 
model organisms have their own specific advantages and disadvantages, they have one major 
disadvantage in common, namely they are not human. Care must always be taken when 
extrapolating from any model system to humans. 
hESC have significant potential to be developed into an acceptable alternative to the model 
systems mentioned previously provided they are fully validated. The main reason for this is 
their capacity for both self renewal and differentiation to specialized cells, such as contracting 
cardiomyocytes, that share many common features with human adult cardiomyocytes. hESC 
technology is expected to contribute to basic studies on human development, drug target 
discovery and drug safety pharmacology.  
In general, model systems are simpler and idealized and are readily accessible and easily 
manipulated2. It needs few arguments to convince that a cell model is much simpler than a 
complete human being. This has clear advantages but also major disadvantages since multi-
cellular or multi-organ processes like cognition and metabolic syndromes are difficult to 
study in a cell model. However processes “at the cellular level” like transcriptional regulation, 
proliferation, differentiation, cell migration and specific cellular functions (e.g. contractility) 
are very well suited to being studied in an in vitro cell model3. Furthermore, it might be 
possible to use advanced tissue engineering and culture conditions to mimic processes that 
can normally only be studied in an animal model4. For example; patterning and alignment 
of cardiomyocytes on thin films results in sheets of cardiomyocytes that can be used to study 
force of contraction5. The aim here has been to address several criteria for translational use of 
pluripotent stem cells, namely their availability and ease of manipulation and the ability to 
direct differentiation into the required cell types for the particular assay in development. 
pluripotent stem cell culture technology
Although discovered more than a decade ago, hESC have been difficult to expand in a controlled 
manner that maintains their undifferentiated status. Furthermore, it has proven to be even 
more difficult to differentiate them with high efficiency in culture to any of the possible 220 cell 
types they might be able to make. Despite great interest, some cell types like skeletal muscle 
cells, germ cells, liver cells and lung cells are still very difficult / impossible to generate in 
culture. For robust efficient differentiation, it is preferable to start with a highly homogeneous 
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defined undifferentiated cell population, which is not available easily in the traditional feeder 
and serum based culture systems. We first decided to focus on developing common culture 
conditions (Chapter 2,3) that would robustly support pluripotency in a wide variety of lines, 
independent of whether these are mechanically (cut-and-paste) or enzymatically passaged, 
cultured using feeder- and serum or one of the (semi-)defined commercial media. It was 
envisaged that this would be particularly useful for genetic modification of hESC lines since 
their derivation and maintenance under various culture conditions before the present work 
required optimization of gene transfer protocols for every individual cell line and growth 
condition6. We found that MEF conditioned medium in combination with Matrigel supported 
all of every 12 hESC lines tested. We then showed that under these conditions hESC could 
be passaged using trypsin and cultured at low density. This allowed us to achieve very high 
transfection efficiencies for multiple types of gene constructs using several of the standard 
gene delivery systems and vectors, like bacterial plasmids, double stranded RNA, adenovirus 
and lentivirus.  
The importance of defining conditions for hESC or stem-/progenitor cell culture in general 
is very evident from studies on signaling pathways in these cells7. Initially, when hESC were 
cultured on poorly defined mouse or human feeder cells and in serum there were significant 
discrepancies in the results reported by independent laboratories. Examples include the 
debated role of LIF and Activin A in hESC self-renewal8,9,10 and chromosomal stability11,12. 
Reverse engineering of the stem cell niche by micro-array and proteomic analyses on feeder 
cells and stem cells have also proven to be difficult/impossible13,14. From the first derivation 
of hESC it took 8 years of research until the Thomson laboratory showed that they could be 
cultured feeder-free in defined medium supplemented with bFGF and TGF-b/Activin A10.  We 
have built on these findings and investigated integrin and matrix expression in hESC, on the 
premise that knowledge of extracellular matrix receptor (integrin) expression, would allow the 
appropriate matrix substrate to be defined and the matrix function (cell attachment, survival 
and proliferation) elucidated. Using blocking antibodies and functional assessment of binding 
capacity we demonstrated that recombinant vitronectin, signaling through integrin aVb5, was 
a robust alternative to MatrigelTM (Chapter 5) and the only factor tested that supported long 
term self renewal. This has recently been validated independently by Stem Cell Technologies 
and Ludwig et al (personal communication) and the latter are now investigating whether 
recombinant vitronectin will support derivation of new hESC lines.  Furthermore, recently it 
has been shown that vitronectin supports hiPSC derivation and growth as well15. Although 
promising, however, the high cost of recombinant vitronectin and the incompatibility with 
enzyme based bulk cultures likely limits its further development. 
regulation of pluripotency
Starting from the question ‘how is pluripotency regulated?’ we characterized hESC as bona 
fide epithelial cells and confirmed the presence of all epithelial junctions at the protein level 
with protein mass-spectroscopy and immuno-fluorescence microscopy (Chapter 4). Since 
epithelial cells are known to require a basement matrix we reasoned that integrin and matrix 
Chapter 10152
expression could be an important determinant of hESC pluripotency (Chapter 5). We showed 
that hESC have the potential to attach to a wide variety of natural substrates, but that only 
recombinant vitronectin by itself was capable of supporting sustained hESC proliferation. To 
investigate hESC further we developed methods for scalable culture of hESC, stable isotope 
labeling of cells in culture (SILAC) and very efficient differentiation from the pluripotent state to 
accommodate proteomic screens (Chapter 6).  We induced differentiation with BMP4 because 
it induced the fastest differentiation evidenced by rapid loss of pluripotent markers SOX2 and 
OCT4 of any growth factor tested and therefore allowed us to investigate the earliest events 
following induction of differentiation, before overt gene expression patterns had changed16. 
This proteomic approach resulted in an extensive hESC proteome profile, which confirmed 
the predicted protein expression based on histone 3 tri-methylation17. More importantly 
our approach generated a dynamic map of protein phosphorylation during the first 4 
hours of hESC differentiation. Linkage analyses of kinases to the identified phosphorylation 
suggest an important role for CDK1/2 in hESC pluripotency. Interestingly, we found a novel 
phosphorylation motif on SOX2, one of the core pluripotency factors. In depth analyses of 
this site confirmed that phosphorylation of SOX2 results in sumoylation. Sumoylaton of SOX2 
is known to inhibit its DNA binding activity as a transcription factor18.  SOX2 phosphorylation 
could therefore be a novel mechanism used by the cell to exit the pluripotent state and 
initiate a differentiation program. We propose that linkage of protein data with genomic, 
epigenomic and transcriptomic approaches will improve our knowledge of cell biology in 
general and of stem cell fate choices in particular. 
differentiation
Differentiation of hESC can occur spontaneously but is usually induced with specific growth 
factors to specify development to a certain lineage. These growth factors are the same or similar 
to the ones active in the embryo during development. A pool of differentiating hESC induced 
towards cardiac differentiation follows a pattern of gene expression changes as expected. 
Differentiation is initiated with down-regulation of stem cell genes, transient up-regulation of 
primitive streak associated genes, transient up-regulation of early mesoderm/mesendoderm 
markers followed by markers associated with cardiac lineage commitment19.  Although there 
is similarity with normal embryonic development described in other vertebrates like mouse, 
neither temporal nor 3-D spatial signaling are entirely recapitulated in a culture dish. 
Differentiation of stem cells to any lineage can be best explained using the ‘chaos theory’20. 
In a highly undifferentiated culture human embryonic stem cells themselves are essentially 
similar to each other, although there may be subtle differences between them. During 
differentiation the number of different cell types increases and cells influence each other in 
both auto- and endocrine fashions as differentiation proceeds. Directed differentiation by 
exogenous growth factors at later stages of the process is therefore problematic and subject 
to interference. 
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Rosenblueth & Wiener already stated in 1945 that an ideal model system must be accessible 
and easily manipulated. In order to study the cardiomyocytes from hESC, it is necessary to 
make them accessible experimentally in large numbers, to purify them and ideally to be 
able to expand their lineage committed progenitors in culture. To be able to understand the 
cardiac differentiation hierarchy being able to select cardiac progenitors and re-plate these 
in defined media allows study of their behavior in response to known signaling cues and 
activators. 
optimized differentiation
The increasing availability of accurate reporter hESC lines, for example like the knock-in of 
EGFP downstream the endogenous promoter of Nkx2-5 (Chapter 7), is expected to contribute 
strongly to the utility of hESC as a model system.  Expression of fluorescent proteins from lineage 
promoters can be used in high content differentiation screens whereby the effects of growth 
factors or small molecules can be investigated in 96- or 384 well plates by automatically 
imaging. Although growth factors and other forms of extracellular signaling mainly regulate fate 
choices in vivo, it will certainly be more interesting to screen small molecules for their ability 
to achieve the same effect in vitro. Small molecules can be specfically optimized to activate 
or deactivate members of the entire ‘druggable genome’21.  By working with the druggable 
genome it is expected that higher specificity for signaling pathways can be achieved since it 
is not limited to receptors but can include kinases, phosphatases, proteases, transporters, 
nuclear hormone receptors, GPCRs and ion channels. This concept has already been applied 
to cardiac differentiated mouse pluripotent stem cells and recently on hESC differentiating 
to pancreas cells22.23. Furthermore, continuous refinement of the fluorescent toolbox24,25 
makes it possible to engineer stem cell fate reporter technology to monitor the whole process 
of differentiation using a multicolor differentiation system. A combination of reporters for 
mesoderm induction, cardiac specification and cardiac maturation would be very interesting 
to optimize growth factor timing. As showed in chapter 7, removal of BMP4/Activin-A/FGF/
VEGF exactly at day 3 of differentiation is crucial for efficient cardiac differentiation. 
Translational cardiac medicine
 
hESC technology is often associated with translational medicine. Translational medicine 
is the workflow – often referred to as “from bench to bedside” – by which the academic 
decision maker takes a focused point of view to move research discoveries from the academic 
laboratory into clinical practice for diagnosis and treatment of patients. One can think of 
various scenarios on how stem cells can be incorporated in the process of translational cardiac 
medicine. The most obvious way is to produce cell types to repair an injured heart. However, 
despite the huge interest relatively little robust progress has been made to achieve this goal 
for the heart (reviewed in Chapter 9). This and the availability of induced pluripotency stem 
cells from humans (hiPSC) and gene targeting to create human disease models are causing a 
shift in focus from cell therapy to drug safety pharmacology and target discovery (Chapter 9).
Chapter 10154
drug discovery
Drug discovery using differentiated stem cells is an exciting new application of stem cell 
technology (Chapter 9). Discovery of novel relevant drug targets is hampered by the fact that 
current disease model systems do not always sufficiently represent or reflect human disease 
and are therefore not ideal for target and subsequent drug discovery. Human evolution 
diverged approximately 65 million ago from small rodents as the mouse26. Therefore it is 
not very surprising that there are clear differences between the species. For example 
cardiac repolarization in mice differs from humans since the primary ion current controlling 
repolarization in these animals is I
to
 rather than I
kr
27. A large class of drugs avidly blocks I
kr
, 
which is a very important risk factor for Torsade de Pointes (TdP) in humans. Due to species 
differences mice are unsuitable to evaluate this risk. The sequencing of the human genome 
and the genome of lower organisms has revealed the presence of a number of human- 
or human-lineage specific genes that have no orthologs in lower species28. The functional 
relevance of at least one of these genes was recently proven. CHC22 turned out to be 
an important regulator of glucose metabolism and the fact that this gene is not present 
in mouse calls into question the use of mice to study some aspects of diabetes29. Finally, 
chromosomal genetic differences between lower species and human makes it very difficult to 
design a model system for karyotypic abnormalities like Down’s syndrome since for example 
mice do not have a chromosome 21. Therefore any possibility to improve model systems 
for decision-making, reduction of attrition rates and timelines into clinical practice would 
provide an enormous benefit to the process of drug discovery and development. hESC and 
hiPSC technology together hold great promise to achieve this goal. The latest differentiation 
and selection procedures, encourages optimism on implementation of these cells in the 
drug discovery pipeline. The possibility to introduce clinically relevant mutations stably by 
gene targeting (Chapter 3,4), or to derive hiPSC cell lines from skin cells of patients with 
the disease of choice, clears the road to creating innovative human disease models, caused 
by both simple as well as complex genetics abnormalities. In addition, non-genetic organ 
diseases could be mimicked in disease models using advanced tissue engineering and culture 
conditions. For example, cardiac hypertrophy, a major determinant of heart failure, can be 
induced using chemicals as angiotensin II and phenylephrine. Examples of heart diseases 
that could be modeled include mutations in ion channel associated with arrhythmia and 
mutations in structural proteins associated with impaired contractility. However, successful 
implementation of stem cells will depend on functional responses of the cells. In general, 
differentiated cells derived from stem cells are immature compared to the cells present in 
the adult human body. Cardiomyocytes, for example, display both an immature electrical 
phenotype as well as an immature sarcomeric organization. It is thought that advanced tissue 
engineering, which could be based on progenitor cells (Chapter 7) and exquisite knowledge 
of cell maturation is required to develop an effective maturation protocol. Furthermore as 
mentioned before, a stem cell model is simpler than a complete animal model, which has the 
disadvantage that the cell type of interest is isolated from other cells/organs. Metabolism of 
compounds by the liver and the effects of these metabolites are difficult to test in vitro, unless 
co-culture systems are developed specifically aimed at these kinds of effects. 
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cardiac safety pharmacology
Proper heart function is one of the essential elements of life and any drug that interferes with 
this process is potentially life threatening. Besides that, the myocardium has a very small 
regenerative capacity30,31. Therefore it is of crucial importance to design safe drugs that have 
no side effects on the heart. 
In 1998 it was widely acknowledged by regulatory bodies that a large class of chemical structures 
interfere with the human Ether-a-go-go Related Gene (hERG) channel32. The hERG channel 
is essential for proper cardiac repolarization and if blocked this can result in life threatening 
ventricular tachy-arrhythmias. We differentiated hESC to cardiomyocytes (hESC-CM), plated 
them on multi-electrode arrays and described systematic generation of field potential dose 
response curves for cardiac and non-cardiac drugs (Chapter 8). Although the field potential 
is a direct reflection of the action potential, it is less defined and more difficult to interpret 
as the action potential33. Despite this, field potential duration prolongation turned out to be 
a useful criterion for drugs affecting QT prolongation in the human heart (Chapter 9).  Assays 
based on hESC-CM could therefore complement or potentially replace some of the preclinical 
tests currently used to select chemical compounds for development as new cardiac drugs and 
improve safety testing of drugs prior to clinical trials. The assays described here are aimed 
to evaluate drug-ion channel interactions directly and might be limited to some extend. 
Some drugs like arsenic trioxide and geldanamycin deviations are reported to affect hERG 
channel trafficking to the plasma membrane, and should be evaluated in long-term assays34. 
Furthermore the downside of a cell model is illustrated by the fact that drug-induced TdP is 
thought to arise from dispersion of cardiac repolarizaton across the transmural ventricular 
myocardium35. Dispersion of repolarization could be the trigger to ventricular arrhythmias, 
which is something difficult to model in an in vitro system. 
Finally, cardiotoxic effects of certain drugs may only become evident under conditions that 
simulate a normal beating heart, in either a physiological (stretch-contraction cycle) or 
pathophysiological situation (e.g. excessive stretch or compensatory mechanisms associated 
with cardiac disease). Through combination of microfabrication and stem cell technology 
we expect to be able to develop flexible stretchable cardiac model systems with integrated 
passive electrodes for electrical and contractility read outs. These kinds of systems will likely 
make major contributions to the development of novel safe effective drugs.
personalized medicine
The option to use a large number of cell lines with different genetic background in parallel 
for drug target validation and safety pharmacology, allows the actual development of a 
tissue-directed in vitro clinical trial, prior to any clinical trial involving patients. Despite the 
limitations of an isolated tissue system, instead of a whole organism, this represents and 
unprecedented step towards personalized medicine. In general, not all individuals receiving 
a drug for a specific indication will exhibit therapeutic responses or toxic side–effects, which 
is, in part, determined by the genetic constitution of the patient. The use of a series of human 
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pluripotent stem cell lines with different genotypes will allow in vitro analyses, predicting both 
drug effectiveness and toxicity at and individual level against a specific genetic background, 
as well as identifying biomarkers for the development of companion diagnostic assays to 
predict individual therapy response and toxicity in the clinic. 
Future prospects and conclusions
 
Over the last years knowledge of human embryonic stem cells has evolved considerably. 
Technology has been developed to grow stem cells in large quantities, manipulate them and 
differentiate them efficiently. It is expected that further developments eventually results in 
high throughput assays for analyses of differentiation, drug safety pharmacology and drug 
discovery. Future studies are required to compare the human stem cell model with the current 
gold standards in the industry eventually leading to broad acceptance of the pluripotent stem 
cell model.
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Human embryonic stem cells (hESC) hold great potential as a model for human development, 
disease pathology, drug discovery and safety pharmacology. All these applications will depend 
on comprehensive knowledge of their biology and control of their signaling mechanisms and 
fate choices. 
To begin to address this, we developed a standardized feeder-free hESC culture protocol. This 
system is optimized and tested for 12 independently derived stem cell lines, and optimal for 
clonal growth and efficient gene transfer without loss of pluripotency (Chapter 2,3). Using 
these protocols we created stem cells ubiquitously expressing EGFP, showed efficient SOX2 
knockdown and created a fluorescent reporter stem cell line for the stem cell regulator OCT4. 
Next we used mass spectroscopy to investigate the plasma membrane of hESC (Chapter 4). We 
were able to show that these cells express a uniform epithelial plasma membrane profile and 
that VIMENTIN, normally associated with mesenchymal cells is also expressed.  This expression 
turned out to be related to stress and associated with hardness of the tissue culture plastic 
substrate rather than differentiation. We continued to investigate the plasma membrane of 
hESC and decided to focus on integrins, the cell surface receptors that bind extracellular matrix 
proteins. Functional analyses of their function showed human embryonic stem cells have the 
capacity to bind to a wide range of extracellular matrix proteins via specific integrin receptors. 
We were able to show that recombinant vitronectin robustly supports the maintenance of 
hESC in an undifferentiated state in completely defined culture medium.  Having validated 
a completely defined culture protocol we began to investigate differentiation mechanisms 
under defined conditions (Chapter 5). We used Stable Isotope Labeling in Cell Culture (SILAC) 
and quantitative phopspho-proteomics to investigate how human embryonic stem cells exit 
the pluripotent state. BMP4 was used to trigger differentiation and protein samples were 
analyzed at 30 min, 60 min and 240 min. We showed that approximately 50% of the 3067 
identified phosphosites were regulated within 1 hr of differentiation induction, revealing 
a complex interplay of phosphorylation networks spanning different signaling pathways. 
Among the phosphorylated proteins was the pluripotency-associated protein SOX2, which 
was SUMOylated as a result of phosphorylation. Using the data to predict kinase-substrate 
relationships we reconstructed the hESC kinome, with CDK1/2 emerging as a key kinase in 
controlling self-renewal and lineage specification. 
Next we used gene targeting to create a fluorescent cardiac reporter cell line. EGFP was targeted 
into one allele of the NKX2-5 gene. EGFP fluorescence driven by the endogenous Nkx2-5 
promoter faithfully reported cardiovascular lineage commitment of differentiating hESC under 
defined culture conditions. Using fluorescence activated cell sorting we showed that the early 
NKX2-5 positive cell population contained multipotent progenitor cells capable of directed 
differentiation to cardiomyocytes, endothelial and vascular smooth muscle cells (Chapter 
7). Finally, we used the cardiomcyocytes from hESC to develop a system for cardiac safety 
pharmacology (Chapter 8). Recent withdrawals of prescription drugs from clinical use because 
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of unexpected side effects on the heart have highlighted the need for more reliable cardiac 
safety pharmacology assays. In particular, blocking of the human Ether-a-go go Related Gene 
ion channel is associated with life-threatening arrhythmias, such as Torsade de Pointes. We 
demonstrated that, as predicted, patient serum levels of drugs and known responses on QT 
interval overlapped with field potential duration values derived from hESC-CM,. On this basis, 
we propose field potential duration prolongation as a directly applicable safety criterion for 
pre-clinical evaluation of new drugs in development. In conclusion, the availability of human 
cardiomyocytes from stem cell sources is now expected to accelerate cardiac drug discovery 
and safety pharmacology by offering more clinically relevant human culture models than 
presently available (Chapter 9,10).
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Een stamcel is een cel die zichzelf kan vermenigvuldigen en zich kan specialiseren tot tenminste 
één andere celsoort. Er zijn twee soorten stamcellen; embryonale stamcellen en volwassen 
stamcellen. Volwassen stamcellen zijn te vinden in een groot aantal organen en kunnen 
zich ontwikkelen tot een beperkt aantal celtypes, terwijl embryonale stamcellen pluripotent 
zijn. Dat wil zeggen dat de stamcellen zich kunnen specialiseren tot alle 220 celtypes die 
voorkomen in het menselijke lichaam. Humane embryonale stamcellen worden geïsoleerd 
uit een celklompje, blastocyst genaamd, wat een overblijfsel is van IVF behandelingen. 
Humane embryonale stamcellen kunnen in een kweekschaaltje eeuwig doorgroeien. Deze 
unieke eigenschappen maken humane embryonale stamcellen zeer aantrekkelijk als model 
om menselijke ontwikkelingsbiologie te onderzoeken, ziekten te bestuderen, medicijnen te 
ontwikkelen en deze op veiligheid te testen.
Om aan deze toepassingen te kunnen werken moeten er eerst een aantal problemen worden 
opgelost (hoofdstuk 1). Zo is het belangrijk dat de stamcellen efficiënt blijven delen. Daarnaast 
moeten de stamcellen hun stamcelidentiteit houden tot het moment dat de onderzoeker 
besluit dat ze zich mogen differentiëren (specialiseren tot een ander celtype). Verder is het 
erg belangrijk dat dit proces goed gestuurd kan worden. Het is nou eenmaal niet handig als 
de onderzoeker in hartspiercellen geïnteresseerd is, terwijl de stamcellen zich differentiëren 
in botcellen. Ten slotte is het van belang dat het DNA van de stamcellen gericht aangepast kan 
worden. Als we geïnteresseerd zijn in een ziekte die door een foutje in het DNA veroorzaakt 
wordt, willen we die fout kunnen aanbrengen in de stamcel om zo de ziekte te kunnen 
bestuderen.
Humane embryonale stamcellen groeien in grote kolonies op een laag van andere cellen die 
ervoor zorgen dat de stamcellen niet differentiëren. Omdat het kweekschaaltje regelmatig 
te klein wordt, moet de kolonie als een soort taart in stukjes verdeeld worden. Deze stukjes 
worden dan over gezet naar een nieuw schaaltje, zodat de cellen weer door kunnen groeien. 
Dit proces is zeer arbeidsintensief en dus inefficiënt. Daarnaast is het zo dat de cellen in 
de kolonies erg dicht op elkaar gepakt zijn, wat het erg moeilijk maakt om het DNA van 
de stamcellen gericht te veranderen. In hoofdstuk 2,3 laten we zien dat we de stamcellen 
kunnen laten groeien op een gel van speciale eiwitten. Door het gebruik van een enzym 
wat eiwitten aan de buitenkant van de cel kapot knipt, kunnen we de cellen van elkaar 
scheiden. De suspensie van cellen kan vervolgens verdeeld worden over een aantal nieuwe 
kweekschaaltjes. Op basis van deze nieuwe kweekmethode hebben we zeer efficiënte 
technieken ontwikkeld om de cellen genetisch aan te passen. Zo hebben we bijvoorbeeld 
een gen van een kwal toegevoegd; dit maakt de cellen groen fluorescent als je er met blauw 
licht op schijnt. 
In hoofdstuk 4 zijn we begonnen met de verdere karakterisering van de stamcellen met 
behulp van massaspectrometrie, een zeer geavanceerde techniek om de aanwezigheid van 
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eiwitten te meten. Hieruit bleek dat stamcellen veel overeenkomsten met epitheelcellen 
vertonen, maar dat ze ook vimentine produceren. Dit zou erop wijzen dat ze een epitheel- 
tot mesenchymale transformatie hebben ondergaan. We hebben kunnen aantonen dat de 
aanwezigheid van vimentine eigenlijk een gevolg van stress is en in dit geval niets te maken 
had met epitheel tot mesenchymale transformatie. Humane embryonale stamcellen hebben 
dus een epitheel fenotype.
Epitheelcellen hechten in het lichaam aan een extracellulaire matrix. We bepaalden daarom 
de samenstelling en oorsprong van de extracellulaire matrix van stamcellen die groeien in 
kolonies op een laag van andere cellen en vonden dat alle bekende matrix eiwitten aanwezig 
waren (hoofdstuk 5). Daarnaast karakteriseerden we ook de receptoren voor extracellulaire 
matrix (integrines) op de stamcellen en concludeerden dat de stamcellen theoretisch aan alle 
extracellulaire matrix moleculen zouden moeten kunnen binden. Functionele experimenten 
wezen uit welke integrines belangrijk waren voor de verschillende matrices en dat stamcellen 
kunnen groeien op recombinant vitronectine. Deze vinding vormde de basis voor het eerste 
stamcelkweeksysteem waarvan alle componenten exact bekend zijn.
Vervolgens besloten we onze aandacht te richten op de vraag hoe stamcellen zich differentiëren. 
Stamcellen werden tot differentiatie gestimuleerd door het toevoegen van de groeifactor 
BMP4. Stamcel eiwitten werden vervolgens geïsoleerd en kwantitatief gemeten op tijdstip 
0, op 30, 60 en 240 minuten na toevoeging van BMP4 (hoofdstuk 6). Naast de eiwitten zelf 
hebben we ook specifiek gekeken naar kinases, eiwitten die fosfaatgroepen toevoegen aan 
eiwitten, en naar gefosforyleerde eiwitten (eiwitten met fosfaat-groepen). Met deze methode 
hebben we 3067 fosfaatgroepen gevonden op een totaal van 5222 eiwitten. Ongeveer 50% 
van deze fosfaatgroepen werden gereguleerd binnen een uur na toevoeging van BMP4, wat op 
een zeer complex netwerk van signaleringsroutes duidt. Een van deze gereguleerde eiwitten 
was SOX2, een belangrijke stamcel eiwit. Dit laat zien dat het reguleren van fosfaatgroepen 
een belangrijk mechanisme voor differentiatie kan zijn. Na bio-informatische analyse vonden 
we de kinase CDK1/2 als een belangrijke regulator van stamcellen.
In hoofdstuk 7 beschrijven we een nieuwe cellijn die groen fluorescent kleurt zodra de 
cellen zich specialiseren tot hartspiercellen. Deze cellijn hebben we gebruikt om exact uit 
te zoeken welke groeifactoren er nodig zijn om hartvoorlopercellen en hartspiercellen te 
maken. We onderzochten deze hartvoorlopercellen verder en ontdekten dat deze cellen naast 
hartspiercellen ook gladde spiercellen en endotheelcellen kunnen worden. Dit laat zien dat 
stamcellen gebruikt kunnen worden om menselijke hartontwikkeling te bestuderen.
Ten slotte ontwikkelden we een methode om medicijnen te testen op bijwerkingen aan het 
hart (hoofdstuk 8). We kunnen menselijke embryonale stamcellen nu gecontroleerd laten 
uitgroeien tot hartspiercellen. Deze hartspiercellen lijken in veel opzichten op de cellen in het 
menselijke hart. Zo vertonen ze elektrische activiteit, waardoor de klompjes hartspiercellen 
ritmisch samentrekken. Medicijnen konden getest worden door deze simpel toe te voegen aan 
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de celkweken en door de elektrische activiteit van deze cellen te meten. Op basis van deze 
metingen hebben we nu voor het eerst laten zien dat we hartspiercellen kunnen gebruiken 
om het effect van medicijnen op het menselijke hart te voorspellen.
In hoofdstuk 9 en 10 bediscussiëren we de voorgaande hoofdstukken en bespreken we de 
grootste hindernissen en kansen voor stamcelonderzoek. We concluderen dat de mogelijkheid 
om hartspiercellen uit stamcellen te maken enorme mogelijkheden biedt voor fundamenteel 
en toegepast wetenschappelijk onderzoek. De komende jaren zullen ontwikkelingsbiologen 
op basis van stamcellen nieuwe ontdekkingen doen, zullen er menselijke ziektemodellen 
gemaakt worden voor geneesmiddelenonderzoek en zullen de testsystemen voor medicijn 
veiligheidstesten verder verfijnd worden. Stamcelonderzoek zal dus bijdragen aan de 
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